Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

27
results for

"Mortality"

Article category

Keywords

Publication year

"Mortality"

Original Article

Normal-weight MASLD: reclassification, characteristics, and adverse liver outcomes across diverse populations
Sherlot Juan Song, Eileen Laureal Yoon, Vincent Wai-Sun Wong, Ae Jeong Jo, Grace Lai-Hung Wong, Jimmy Che-To Lai, Dae Won Jun, Terry Cheuk-Fung Yip
Received July 28, 2025  Accepted December 9, 2025  Published online December 12, 2025  
DOI: https://doi.org/10.3350/cmh.2025.0851    [Accepted]
Background & Aims
Previous studies have identified a substantial degree of agreement between the non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) populations, but the same notion may not apply to normal-weight patients with a lower cardiometabolic risk burden. This study aims to investigate the CMRF distributions between normal-weight and overweight/obese MASLD, the agreement between historical NAFLD and MASLD, and to compare the risk of liver-related events (LREs) and all-cause mortality in normal-weight versus overweight or obese MASLD.
Methods
This study included participants with steatotic liver disease (SLD) from five cohorts in Hong Kong, South Korea, and the United States. Participants were recruited from settings including both hospitals and communities. Individuals were classified into normal-weight and overweight/obese groups.
Results
This study included 33,793 participants with SLD from five cohorts, of whom 20,893 and 20,701 patients met the diagnosis of NAFLD and MASLD, respectively. Normal-weight patients with NAFLD demonstrated a lower CMRF distribution compared to those with overweight/obese NAFLD. In the community-based cohorts, the proportions of 0 CMRF ranged from 9.0-26.7% among normal-weight NAFLD, representing the discrepancy between MASLD and NAFLD definitions. Compared with the overweight/obese MASLD, the normal-weight MASLD had increased all-cause mortality (normal-weight vs. overweight/obese, 23.44 and 13.80 per 1000 person-years; p<0.001) but not LREs (2.81 and 2.59 per 1000 person-years; p=0.54) in the HK CDARS cohort.
Conclusions
Normal-weight individuals with NAFLD demonstrated a lower distribution of CMRFs, resulting in the incomplete agreement between historical NAFLD and MASLD.
Ethical Compliance
For all involved cohorts, the study protocols conformed to the ethical guidelines of the 1975 Declaration of Helsinki and were approved by the appropriate clinical research ethics committee and/or institutional review board, which provided either written consent or a waiver of informed consent.
  • 808 View
  • 110 Download

Correspondence

Letter to the Editor

Steatotic liver disease

  • 5,865 View
  • 40 Download

Review

Steatotic liver disease

Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations
Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim
Clin Mol Hepatol 2025;31(1):74-89.
Published online October 23, 2024
DOI: https://doi.org/10.3350/cmh.2024.0631
One-third of adults across the globe exhibit metabolic dysfunction-associated steatotic liver disease (MASLD)―formerly known as nonalcoholic fatty liver disease (NAFLD). To date, MASLD is the fastest-growing etiology of chronic liver disease and hepatocellular carcinoma (HCC). Besides the population with obesity, MASLD can also be found in lean populations, accounting for 13% of the global population, especially Asians. Notably, individuals with lean MASLD face equal or higher overall mortality rates compared to their non-lean counterparts. Risk modifiers encompass advanced age, hepatic fibrosis, and type 2 diabetes mellitus (T2DM). Moreover, the population with lean MASLD is associated with an increased risk of HCC, while their non-lean counterparts are more prone to cardiovascular outcomes and T2DM. Existing evidence indicates a similar risk of liver-related events and extrahepatic cancer between the two groups. However, MASLD-related genetic variants, such as PNPLA3 and TM6SF2, did not significantly affect mortality between the two populations. Still, underreporting alcohol consumption and regional representation limits the study’s comprehensiveness. Longitudinal studies and mechanistic explorations are needed to understand differences in lean versus non-lean MASLD populations. This review highlights the need for awareness and tailored interventions in managing MASLD, considering lean individuals’ unique risks.

Citations

Citations to this article as recorded by  Crossref logo
  • Dietary vitamin E intake in metabolic dysfunction–associated steatotic liver disease and all-cause/cause-specific mortality
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed
    European Journal of Gastroenterology & Hepatology.2026; 38(1): 63.     CrossRef
  • Phthalates exposure, biological aging, and increased risks of insulin resistance, prediabetes, and diabetes in adults with metabolic dysfunction-associated steatotic liver disease
    Yueru Yang, Shuhui Wan, Linling Yu, Wei Liu, Jiahao Song, Da Shi, Yongfang Zhang, Weihong Chen, Weihong Qiu, Bin Wang
    Diabetes & Metabolism.2025; 51(1): 101602.     CrossRef
  • Increased MASH-associated liver cancer in younger demographics
    Pojsakorn Danpanichkul, Yanfang Pang, Kanokphong Suparan, Thanida Auttapracha, Supapitch Sirimangklanurak, Abdelrahman M. Attia, Chanattha Thimphitthaya, Michelle Shi Ni Law, Zhenning Yu, Mostafa A. Soliman, Natchaya Polpichai, Chanakarn Kanitthamniyom, D
    Hepatology Communications.2025;[Epub]     CrossRef
  • Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
    Pojsakorn Danpanichkul, Kwanjit Duangsonk, Markos Kalligeros, Michael B. Fallon, Chawinthorn Vuthithammee, Chun Wei Pan, Preenapun Saokhieo, William Derrick, Yanfang Pang, Vincent L. Chen, Donghee Kim, Amit G. Singal, Ju Dong Yang, Karn Wijarnpreecha
    Alimentary Pharmacology & Therapeutics.2025; 61(6): 959.     CrossRef
  • Current Burden of Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease Among US Adults, 2017–2023
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
    Alimentary Pharmacology & Therapeutics.2025; 61(5): 891.     CrossRef
  • Comparative application of MAFLD and MASLD diagnostic criteria on NAFLD patients: insights from a single-center cohort
    Maha Elsabaawy, Madiha Naguib, Ahmed Abuamer, Ahmed Shaban
    Clinical and Experimental Medicine.2025;[Epub]     CrossRef
  • Advanced lung cancer inflammation index: a key predictor of hepatic steatosis and fibrosis severity
    Yajie Liu, Ruilin Wang
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
    Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785.     CrossRef
  • Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
    Clinical and Molecular Hepatology.2025; 31(2): e180.     CrossRef
  • Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
    Clinical and Molecular Hepatology.2025; 31(2): 382.     CrossRef
  • Liver cirrhosis in metabolic dysfunction-associated steatohepatitis
    Donghyun Ko, Do Han Kim, Pojsakorn Danpanichkul, Masahito Nakano, Chitchai Rattananukrom, Karn Wijarnpreecha, Cheng Han Ng, Mark D Muthiah
    Gastroenterology Report.2025;[Epub]     CrossRef
  • Advances in identifying risk factors of metabolic dysfunction-associated alcohol-related liver disease
    Rui-Qi Ye, Yi-Fan Chen, Chang Ma, Xi Cheng, Wei Guo, Sha Li
    Biomedicine & Pharmacotherapy.2025; 188: 118191.     CrossRef
  • Increased Mortality Among Lean Versus Non‐Lean Adults With MASLD: A Multicenter Study
    Leith Ghani, Majd B. Aboona, Claire S. Faulkner, Pooja Rangan, Moises Nevah Rubin, Ma Ai Thanda Han, Michael B. Fallon, Vincent L. Chen, Karn Wijarnpreecha
    Journal of Gastroenterology and Hepatology.2025; 40(8): 1919.     CrossRef
  • Evolving Public Attention to Steatotic Liver Disease: A 20‐Year Analysis (2004–2024)
    Pojsakorn Danpanichkul, Charat Thongprayoon, Kanokphong Suparan, Donghee Kim, Ornpailin Wanichthanaolan, Phuuwadith Wattanachayakul, Yanfang Pang, Mark D. Muthiah, Anand V. Kulkarni, Ju Dong Yang, Apichat Kaewdech, Wisit Cheungpasitporn, Karn Wijarnpreech
    Journal of Gastroenterology and Hepatology.2025; 40(8): 2053.     CrossRef
  • Meta‐Analysis: Effects of Steatotic Liver Disease‐Associated Genetic Risk Alleles on Longitudinal Outcomes
    Matthew Kubina, Vitchapong Prasitsumrit, Jarell Tan, Joo Wei Ethan Quek, Dhiraj Peddu, Ankit Mishra, Pojsakorn Danpanichkul, Jake P. Mann, Eric Trépo, Stephan Buch, Daniel Q. Huang, Cheng Han Ng, Mark D. Muthiah, Yu Jun Wong, Karn Wijarnpreecha, Vincent L
    Alimentary Pharmacology & Therapeutics.2025; 62(3): 244.     CrossRef
  • Metabolic Impact of Alcohol Consumption in MASLD: Understanding MetALD and Beyond
    Eva Juárez-Hernández, Montserrat Berrospe-Alfaro, Misael Uribe, Iván López-Mendez
    Journal of Clinical and Experimental Hepatology.2025; 15(6): 103114.     CrossRef
  • Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023
    Donghee Kim, Rohit Loomba, Aijaz Ahmed
    Clinical and Molecular Hepatology.2025; 31(3): e235.     CrossRef
  • Predicting the risk of lean non-alcoholic fatty liver disease based on interpretable machine models in a Chinese T2DM population
    Shixue Bao, Qiankai Jin, Tieqiao Wang, Yushan Mao, Guoqing Huang
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Effect of varenicline on major adverse liver outcomes in alcohol‐associated liver disease: An exploratory analysis
    Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanathip Suenghataiphorn, Donghyun Ko, Andrew F. Ibrahim, Vitchapong Prasitsumrit, Kwanjit Duangsonk, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul
    Alcohol, Clinical and Experimental Research.2025; 49(11): 2451.     CrossRef
  • Paradoxical association between steatotic liver disease and favorable hepatic outcomes in HCV patients with SVRs
    Ming-Ling Chang, Jur-Shan Cheng, Jennifer Tai, Wei-Ting Chen, Sien-Sing Yang, Cheng-Hsun Chiu, Rong-Nan Chien, Chia-Lin Hsu, Shang-Jung Wu, Cathy SJ Fann
    Hepatology International.2025; 19(6): 1347.     CrossRef
  • Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
    Anoushka Shenoy, Aijaz Ahmed, Donghee Kim
    Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
  • Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction
    Wooyoung Choi, Gun Ha Woo, Tae-Hwan Kwon, Jae-Han Jeon
    International Journal of Molecular Sciences.2025; 26(19): 9715.     CrossRef
  • Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed
    Alimentary Pharmacology & Therapeutics.2025;[Epub]     CrossRef
  • Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts
    Zhenyu Huo, Yijun Chen, Yating Huang, Zhirong Yang, Yujun Long, Qian Zhang, Shuohua Chen, Guodong Wang, Shengtao Zhu, Dianjianyi Sun, Canqing Yu, Jun Lv, Liming Li, Ming-Hua Zheng, Shouling Wu, Yuanjie Pang, Shanshan Wu
    Gut.2025; : gutjnl-2025-336127.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease: Prevalence and progression in lean patients
    Gerard Stupecki, Emilia Kowalczyk, Agnieszka Ciba-Stemplewska, Magdalena Dolecka-Ślusarczyk, Iwona Gorczyca-Głowacka
    Polish Annals of Medicine.2025; : 1.     CrossRef
  • Increasing Prevalence of Steatotic Liver Disease in a Japanese Health Checkup Population, 2004–2022
    Yuki Nakahata, Takao Miwa, Akihiro Obora, Takao Kojima, Nobuaki Yagi, Masahito Shimizu
    Liver International.2025;[Epub]     CrossRef
  • The global landscape of lean metabolic dysfunction-associated steatotic liver disease: insight from Asia and the West
    Hery Djagat Purnomo, Randy Adiwinata, Cecilia Oktaria Permatadewi, Hesti Triwahyu Hutami, Didik Indiarso
    Frontiers in Gastroenterology.2025;[Epub]     CrossRef
  • Role of ChREBP–PPARα–FGF21 Axis in Metabolic Dysfunction of MASLD
    Karina Mireya Palacios Girón, Zamira Helena Hernandez Nazara, Montserrat Maldonado-González, Erika Martínez-López, Martha P. Sánchez Muñoz, Carlos Alfredo Bautista López, Ma. Soledad Aldana Aguiñaga, Jose Alfredo Dominguez-Rosales, Belinda Vargas-Guerrero
    International Journal of Molecular Sciences.2025; 26(23): 11425.     CrossRef
  • Implication of the Androgen Receptor in Muscle–Liver Crosstalk: An Overlooked Mechanistic Link in Lean-MASLD
    Eleni Myrto Trifylli, Christiana Charalambous, Nikolaos Spiliotopoulos, Nikolaos Papadopoulos, Anastasia Oikonomou, Spilios Manolakopoulos, Melanie Deutsch
    Livers.2025; 5(4): 65.     CrossRef
  • Intestinal NLRP3 Deficiency Exacerbates MASLD in Male Mice via Reduced Butyrate Production
    Li Chen, Jing Li, Hao Yu Jia, Chun Liu, Shan Shan Li, Feng Shang Zhu, Chang Qing Yang
    Journal of Digestive Diseases.2025;[Epub]     CrossRef
  • PNPLA3 as a driver of steatotic liver disease: navigating from pathobiology to the clinics via epidemiology
    Ralf Weiskirchen, Amedeo Lonardo
    Journal of Translational Genetics and Genomics.2024; 8(4): 355.     CrossRef
  • 12,524 View
  • 479 Download
  • 25 Web of Science
  • Crossref

Letters to the Editor

Steatotic liver disease

Citations

Citations to this article as recorded by  Crossref logo
  • MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort st
    Ying Wang, Shengfeng Wang, Xiude Fan, Jiajun Zhao, Yongfeng Song
    Clinical and Molecular Hepatology.2025; 31(2): e128.     CrossRef
  • 4,707 View
  • 87 Download
  • 1 Web of Science
  • Crossref

Hepatic neoplasm

Citations

Citations to this article as recorded by  Crossref logo
  • CXCL12 as a Potential Hub Gene for N-Acetylcysteine Treatment of T1DM Liver Disease
    Menglong Zhao, Mingzheng Han, Shuaihao Guo, Zhaoxin Tang
    Biomolecules.2025; 15(2): 176.     CrossRef
  • Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer
    Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip
    Alimentary Pharmacology & Therapeutics.2025;[Epub]     CrossRef
  • Prognostic Impact of DPP4 Inhibitors on Systemic Drug Therapy for Advanced Kidney Cancer Patients
    Shuhei Kamada, Sachi Kitayama, Ryosuke Yamase, Kazuhiro Ikeda, Wataru Sato, Tomokazu Sazuka, Hideki Takeshita, Shinichi Sakamoto, Akihiro Yano, Kuniko Horie, Tomohiko Ichikawa, Satoru Kawakami, Satoshi Inoue
    Cancer Science.2025;[Epub]     CrossRef
  • 4,514 View
  • 72 Download
  • 3 Web of Science
  • Crossref

Editorial

Steatotic liver disease

Citations

Citations to this article as recorded by  Crossref logo
  • Associations between systemic inflammatory biomarkers and metabolic dysfunction associated steatotic liver disease: a cross-sectional study of NHANES 2017–2020
    Xin Qiu, Shuang Shen, Nizhen Jiang, Yifei Feng, Guodong Yang, Donghong Lu
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Liver-related Events and Outcomes in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease Varies With the Type of Cardiometabolic Risk Factor
    Shekhar Swaroop, Sagnik Biswas, Shubham Mehta, Arnav Aggarwal, Umang Arora, Samagra Agarwal, Amitkumar Chavan, Baibaswata Nayak, Shalimar
    Journal of Clinical and Experimental Hepatology.2025; 15(5): 102559.     CrossRef
  • Shared genetic architecture between metabolic dysfunction-associated steatotic liver disease and cardiometabolic traits comorbidities: a genome-wide pleiotropic and multi-omics study
    Xuan-Yu Wang, Qiong Lyu, Yang-Yang Zhang, Yue Su, Hongjie Zhao, Hui-Hui Shen, Ying-Yu Xie
    Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
  • Association of advanced lung cancer inflammation index with all-cause and cardiovascular mortality in metabolic dysfunction associated steatotic liver disease
    Xin Qiu, Shuang Shen, Nizhen Jiang, Yifei Feng, Guodong Yang, Donghong Lu
    Scientific Reports.2025;[Epub]     CrossRef
  • Cardiometabolic dysfunction burden and mortality outcomes in metabolic dysfunction-associated steatotic liver disease
    Ying Wen, Yu Min, Yi Lei, Zhigong Wei, Sophia Eugenia Martínez-Vázquez
    PLOS One.2025; 20(7): e0327772.     CrossRef
  • Steatotic liver disease: radiological and ultrasound point of view
    Alexey V. Borsukov, Daria Yu. Shestakova
    Consilium Medicum.2025; 27(5): 296.     CrossRef
  • Phocaeicola dorei ameliorates progression of steatotic liver disease by regulating bile acid, lipid, inflammation and proliferation
    Jieun Choi, Ye Rin Choi, Min Kyo Jeong, Hyun Ho Song, Jeong Seok Yu, Seol Hui Song, Jeong Ha Park, Min Ju Kim, Hyunjoon Park, Young Lim Ham, Sang Hak Han, Dong Joon Kim, Do Yup Lee, Ki Tae Suk
    Gut Microbes.2025;[Epub]     CrossRef
  • Resolution of Metabolic Dysfunction Improves Liver Health Among Chinese Children: Evidence From Two Prospective Cohorts
    Lili Yang, Menglong Li, Min Zhao, Yifei Hu, Bo Xi
    Clinical Gastroenterology and Hepatology.2025;[Epub]     CrossRef
  • Correspondence on Letter regarding “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study”
    Hideki Fujii, Michihiro Iwaki, Yoshihiro Kamada
    Clinical and Molecular Hepatology.2024; 30(2): 281.     CrossRef
  • Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”
    Eileen Laurel Yoon, Dae Won Jun
    Clinical and Molecular Hepatology.2024; 30(4): 1033.     CrossRef
  • Evolving epidemiology of non-alcoholic fatty liver disease in South Korea: incidence, prevalence, progression, and healthcare implications from 2010 to 2022
    Jae Woo Park, Jeong-Ju Yoo, Dong Hyeon Lee, Young Chang, Hoongil Jo, Young Youn Cho, Sangheun Lee, Log Young Kim, Jae Young Jang
    The Korean Journal of Internal Medicine.2024; 39(6): 931.     CrossRef
  • 5,967 View
  • 110 Download
  • 9 Web of Science
  • Crossref

Original Articles

Viral hepatitis

Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study
Chang Hun Lee, Gwang Hyeon Choi, Hwa Young Choi, Sojung Han, Eun Sun Jang, Young Eun Chon, Young Chang, Kyung-Ah Kim, Do Young Kim, Hyung Joon Yim, Hye-Lin Kim, Sook-Hyang Jeong, In Hee Kim
Clin Mol Hepatol 2023;29(3):779-793.
Published online May 15, 2023
DOI: https://doi.org/10.3350/cmh.2023.0110
Background/Aims
To eliminate hepatitis B virus (HBV) and hepatitis C virus (HCV) according to the World Health Organization (WHO) criteria in 2021, this study investigated the national core indicators representing the current status of viral hepatitis B and C in South Korea.
Methods
We analyzed the incidence, linkage-to-care, treatment, and mortality rates of HBV and HCV infection using the integrated nationwide big data of South Korea.
Results
According to data from 2018–2020, the incidence of acute HBV infection in South Korea was 0.71 cases per 100,000 population; tthe linkage-to-care rate was only 39.4%. Among those who need hepatitis B treatment, the treatment rate was 67.3%, which was less than 80% reported in the WHO program index. The annual liver-related mortality due to HBV was 18.85 cases per 100,000 population, exceeding the WHO target of four; the most frequent cause of death was liver cancer (54.1%). The annual incidence of newly diagnosed HCV infection was 11.9 cases per 100,000 population, which was higher than the WHO impact target of five. Among HCV-infected patients, the linkage-to-care rate was 65.5% while the treatment rate was 56.8%, which were below the targets of 90% and 80%, respectively. The liver-related annual mortality rate due to HCV infection was 2.02 cases per 100,000 population.
Conclusions
Many of the current indicators identified in the Korean population did not satisfy the WHO criteria for validation of viral hepatitis elimination. Hence, a comprehensive national strategy should be urgently developed with continuous monitoring of the targets in South Korea.

Citations

Citations to this article as recorded by  Crossref logo
  • Implementation of an alert system for the care cascade of Hepatitis C infection in patients undergoing elective surgery
    Jae Seung Lee, Ho Soo Chun, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Journal of Infection and Public Health.2026; 19(2): 103076.     CrossRef
  • AI-Safe-C score: Assessing liver-related event risks in patients without cirrhosis after successful direct-acting antiviral treatment
    Huapeng Lin, Terry Cheuk-Fung Yip, Hye Won Lee, Xiangjun Meng, Jimmy Che-To Lai, Sang Hoon Ahn, Wenjing Pang, Grace Lai-Hung Wong, Lingfeng Zeng, Vincent Wai-Sun Wong, Victor de Lédinghen, Seung Up Kim
    Journal of Hepatology.2025; 82(3): 456.     CrossRef
  • Burden, trends, and predictions of liver cancer in China, Japan, and South Korea: analysis based on the Global Burden of Disease Study 2021
    Si Yang, Yujiao Deng, Yi Zheng, Jing Zhang, Dongdong He, Zhijun Dai, Changcun Guo
    Hepatology International.2025; 19(2): 441.     CrossRef
  • Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults
    Donghee Kim, Won Kim, Aijaz Ahmed
    Clinical and Molecular Hepatology.2025; 31(1): e5.     CrossRef
  • Etiologic, epidemic, medical and economic aspects of hepatocellular carcinoma
    N. A. Vlasova, V. I. Apanasevich, E. V. Eliseeva, S. S. Startsev
    Сибирский научный медицинский журнал.2025; 45(1): 6.     CrossRef
  • HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of dis
    Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn
    Clinical and Molecular Hepatology.2025; 31(2): e163.     CrossRef
  • Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiven
    Eun Sun Jang
    Clinical and Molecular Hepatology.2025; 31(2): 596.     CrossRef
  • Temporal and geospatial patterns of hepatitis C virus prevalence: a longitudinal examination using national health insurance service data in the Republic of Korea (2005–2022)
    Hwa Young Choi, Moran Ki
    BMC Public Health.2025;[Epub]     CrossRef
  • Correspondence to letter to the editor on “Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults”
    Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong
    Clinical and Molecular Hepatology.2025; 31(2): e149.     CrossRef
  • Incidence of Osteopenia or Osteoporosis in Asian Patients With Chronic Hepatitis B
    Hye Won Lee, Sungshin Kwon, Yeo Rae Moon, Hyunjung Ahn, Juyeon Lee, Sang‐Hoon Ahn
    Journal of Gastroenterology and Hepatology.2025; 40(6): 1586.     CrossRef
  • A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profiles
    Lindsey Hiebert-Suwondo, Jana Manning, Rania A Tohme, Maria Buti, Loreta A Kondili, C Wendy Spearman, Nishi Prabdial-Sing, Victoria Turnier, Jeffrey V Lazarus, Imam Waked, John W Ward, Angelica Miranda, Aya Sugiyama, Behzad Hajarizadeh, Carlos Varaldo, Ca
    The Lancet Gastroenterology & Hepatology.2025; 10(7): 671.     CrossRef
  • Service delivery models and care cascade outcomes for people living with chronic hepatitis B: a global systematic review and meta-analysis
    Alexander J Stockdale, Bethany Holt, Ajeet Singh Bhadoria, Abhishek Sadasivan, Daniel Ikeda, Todd Pollack, Janus P Ong, Thuy Pham, David B Duong, Vy Nguyen, Gibril Ndow, Roger Chou, Philippa Easterbrook
    The Lancet Gastroenterology & Hepatology.2025; 10(11): 1013.     CrossRef
  • Prevalence, Clinical Characteristics, and Treatment Status of Hepatitis C Virus Infection among People Who Use Drugs in South Korea: A Prospective Multicenter Study
    Gwang Hyeon Choi, Young-Hoon Chon, Do Hoon Kwon, Sung Nam Jo, Og-Jin Jang, Kyung-Ah Kim, Dahye Baik, Eun Sun Jang, Sook-Hyang Jeong
    Gut and Liver.2025; 19(5): 725.     CrossRef
  • Etiological, Epidemiological, and Medical-Economic Aspects of Hepatocellular Carcinoma (A Review)
    N. A. Vlasova, V. I. Apanasevich, E. V. Eliseeva, S. S. Startsev
    Cell and Tissue Biology.2025; 19(6): 525.     CrossRef
  • Monitoring and evaluation of community interventions for viral hepatitis among migrants and refugees: a Delphi-based study
    Domenico Pascucci, Aina Nicolàs, Abdelrahman Taha, Jeffrey V Lazarus, Matteo Di Pumpo, Vittoria Tricomi, Francesco Di Berardino, Carlo La Vecchia, José A Perez-Molina, Giuseppe Colucci, Camila A Picchio, Angelo Maria Pezzullo, Stefania Boccia
    Journal of Global Health.2025;[Epub]     CrossRef
  • Disease burden of chronic hepatitis B and C patients in South Korea: a population-based 16-year cohort study
    Oeuk Jeong, Changhee Chu, Jungyeon Kim, Jae Seung Lee, Jun Yong Park, Kyung Eun Lee, Jaehyun Seong, Min Jin Go
    BMC Infectious Diseases.2025;[Epub]     CrossRef
  • Effect of direct-acting antivirals on disease burden of hepatitis C virus infection in South Korea in 2007–2021: a nationwide, multicentre, retrospective cohort study
    Won Sohn, Soo Young Park, Tae Hee Lee, Young Eun Chon, In Hee Kim, Byung-Seok Lee, Ki Tae Yoon, Jae Young Jang, Yu Rim Lee, Su Jong Yu, Won-Mook Choi, Sang Gyune Kim, Dae Won Jun, Joonho Jeong, Ji Hoon Kim, Eun Sun Jang, Hwi Young Kim, Sung Bum Cho, Byoun
    eClinicalMedicine.2024; 73: 102671.     CrossRef
  • Linvencovir: Paving the way for functional cure in hepatitis B
    Jiwon Yang, Jonggi Choi
    Clinical and Molecular Hepatology.2024; 30(2): 164.     CrossRef
  • Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis
    Makiko Kimura, Tomoki Nishikawa, Tetsuro Shimakami, Takeshi Terashima, Rika Horii, Masako Fukuda, Mika Yoshita, Noboru Takata, Tomoyuki Hayashi, Masaya Funaki, Kouki Nio, Hajime Takatori, Kuniaki Arai, Tatsuya Yamashita, Masao Honda, Junko Tanaka, Shuichi
    Global Health & Medicine.2024; 6(6): 404.     CrossRef
  • Activation of Nrf2 and FXR via Natural Compounds in Liver Inflammatory Disease
    Marta Belka, Aleksandra Gostyńska-Stawna, Maciej Stawny, Violetta Krajka-Kuźniak
    International Journal of Molecular Sciences.2024; 25(20): 11213.     CrossRef
  • Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”
    Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong
    Clinical and Molecular Hepatology.2024; 30(4): 997.     CrossRef
  • Elimination of viral hepatitis: How far are we?: Editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”
    Eun Ju Cho
    Clinical and Molecular Hepatology.2024; 30(4): 663.     CrossRef
  • 9,489 View
  • 222 Download
  • 20 Web of Science
  • Crossref

Viral hepatitis

Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis
Yu Jun Wong, Vy H. Nguyen, Hwai-I Yang, Jie Li, Michael Huan Le, Wan-Jung Wu, Nicole Xinrong Han, Khi Yung Fong, Elizebeth Chen, Connie Wong, Fajuan Rui, Xiaoming Xu, Qi Xue, Xin Yu Hu, Wei Qiang Leow, George Boon-Bee Goh, Ramsey Cheung, Grace Wong, Vincent Wai-Sun Wong, Ming-Whei Yu, Mindie H. Nguyen
Clin Mol Hepatol 2023;29(3):705-720.
Published online May 8, 2023
DOI: https://doi.org/10.3350/cmh.2023.0004
Background/Aims
Chronic hepatitis B (CHB) and fatty liver (FL) often co-exist, but natural history data of this dual condition (CHB-FL) are sparse. Via a systematic review, conventional meta-analysis (MA) and individual patient-level data MA (IPDMA), we compared liver-related outcomes and mortality between CHB-FL and CHB-no FL patients.
Methods
We searched 4 databases from inception to December 2021 and pooled study-level estimates using a random- effects model for conventional MA. For IPDMA, we evaluated outcomes after balancing the two study groups with inverse probability treatment weighting (IPTW) on age, sex, cirrhosis, diabetes, ALT, HBeAg, HBV DNA, and antiviral treatment.
Results
We screened 2,157 articles and included 19 eligible studies (17,955 patients: 11,908 CHB-no FL; 6,047 CHB-FL) in conventional MA, which found severe heterogeneity (I2=88–95%) and no significant differences in HCC, cirrhosis, mortality, or HBsAg seroclearance incidence (P=0.27–0.93). IPDMA included 13,262 patients: 8,625 CHB-no FL and 4,637 CHB-FL patients who differed in several characteristics. The IPTW cohort included 6,955 CHB-no FL and 3,346 CHB-FL well-matched patients. CHB-FL patients (vs. CHB-no FL) had significantly lower HCC, cirrhosis, mortality and higher HBsAg seroclearance incidence (all p≤0.002), with consistent results in subgroups. CHB-FL diagnosed by liver biopsy had a higher 10-year cumulative HCC incidence than CHB-FL diagnosed with non-invasive methods (63.6% vs. 4.3%, p<0.0001).
Conclusions
IPDMA data with well-matched CHB patient groups showed that FL (vs. no FL) was associated with significantly lower HCC, cirrhosis, and mortality risk and higher HBsAg seroclearance probability.

Citations

Citations to this article as recorded by  Crossref logo
  • Impact of Non‐Alcoholic Fatty Liver Disease on the HBsAg Loss of Patients With Chronic Hepatitis B Treated in Pegylated Interferon Alpha
    Chujing Li, Lihua Lin, Pei Zhou, Haiyi Cai, Songlian Liu, Xiaoyuan Chen, Aiqi Lu, Bo Li, Yaping Wang, Chuanghua Luo, Jianping Li, Yujuan Guan, Zhiwei Xie
    Journal of Viral Hepatitis.2026;[Epub]     CrossRef
  • Association between deletions in the preS1/2 region of the hepatitis B virus genome and persistently abnormal ALT levels in patients with chronic hepatitis B treated with nucleos(t)ide analogs
    Yurina Sato, Kotaro Doi, Jun Inoue, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Masazumi Onuki, Satoko Sawahashi, Keishi Ouchi, Kengo Watanabe, Hirofumi Niitsuma, Atsushi Masamune
    Archives of Virology.2026;[Epub]     CrossRef
  • Risk stratification of metabolic dysfunction-associated steatotic liver disease: The KASL pathway: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease”
    May Xuan Goh, Xin En Goh, Jarell Jie-Rae Tan, Vincent L Chen, Yu Jun Wong
    Clinical and Molecular Hepatology.2026; 32(1): 429.     CrossRef
  • Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
    Shang-Chin Huang, Jia-Horng Kao
    Clinical and Molecular Hepatology.2026; 32(1): 423.     CrossRef
  • Diagnostic value of transient elastography in assessing the degree of liver fibrosis in chronic hepatitis B patients with low alanine aminotransferase levels and concomitant hepatic steatosis
    Aili Wang, Qingqing Wang, Huaie Liu
    Saudi Journal of Gastroenterology.2026;[Epub]     CrossRef
  • Obesity management for the hepatologist—What to do, how to do it and why?
    Kymberly D. Watt, Sonali Paul, Mohammad Qasim Khan, Mohammad Siddiqui, Jenny Lam, Tayyab S. Diwan, Michael Camilleri
    Hepatology.2025; 81(5): 1607.     CrossRef
  • Pre-Existing and New-Onset Metabolic Dysfunctions Increase Cirrhosis and Its Complication Risks in Chronic Hepatitis B
    Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Sih-Han Liao, Shih-Jer Hsu, Chun-Ming Hong, Ting-Yuan Lan, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao
    American Journal of Gastroenterology.2025; 120(2): 401.     CrossRef
  • Outcomes of radiofrequency ablation for hepatocellular carcinoma with concurrent steatotic liver disease
    Feng‐Pai Tsai, Tung‐Hung Su, Shang‐Chin Huang, Tai‐Chung Tseng, Shih‐Jer Hsu, Sih‐Han Liao, Chun‐Ming Hong, Chen‐Hua Liu, Hung‐Chih Yang, Chun‐Jen Liu, Pei‐Jer Chen, Jia‐Horng Kao
    Cancer.2025;[Epub]     CrossRef
  • Impact of age at HBsAg seroclearance on hepatic outcomes and life expectancy in men with chronic HBV infection based on multi-state modeling of the natural history
    Wen-Jie Liu, Wan-Jung Wu, Chih-Lin Lin, Chun-Jen Liu, Yi-Wen Huang, Jui-Ting Hu, Ming-Whei Yu
    Journal of Gastroenterology.2025; 60(1): 107.     CrossRef
  • All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease
    Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Shih-Jer Hsu, Chun-Ming Hong, Ting-Yuan Lan, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao
    Journal of Hepatology.2025; 83(1): 43.     CrossRef
  • The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: Main changes and potential implications for the next major liver society clinical practice guidelines
    Grace Lai-Hung Wong, Maud Lemoine
    Journal of Hepatology.2025; 82(5): 918.     CrossRef
  • The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
    Mohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, Vincent Wai-Sun Wong, Ian Homer Cua, Chun-Jen Liu, Tawesak Tanwandee, Rino Gani, Wai-Kay Seto, Shahinul Alam, Dan Yock Young, Saeed Hamid, Ming-Hua Zheng, Takumi Kawaguchi, Wah-Kheong Chan, Diana Payawal, Soek-S
    Hepatology International.2025; 19(2): 261.     CrossRef
  • SLC22A1 Resists Hepatitis B Virus by Activating the JAK/STAT Pathway and Predicts the Effect of Pegylated Interferon α–Based Therapy on Chronic Hepatitis B
    Huiying Yu, Bin Li, Huili Guo, Lin Li, Xiaoquan Liu, Lili Wu, Na Gao, Qiyi Zhao, Xiuqing Pang, Zhiliang Gao
    The Journal of Infectious Diseases.2025; 232(2): 474.     CrossRef
  • Impact of hepatic steatosis on mortality, hepatocellular carcinoma, end-stage liver disease and HBsAg seroclearance in chronic hepatitis B: a United States cohort study
    George A. Yendewa, Abbinaya Elangovan, Temitope Olasehinde, Frank Mulindwa, Mackenzie G. Cater, Robert A. Salata, Jeffrey M. Jacobson
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Cohort Profile: Taizhou Study of Liver Diseases (T-SOLID)
    Zhenqiu Liu, Yanfeng Jiang, Chen Suo, Huangbo Yuan, Ziyu Yuan, Tiejun Zhang, Li Jin, Xingdong Chen
    International Journal of Epidemiology.2025;[Epub]     CrossRef
  • Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study
    Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani
    Health Science Reports.2025;[Epub]     CrossRef
  • EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
    Markus Cornberg, Lisa Sandmann, Jerzy Jaroszewicz, Patrick Kennedy, Pietro Lampertico, Maud Lemoine, Sabela Lens, Barbara Testoni, Grace Lai-Hung Wong, Francesco Paolo Russo
    Journal of Hepatology.2025; 83(2): 502.     CrossRef
  • Increasing Treatment Uptake for Chronic Hepatitis B in South America: A Comparative Analysis of Country‐Specific and WHO 2024 Guidelines
    Manuel Mendizabal, Constanza D. Sabate, Esteban González Ballerga, Fernando Gruz, Ezequiel Ridruejo, Alejandro Soza, Jaime Poniachik, Grace Vergara, Victoria Mainardi, Gabriel Mezzano, Fernando Bessone, Margarita Anders, Mario G. Pessoa, Fernando Cairo, D
    Journal of Viral Hepatitis.2025;[Epub]     CrossRef
  • Differential HCC risk among HBV indeterminate types at baseline and by phase transition
    Rui Huang, Huy N Trinh, Satoshi Yasuda, Angela Chau, Mayumi Maeda, Ai-Thien Do, Daniel Q Huang, Takanori Ito, Takashi Honda, Masatoshi Ishigami, Ritsuzo Kozuka, Carmen Monica Preda, Cheng-Hao Tseng, Sebastián Marciano, Pei-Chien Tsai, Dong Hyun Lee, Chris
    Gut.2025; 74(11): 1873.     CrossRef
  • Impact of Metabolic Dysfunction-Associated Fatty Liver Disease of Varying Severity on Antiviral Treatment Outcomes and Clinical Prognosis in Patients with Chronic Hepatitis B: A Systematic Review and Meta-analysis
    Qianqian Zhu, Chengde Su, Mingdan Li, Yali Xu, Qian Liu, Ying Zhang, Xinyi Zhang, Qiuxiang Li, Huajun Wang, Yawen Luo, Ping Yang
    Infectious Diseases and Therapy.2025; 14(8): 1599.     CrossRef
  • Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues
    Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Ats
    Clinical and Molecular Hepatology.2025; 31(3): 1003.     CrossRef
  • Steatotic Liver Disease‐Related Polygenetic Risk Score Prediction of Hepatocellular Carcinoma in Nucleotide/Nucleoside Analog‐Treated Chronic Hepatitis B
    Tyng‐Yuan Jang, Chih‐Wen Wang, Po‐Cheng Liang, Yu‐Ju Wei, Ming‐Lun Yeh, Yi‐Hung Lin, Chao‐Kuan Huang, Pei‐Chien Tsai, Yu‐Min Ko, Yi‐Shan Tsai, Kuan‐Yu Chen, Ching‐Chih Lin, Zu‐Yau Lin, Jee‐Fu Huang, Chia‐Yen Dai, Chung‐Feng Huang, Wan‐Long Chuang, Ming‐Lu
    Journal of Gastroenterology and Hepatology.2025; 40(9): 2290.     CrossRef
  • Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis
    Jie Li, Liang Xu, Fajuan Rui, Sally Tran, Pei-Chien Tsai, Youwen Tan, Hidenori Toyoda, Qing-Lei Zeng, Huy Trinh, Yao-Chun Hsu, Tsunamasa Watanabe, Hiroshi Abe, Hiroyuki Motoyama, Yoko Yoshimaru, Takanori Suzuki, Taeang Arai, Masanori Atsukawa, Phillip Vut
    Hepatology.2025;[Epub]     CrossRef
  • Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study
    Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Ats
    eClinicalMedicine.2025; 87: 103407.     CrossRef
  • Prediction of Hepatocellular Carcinoma and Other Liver‐Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction‐Associated Steatotic Liver Disease
    Lesley A. Patmore, Ivana Carey, Jordan J. Feld, Willem P. Brouwer, Keyur Patel, Maria Buti, Pieter Honkoop, Douwe F. Postma, Hans Blokzijl, Özgur. M. Koc, Eva van Oorschot, Kosh Agarwal, Marc van der Valk, Faydra I. Lieveld, Mai Kilany, Matthijs Kramer, J
    Alimentary Pharmacology & Therapeutics.2025;[Epub]     CrossRef
  • Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy
    Yu Jun Wong
    Alimentary Pharmacology & Therapeutics.2025;[Epub]     CrossRef
  • Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis
    Frances Sze Kei Sun, Jeffrey Sum Lung Wong, Lung-Yi Mak, Carmen Chak-Lui Wong, Valerie Chew, Bryan Cho Wing Li, Roland Leung, Tan To Cheung, Thomas Yau
    Liver Cancer.2025; : 1.     CrossRef
  • Impact of fatty liver disease on hepatic function and fibrosis progression in chronic hepatitis B patients: a narrative review
    Rushi V. Mukkawar, Nishant Rathod, Rajvardhan Patil, Sunil Kumar, Sourya Acharya
    International Journal of Nutrition, Pharmacology, Neurological Diseases.2025; 15(4): 368.     CrossRef
  • Association Between SGLT2 Inhibitor Use and Reduced Risk of Liver-Related Events, Including Hepatocellular Carcinoma, in Diabetic Patients with Viral Hepatitis: A Nationwide Cohort Study
    Seong Hee Kang, Jimi Choi, Hyung Joon Yim, Young Kul Jung, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun
    Cancers.2025; 18(1): 120.     CrossRef
  • Chronic Hepatitis B and Steatotic Liver Disease: A Blessing in Disguise?
    Xiaoming Xu, Mindie H. Nguyen, Jie Li
    Clinical Gastroenterology and Hepatology.2024; 22(9): 1956.     CrossRef
  • Liver function indicators and risk of hepatocellular carcinoma: a bidirectional mendelian randomization study
    Shanshan Qin, Jing Wang, Haiqing Yuan, Jingzhen He, Shoujing Luan, Yan Deng
    Frontiers in Genetics.2024;[Epub]     CrossRef
  • The co-existence of NAFLD and CHB is associated with suboptimal viral and biochemical response to CHB antiviral therapy: a systematic review and meta-analysis
    Georgia Zeng, Benjamin R. Holmes, Saleh A. Alqahtani, Upkar S. Gill, Patrick T. F. Kennedy
    Frontiers in Gastroenterology.2024;[Epub]     CrossRef
  • Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond
    Allison Soto, Colby Spongberg, Alessandro Martinino, Francesco Giovinazzo
    Biomedicines.2024; 12(2): 397.     CrossRef
  • Impact of chronic hepatitis B and concurrent steatosis on the risk of hepatocellular carcinoma
    Ibrahim Ayada, Jiajing Li, Willem Pieter Brouwer, Robert J. de Knegt, Qiuwei Pan
    Hepatology International.2024; 18(3): 1053.     CrossRef
  • Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study
    Tyng‐Yuan Jang, Po‐Cheng Liang, Dae Won Jun, Jang Han Jung, Hidenori Toyoda, Chih‐Wen Wang, Man‐Fung Yuen, Ka Shing Cheung, Satoshi Yasuda, Sung Eun Kim, Eileen L Yoon, Jihyun An, Masaru Enomoto, Ritsuzo Kozuka, Makoto Chuma, Akito Nozaki, Toru Ishikawa,
    Journal of Gastroenterology and Hepatology.2024; 39(6): 1190.     CrossRef
  • Impact of metabolic disorders on chronic hepatitis B
    Shang-Chin Huang, Chun-Jen Liu, Jia-Horng Kao
    Clinical Liver Disease.2024;[Epub]     CrossRef
  • Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta‐analysis
    Fajuan Rui, Elizabeth Garcia, Xinyu Hu, Wenjing Ni, Qi Xue, Yayun Xu, Xiaoming Xu, Junping Shi, Mindie H. Nguyen, Ramsey C. Cheung, Jie Li
    Journal of Viral Hepatitis.2024; 31(7): 372.     CrossRef
  • Inpatient Cost Burdens of Treating Chronic Hepatitis B in US Hospitals: A Weighted Analysis of a National Database
    David Uihwan Lee, Kuntal Bhowmick, Sindhura Kolachana, Kimberly Schuster, Aneesh Bahadur, Ashton Harmacinski, Sophie Schellhammer, Gregory Hongyuan Fan, Ki Jung Lee, Catherine Sun, Hannah Chou, Zurabi Lominadze
    Digestive Diseases and Sciences.2024; 69(7): 2401.     CrossRef
  • Hepatocellular carcinoma surveillance after HBsAg seroclearance
    Jimmy Che-To Lai, Vicki Wing-Ki Hui, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
    Exploration of Digestive Diseases.2024; : 175.     CrossRef
  • Liver health in hemophilia in the era of gene therapy
    Yesim Dargaud, Massimo Levrero, François Bailly, Anne Lienhart, Fabien Zoulim
    Thrombosis Research.2024; 240: 109064.     CrossRef
  • Global epidemiology, natural history, maternal-to-child transmission, and treatment with DAA of pregnant women with HCV: a systematic review and meta-analysis
    Joo Wei Ethan Quek, Jing Hong Loo, En Qi Lim, Ambrose Hon-Lam Chung, Abu Bakar Bin Othman, Jarell Jie-Rae Tan, Scott Barnett, Mindie H. Nguyen, Yu Jun Wong
    eClinicalMedicine.2024; 74: 102727.     CrossRef
  • Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD
    Chun-Jen Liu, Wai Kay Seto, Ming-Lung Yu
    Hepatology International.2024; 18(S2): 897.     CrossRef
  • Canadian Association for the Study of the Liver Single Topic Conference on Hepatitis B Virus: ‘Progress toward hepatitis B elimination in Canada’
    Julian Hercun, Golasa Samadi Kochaksaraei, Simmone D'souza, Rachel Talavlikar, Jennifer Van Gennip, Carla Osiowy, Carla S Coffin, Harley Crowshoe
    Canadian Liver Journal.2024; 7(3): 385.     CrossRef
  • Chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease: Metabolic risk factors are key drivers of hepatocellular carcinoma
    Gupse Adali, Huseyin Aykut, Nermin Mutlu Bilgic, Yusuf Yilmaz
    Heliyon.2024; 10(18): e37990.     CrossRef
  • Influence of nonalcoholic fatty liver disease on the therapeutic effect of nucleoside (acid) analogs for hepatitis B virus
    Hua-Dong Li, Ya-Nan Liu, Shuang Wu, Xu-Feng Quan, Xiao-Yan Wang, Tian-Dan Xiang, Shu-Meng Li, Ling Xu, Tong Wang, Hua Wang, Xin Zheng
    World Journal of Hepatology.2024; 16(12): 1395.     CrossRef
  • Revolutionizing the understanding of liver disease: Metabolism, function and future
    Arnulfo E Morales-Galicia, Mariana M Ramírez-Mejía, Guadalupe Ponciano-Rodriguez, Nahum Méndez-Sánchez
    World Journal of Hepatology.2024; 16(12): 1365.     CrossRef
  • The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B
    Xianhua Mao, Lung Yi Mak, Wai-Kay Seto
    Clinical and Molecular Hepatology.2023; 29(3): 690.     CrossRef
  • Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease
    Yajing You, Tao Yang, Shuhang Wei, Zongxin Liu, Chenxi Liu, Zijian Shen, Yinuo Yang, Yuemin Feng, Ping Yao, Qiang Zhu
    Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 2283.     CrossRef
  • From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
    Ming-Lun Yeh, Ming-Lung Yu
    Clinical and Molecular Hepatology.2023; 29(4): 969.     CrossRef
  • Persistent steatosis correlates with decreased fibrosis regression during anti‐HBV treatment in patients with chronic HBV infection
    Mengyang Zhang, Shuyan Chen, Xiaoning Wu, Jialing Zhou, Tailing Wang, Hui Liu, Xinyan Zhao, Bingqiong Wang, Xinyu Zhao, Yuanyuan Kong, Gwyneth Shook Ting Soon, Xiaojuan Ou, Jidong Jia, Wei Chen, Yameng Sun, Hong You
    Journal of Medical Virology.2023;[Epub]     CrossRef
  • Waiting for the changes after the adoption of steatotic liver disease
    Eileen L. Yoon, Dae Won Jun
    Clinical and Molecular Hepatology.2023; 29(4): 844.     CrossRef
  • 12,305 View
  • 383 Download
  • 45 Web of Science
  • Crossref

Editorials

Steatotic liver disease

Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
Ho Soo Chun, Minjong Lee
Clin Mol Hepatol 2023;29(2):377-380.
Published online March 9, 2023
DOI: https://doi.org/10.3350/cmh.2023.0061

Citations

Citations to this article as recorded by  Crossref logo
  • Cross-ancestry discovery of genetic risk variants for lean metabolic dysfunction-associated steatotic liver disease
    Shan-Wei Hsu, Min-Rou Lin, Wan-Hsuan Chou, Yu-Jui Yvonne Wan, Wei-Yu Kao, Wei-Chiao Chang
    Cell & Bioscience.2025;[Epub]     CrossRef
  • Research trends on the quality of life in patients with metabolic dysfunction-associated fatty liver diseases: a scientific metrology study
    Can Huang, Meng Chen, Yanfang Sun, Lin Zhang, Wei Liu
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Beyond the liver: targeting the hepatic microenvironment and multi-organ networks for innovative MASH therapy
    Rong Fu, Fuyuan Zhang, Jingran Fu, Yuqian Li, Xuanzhe Zhu, Qian Ding, Yi-Zhun Zhu
    Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
  • Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?
    Eugene Han, Yong-ho Lee
    Clinical and Molecular Hepatology.2023; 29(4): 980.     CrossRef
  • 7,906 View
  • 125 Download
  • 4 Web of Science
  • Crossref

Steatotic liver disease

The growing burden of non-alcoholic fatty liver disease on mortality
Ju-Yeon Cho, Won Sohn
Clin Mol Hepatol 2023;29(2):374-376.
Published online March 6, 2023
DOI: https://doi.org/10.3350/cmh.2023.0084

Citations

Citations to this article as recorded by  Crossref logo
  • A landscape of liver cirrhosis and transplantation in Mexico: Changing leading causes and transplant as response
    Icela Palma-Lara, María Guadalupe Ortiz-López, José Bonilla-Delgado, Juanita Pérez-Escobar, Ricardo Godínez-Aguilar, Claudia Luévano-Contreras, Ana María Espinosa-García, Javier Pérez-Durán, Patricia García Alonso-Themann, Manuel Nolasco-Quiroga, Javier F
    Annals of Hepatology.2025; 30(1): 101562.     CrossRef
  • Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fib
    Won Sohn
    Clinical and Molecular Hepatology.2025; 31(1): 277.     CrossRef
  • Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease
    Klaudia Nowak, Krzysztof Łupina, Anna Romac, Aleksandra Kalisz, Łucja Ilkiewicz, Jakub Janczura
    Annals of Pharmacotherapy.2025; 59(10): 928.     CrossRef
  • Hepatoprotective activity of mulberry extract in NAFLD mice for regulating lipid metabolism and inflammation identified via AMPK/PPAR-γ/NF-κB axis
    Li-juan Zhang, Shun-ying Li, Shao-li Fan, Aobulikasimu nuerbiye, Jiu-yang Zhao, Bahetiyaer Keremu, Lu Yang, Ke Zhang, Hang-yu Wang, Jin-hui Wang
    Journal of Ethnopharmacology.2025; 351: 120108.     CrossRef
  • Non-alcoholic fatty liver disease versus cirrhosis in rotator cuff repair: Differential risks and complication profiles in a matched national cohort
    Catherine Hand, Jared Sasaki, Camden Bohn, Francis Hand, Kyleen Jan, Daniel Shinn, Brian Forsythe
    Journal of Orthopaedics.2025; 69: 244.     CrossRef
  • A New Korean Nomenclature for Steatotic Liver Disease

    The Korean Journal of Medicine.2024; 99(4): 189.     CrossRef
  • A New Korean Nomenclature for Steatotic Liver Disease

    The Korean Journal of Gastroenterology.2024; 84(1): 1.     CrossRef
  • A New Korean Nomenclature for Steatotic Liver Disease

    Gut and Liver.2024; 18(5): 924.     CrossRef
  • A new Korean nomenclature for steatotic liver disease

    Clinical and Molecular Hepatology.2024; 30(Suppl): S214.     CrossRef
  • 7,328 View
  • 82 Download
  • 8 Web of Science
  • Crossref

Original Articles

Hepatic neoplasm

Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study
Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith
Clin Mol Hepatol 2023;29(2):433-452.
Published online January 4, 2023
DOI: https://doi.org/10.3350/cmh.2022.0316
Background/Aims
Global distribution of dominant liver cancer aetiologies has significantly changed over the past decades. This study analyzed the updated temporal trends of liver cancer aetiologies and sociodemographic status in 204 countries and territories from 1990 to 2019.
Methods
The Global Burden of Disease 2019 report was used for statistical analysis. In addition, we performed stratification analysis to five quintiles using sociodemographic index and 21 geographic regions.
Results
The crude numbers of liver cancer disease-adjusted life years (DALYs) and deaths significantly increased during the study period (DALYs; 11,278,630 in 1990 and 12,528,422 in 2019, deaths; 365,215 in 1990 and 484,577 in 2019). However, the Age-standardized DALY and mortality rates decreased. Hepatitis B virus (HBV) remains the leading cause of liver cancer DALYs and mortality, followed by hepatitis C virus (HCV), alcohol consumption, and non-alcoholic steatohepatitis/non-alcoholic fatty liver disease (NASH/NAFLD). Although Age-standardized DALY and mortality rates of liver cancer due to HBV and HCV have decreased, the rates due to alcohol consumption and NASH/NAFLD have increased. In 2019, the population of the East Asia region had the highest Age-standardized DALY and mortality rates, followed by high-income Asia-Pacific and Central Asia populations. Although East Asia and high-income Asia-Pacific regions showed a decrease during the study period, Age-standardized DALY rates increased in Central Asia. High-income North American and Australasian populations also showed a significant increase in Age-standardized DALY.
Conclusions
Liver cancer remains an ongoing global threat. The burden of liver cancer associated with alcohol consumption and NASH/NAFLD is markedly increasing and projected to continuously increase.

Citations

Citations to this article as recorded by  Crossref logo
  • Implementation of an alert system for the care cascade of Hepatitis C infection in patients undergoing elective surgery
    Jae Seung Lee, Ho Soo Chun, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Journal of Infection and Public Health.2026; 19(2): 103076.     CrossRef
  • In vitro β-catenin attenuation by a mefloquine-loaded core–shell nano emulsion strategy to suppress liver cancer cells
    Priyadarshini Mohapatra, Natarajan Chandrasekaran
    Nanoscale Advances.2025; 7(3): 748.     CrossRef
  • Epidemiological trends in gastrointestinal cancers and risk factors across U.S. states from 2000 to 2021: a systematic analysis for the global burden of disease study 2021
    Jiahao Jiang, Zhiqin Xie, Qingbin Wang, Bingkun Wang, Rong Huang, Weikai Xu, Changzhen Shang, Yajin Chen
    BMC Public Health.2025;[Epub]     CrossRef
  • Regional Variations in the Prevalence of Risk Factors and Non-Communicable Diseases in Papua New Guinea: A Scoping Review
    Bobby Porykali, Ryley Gronau, Phyllis Tran, Juliana Chen, Margaret Allman-Farinelli, Anna Rangan, Shelina Porykali, Robin Oge, Hans Nogua, Alyse Davies
    International Journal of Environmental Research and Public Health.2025; 22(1): 102.     CrossRef
  • Burden, trends, and predictions of liver cancer in China, Japan, and South Korea: analysis based on the Global Burden of Disease Study 2021
    Si Yang, Yujiao Deng, Yi Zheng, Jing Zhang, Dongdong He, Zhijun Dai, Changcun Guo
    Hepatology International.2025; 19(2): 441.     CrossRef
  • Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study
    Edison Xu, Parissa Tabrizian, Julio Gutierrez, Maarouf Hoteit, Tara Ghaziani, Kali Zhou, Neehar Parikh, Veeral Ajmera, Elizabeth Aby, Amy Shui, Rebecca Marino, Allison Martin, Christopher Wong, Karissa Kao, Shravan Dave, Sander Florman, Francis Yao, Neil
    Hepatology.2025; 82(3): 612.     CrossRef
  • Global, regional and country burden of high BMI-related liver cancer among individuals aged above 70: trends from 1990 to 2021 and projections to 2044
    Ke-Jie He, Wanyi Shu, Yanggang Hong
    Frontiers in Public Health.2025;[Epub]     CrossRef
  • Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
    Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang
    Clinical and Molecular Hepatology.2025; 31(Suppl): S228.     CrossRef
  • Hepatitis B surface antigen: carcinogenesis mechanisms and clinical implications in hepatocellular carcinoma
    Bingyan Hao, Yachong Liu, Bohan Wang, Haofeng Wu, Yan Chen, Lei Zhang
    Experimental Hematology & Oncology.2025;[Epub]     CrossRef
  • Systems pharmacology of phytochemical anacardic acid in the chemoprevention of hepatocellular carcinoma
    Sangita Panda, Enketeswara Subudhi, Sweta Padma Routray, Sujit Nair
    Drug Metabolism and Personalized Therapy.2025; 40(2): 107.     CrossRef
  • Mediational role of metabolic syndrome between physical activity, sedentary behavior and non-alcoholic fatty liver disease: a cross-sectional study
    Zhaoyu Ren, Hongxuan Fan, Yaya Xue, Xinyu Yang, Xuchang Liu, Jing Luo, Jianqi Zhao, Leigang Wang, Yao Zhang, Bin Liang
    BMC Public Health.2025;[Epub]     CrossRef
  • Effectiveness of herbal medicine for liver cancer treatment as revealed by a bibliometric and visualization analysis
    Yusha Shi, Juwei Wang, Yahui Zhang, Kai Wu, Yibo Zhu, Kaiwen Yan, Qin Ouyang
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • The spatio-temporal trends and determinants of liver cancer attributable to specific etiologies: a systematic analysis from the Global Burden of Disease Study 2021
    Jinli Liu, Tingling Xu, Yanan Wang, Fanpu Ji, Lei Zhang
    Global Health Research and Policy.2025;[Epub]     CrossRef
  • Targeting super-enhancers in liver cancer: from pathogenic mechanisms to clinical applications
    Chang-Lei Li, Zhi-Yuan Yao, Ao Sun, Jing-Yu Cao, Zu-Sen Wang
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • The CRP–albumin–lymphocyte index provides enhanced prognostic value in liver cancer compared to the TNM staging system
    Hong Zhao, Bing Yin, Xiang-Rui Li, Xiao-Yue Liu, Zhao-Ting Bu, Han-Ping Shi
    Scientific Reports.2025;[Epub]     CrossRef
  • Dynamic changes of serum cytokines and their prognostic values in patients with hepatocellular carcinoma treated by thermal ablation
    Kelvin K. C. Ng, Charing C. N. Chong, Chun‐Kwok Wong, Nathalie Wong
    Surgical Practice.2025; 29(3): 154.     CrossRef
  • Liver‐specific lncRNAs associated with liver cancers
    Olga Y. Burenina, Roman K. Makarchenko, Maria P. Rubtsova, Olga A. Dontsova
    FEBS Open Bio.2025; 15(9): 1383.     CrossRef
  • Global trends and heterogeneity in the burden of brain and central nervous system cancers among children and adolescents: An analysis based on GBD 2021 data
    Libo Xu, Zhenhao Wang, Qingsong Li
    Journal of Clinical Neuroscience.2025; 139: 111452.     CrossRef
  • Epidemiological Trends and Projection of Liver Cancer Due to Nonalcoholic Steatohepatitis Among People Aged 55 Years and Older in China From 1990 to 2030: An Analysis of the Global Burden of Disease Study 2021
    Xi Yang, Xiaodan Yin, Huiqi Wu, Qiaomei Li, Yang Shen
    Clinical and Translational Gastroenterology.2025; 16(8): e00872.     CrossRef
  • Global, regional, and national burden of liver cancer due to hepatitis B, 1990–2021 and projections to 2051: a systematic analysis of the Global Burden of Disease Study 2021
    Peipei Yang, Wenjie Huang, Yuanyuan Xu, Qiurong Li, Xinyan Shu, Jiaqian Zuo, Wenqin Ren, Yujie Huang, Yuhao Teng, Peng Shu
    European Journal of Gastroenterology & Hepatology.2025;[Epub]     CrossRef
  • Epidemiology of liver cancer in Kazakhstan: data from the Unified National Electronic Health System, 2014–2023
    Ayana Ablayeva, Dmitriy Syssoyev, Ruslan Akhmedullin, Altynay Beyembetova, Diyora Abdukhakimova, Temirgali Aimyshev, Iliyar Arupzhanov, Gulnur Zhakhina, Aigerim Biniyazova, Temirlan Seyil, Nurbek Igissin, Yuliya Semenova, Abduzhappar Gaipov, Ali Faramarzi
    PLOS One.2025; 20(8): e0330423.     CrossRef
  • Exploration of the Mechanism of Action of Dendrobium officinale in the Treatment of Liver Cancer Based on Network Pharmacology, Molecular Docking and in vitro Validation
    Shuimeng Zhan, Xinyan Lu, Hongyan Guo, Yang Liu, Zhi Li, Wei Xu, Fang Xia, Huanjun Tang, Yi Tian, Jing Chen, Xuan Lin
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 1973.     CrossRef
  • Translational Potential of Surface Engineered Extracellular Vesicles as Theranostic Nanocarriers in Cancer Management: Recent Developments from Bench to Bedside
    Ravindra Vasave, Rohit Bhawale, Omar Khan, Ekta Pardhi, Naveen Rajana, Nalla Usha Kumari, Padakanti Sandeep Chary, Neelesh Kumar Mehra
    ACS Applied Bio Materials.2025; 8(8): 6647.     CrossRef
  • Novel Therapeutics for Hepatocellular Carcinoma
    Mohamed I. Elsaid, Ashish Manne
    Clinics in Liver Disease.2025; 29(4): 673.     CrossRef
  • The global epidemiology of gastrointestinal cancers attributable to high-BMI: findings from the Global Burden of Disease Study 2021
    Laiang Yao, Tao Ji, Hailian Mu, Xiangming Xu
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis
    Brian Lee, Ussama Ghumman, Lisa D. Pedicone, Andres Gomez Aldana, Eric Lawitz
    Clinical and Molecular Hepatology.2025; 31(4): 1167.     CrossRef
  • The economic ramifications of liver cancer on a global, regional, and national scale
    Jie Yu, Qiaoyi Chen, Jin Ma
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Ficus pandurata as a Functional Phytotherapeutic: Inhibiting JAK2/STAT3 Signaling and Activating Mitochondrial Apoptosis in Hepatocellular Carcinoma
    Muhammad Majid, Bing Tang, Yingyao Lai, Xiaoyan Pang, Yongdui Ruan, Hui Shi, Weiwen Peng, Weibo Dai, Xianjing Hu
    Food Science & Nutrition.2025;[Epub]     CrossRef
  • Epidemiological trends and age–period–cohort analysis of alcoholic liver cancer from 1990 to 2021
    Jiajia Chen, Runhua Li, Xiaojie Li, Kai Shi, Rui Zeng, Kunpeng Hu, Qingliang Wang
    Hepatology International.2025;[Epub]     CrossRef
  • Mangiferin: a novel hepatoprotective for liver cirrhosis via modulation of histological, cellular, biochemical, inflammatory markers and oxidative stress
    Khaled Abdul-Aziz Ahmed, Suhayla Hamad Shareef, Haween Toufiq Nanakaly, Mohammed A. Ali, Derin Nabaz Fisal, Peshawa Yunis Aziz, Nabaz Fisal Shakir Agha, Mahmood Ameen Abdulla, Ahmed A. Salman
    BMC Pharmacology and Toxicology.2025;[Epub]     CrossRef
  • The Epidemiology of Hepatitis B Virus Infection in Korea: 15-Year Analysis
    Log Young Kim, Jeong-Ju Yoo, Young Chang, Hoongil Jo, Young Youn Cho, Sangheun Lee, Dong Hyeon Lee, Jae Young Jang
    Journal of Korean Medical Science.2024;[Epub]     CrossRef
  • Investigating Alternative Treatment Options Unfeasible for Local Ablation Therapy in Patients with Small Solitary Hepatocellular Carcinomas
    Chang Hun Lee, In Hee Kim
    Gut and Liver.2024; 18(1): 5.     CrossRef
  • Hepatitis B Virus Elimination Strategies
    Mimi Xu, Norah A. Terrault
    Current Hepatology Reports.2024; 23(2): 268.     CrossRef
  • Role of Imaging in Screening for Hepatocellular Carcinoma
    Irfan A. Kazi, Vinay Jahagirdar, Bareen W. Kabir, Almaan K. Syed, Asad W. Kabir, Abhilash Perisetti
    Cancers.2024; 16(19): 3400.     CrossRef
  • The HHEX-ABI2/SLC17A9 axis induces cancer stem cell-like properties and tumorigenesis in HCC
    Huizi Li, Jin Liu, Jie Lai, Xinyao Su, Xiaofeng Wang, Jiaqing Cao, Shengxun Mao, Tong Zhang, Qiuping Gu
    Journal of Translational Medicine.2024;[Epub]     CrossRef
  • Impact of drug dispersion on tumor-effector dynamics during combined chemo-immunotherapy with sensitivity analysis
    Lazaro Revocatus Mashiku, Joseph Protas Ndenda, Reuben Maghembe, Sachin Shaw
    Applied Mathematical Modelling.2024; 134: 148.     CrossRef
  • Inflammation as a pathway for heavy metal-induced liver damage—Insights from a repeated-measures study in residents exposed to metals and bioinformatics analysis
    Shuanzheng Zhao, Guohuan Yin, Meiduo Zhao, Jingtao Wu, Xiaolin Liu, Lanping Wei, Qun Xu, Jing Xu
    International Journal of Hygiene and Environmental Health.2024; 261: 114417.     CrossRef
  • Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients
    Maria Eva Argenziano, Mi Na Kim, Michele Montori, Alessandro Di Bucchianico, Daniele Balducci, Sang Hoon Ahn, Gianluca Svegliati Baroni
    Hepatology International.2024; 18(S2): 922.     CrossRef
  • An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences
    Roaa Khalil, Kholoud Al-Mahzoum, Muna Barakat, Malik Sallam
    Pathogens.2024; 13(8): 674.     CrossRef
  • Burden of alcohol use disorder and its consequences in Iran from 1990 to 2019: Findings from the global burden of disease study
    Khashayar Danandeh, Pegah Rasoulian, Homa Seyedmirzaei, Behnaz Mahmoudvand, Behnood Avand Amini, Fatemeh Samadian, Golnaz Ranjbar Pazuki, Amir Hossein Memari, Amin Nakhostin-Ansari
    Preventive Medicine Reports.2024; 46: 102872.     CrossRef
  • Correlation with Apoptosis Process through RNA-Seq Data Analysis of Hep3B Hepatocellular Carcinoma Cells Treated with Glehnia littoralis Extract (GLE)
    Min-Yeong Park, Sujin Lee, Hun-Hwan Kim, Se-Hyo Jeong, Abuyaseer Abusaliya, Pritam Bhangwan Bhosale, Je-Kyung Seong, Kwang-Il Park, Jeong-Doo Heo, Meejung Ahn, Hyun-Wook Kim, Gon-Sup Kim
    International Journal of Molecular Sciences.2024; 25(17): 9462.     CrossRef
  • Global epidemiology of liver cancer 2022: An emphasis on geographic disparities
    Qianru Li, Chao Ding, Maomao Cao, Fan Yang, Xinxin Yan, Siyi He, Mengdi Cao, Shaoli Zhang, Yi Teng, Nuopei Tan, Jiachen Wang, Changfa Xia, Wanqing Chen
    Chinese Medical Journal.2024; 137(19): 2334.     CrossRef
  • Liver Cancer and Risk Factors in the MENA Region: Epidemiology and Temporal Trends Based on the 2019 Global Burden of Disease Data
    Najla A. Lakkis, Nour M. Mokalled, Mona H. Osman, Umayya M. Musharrafieh, Mohammad Eljammal
    Cancer Control.2024;[Epub]     CrossRef
  • Liver Cancer Etiology: Old Issues and New Perspectives
    Jian-Guo Chen, Yong-Hui Zhang, Jian-Hua Lu, Thomas W. Kensler
    Current Oncology Reports.2024; 26(11): 1452.     CrossRef
  • Neighborhood opportunity is associated with completion of hepatocellular carcinoma surveillance prior to the diagnosis of hepatocellular carcinoma in patients with cirrhosis
    Joanna Jiang, Erin Bouquet, Yesung Kweon, Mohamed I. Elsaid, Dayssy A. Diaz, Lanla Conteh, Lindsay A. Sobotka
    Clinics and Research in Hepatology and Gastroenterology.2024; 48(10): 102485.     CrossRef
  • Incorporating ALBI Grade with Geriatric Nutritional Risk Index Enhances Hepatocellular Carcinoma Risk Stratification
    Heechul Nam, Pil Soo Sung, Sung Won Lee, Do Seon Song, Jung Hyun Kwon, Jeong Won Jang, Chang Wook Kim, Si Hyun Bae
    Liver Cancer.2024; : 1.     CrossRef
  • The Evolving Landscape of Hepatocellular Carcinoma Mortality in the US
    Emad Qayed
    JAMA Network Open.2024; 7(11): e2445533.     CrossRef
  • Phytochemical Profiling, Acute Toxicity, and Hepatoprotective Effects of Anchusa Limbata in Thioacetamide‐Induced Liver Cirrhosis in Rats
    Khaled Abdul‐Aziz Ahmed, Ahmed A. J. Jabbar, Mohammed M. Hussein M. Raouf, Ayman M. Al‐Qaaneh, Rawaz Rizgar Hassan, Musher Ismael Salih, Ramzi A. Mothana, Gadah Abdulaziz Al‐Hamoud, Mahmood Ameen Abdulla, Sidgi Hasson, Parween Abdul‐samad Ismail
    Food Science & Nutrition.2024; 12(12): 10628.     CrossRef
  • Withdrawn: Acute Rejection was Observed in a Combination Therapy of CTLA-4 and PD-1 Inhibitors Before Liver Transplantation: A Case Report and Literature Review
    Pengpeng Zhang, Tianyin Wang, Hong Liu, Xingguo She, Ke Chen, Yujun Zhao, Yingzi Ming
    iLIVER.2023;[Epub]     CrossRef
  • The latest global burden of liver cancer: A past and present threat
    Joo Hyun Oh, Dae Won Jun
    Clinical and Molecular Hepatology.2023; 29(2): 355.     CrossRef
  • The current trends in the health burden of primary liver cancer across the globe
    Peter Konyn, Aijaz Ahmed, Donghee Kim
    Clinical and Molecular Hepatology.2023; 29(2): 358.     CrossRef
  • Global trajectories of liver cancer burden from 1990 to 2019 and projection to 2035
    Fan Yang, Dianqin Sun, Changfa Xia, He Li, Maomao Cao, Xinxin Yan, Siyi He, Shaoli Zhang, Wanqing Chen
    Chinese Medical Journal.2023; 136(12): 1413.     CrossRef
  • Evaluation of the Safety and Efficacy of Conventional Transarterial Chemoembolization (cTACE) and Drug-Eluting Bead (DEB)-TACE in the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review
    Javaria Ayyub, Karan Nareshbhai Dabhi, Namra V Gohil, Nida Tanveer, Sally Hussein, Shravya Pingili, Vijaya Krishna Makkena, Arturo P Jaramillo, Babatope L Awosusi, Tuheen Sankar Nath
    Cureus.2023;[Epub]     CrossRef
  • Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study
    Chang Hun Lee, Gwang Hyeon Choi, Hwa Young Choi, Sojung Han, Eun Sun Jang, Young Eun Chon, Young Chang, Kyung-Ah Kim, Do Young Kim, Hyung Joon Yim, Hye-Lin Kim, Sook-Hyang Jeong, In Hee Kim
    Clinical and Molecular Hepatology.2023; 29(3): 779.     CrossRef
  • Risk factors associated with late hepatocellular carcinoma detection in patients undergoing regular surveillance
    Sangmi Jang, Young-Joo Jin, Jin-Woo Lee, Dam Kwon, Jung Hwan Yu
    Medicine.2023; 102(32): e34637.     CrossRef
  • Global, regional, and national burden of liver cancer due to non-alcoholic steatohepatitis, 1990–2019: a decomposition and age–period–cohort analysis
    Chunlong Liu, Shijie Zhu, Jian Zhang, Panpan Wu, Xuan Wang, Sen Du, Enzhao Wang, Yunkang Kang, Kun Song, Jiangtao Yu
    Journal of Gastroenterology.2023; 58(12): 1222.     CrossRef
  • Nonalcoholic Fatty Liver Disease as a Systemic Disease and the Need for Multidisciplinary Care
    Masato Yoneda, Takashi Kobayashi, Michihiro Iwaki, Asako Nogami, Satoru Saito, Atsushi Nakajima
    Gut and Liver.2023; 17(6): 843.     CrossRef
  • Potential Anti-Cancer Effects of Extra Virgin Olive Oil and Its Phenolic Extracts on Hepatocellular Carcinoma Cells
    Gül KAHRAMAN, Mücahit Taha ÖZKAYA, Özlem YILDIRIM
    International Journal of Nature and Life Sciences.2023; 7(2): 112.     CrossRef
  • Current epidemiology of chronic liver disease
    Richie Manikat, Aijaz Ahmed, Donghee Kim
    Gastroenterology Report.2023;[Epub]     CrossRef
  • 14,525 View
  • 300 Download
  • 57 Web of Science
  • Crossref
Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department: A multicenter study
Ji Hyun Kim, Baek Gyu Jun, Minjong Lee, Hye Ah Lee, Tae Suk Kim, Jeong Won Heo, Da Hye Moon, Seong Hee Kang, Ki Tae Suk, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim, Dae Hee Choi
Clin Mol Hepatol 2022;28(3):540-552.
Published online May 6, 2022
DOI: https://doi.org/10.3350/cmh.2021.0169
Background/Aims
Sepsis-3 criteria and quick Sequential Organ Failure Assessment (qSOFA) have been advocated to be used in defining sepsis in the general population. We aimed to compare the Sepsis-3 criteria and Chronic Liver Failure-SOFA (CLIF-SOFA) scores as predictors of in-hospital mortality in cirrhotic patients admitted to the emergency department (ED) for infections.
Methods
A total of 1,622 cirrhosis patients admitted at the ED for infections were assessed retrospectively. We analyzed their demographic, laboratory, and microbiological data upon diagnosis of the infection. The primary endpoint was inhospital mortality rate. The predictive performances of baseline CLIF-SOFA, Sepsis-3, and qSOFA scores for in-hospital mortality were evaluated.
Results
The CLIF-SOFA score proved to be significantly better in predicting in-hospital mortality (area under the receiver operating characteristic curve [AUROC], 0.80; 95% confidence interval [CI], 0.78–0.82) than the Sepsis-3 (AUROC, 0.75; 95% CI, 0.72–0.77, P<0.001) and qSOFA (AUROC, 0.67; 95% CI, 0.64–0.70; P<0.001) score. The CLIF-SOFA, CLIF-C-AD scores, Sepsis-3 criteria, septic shock, and qSOFA positivity were significantly associated with in-hospital mortality (adjusted hazard ratio [aHR], 1.24; 95% CI, 1.19–1.28; aHR, 1.13; 95% CI, 1.09–1.17; aHR, 1.19; 95% CI, 1.15–1.24; aHR, 1.88; 95% CI, 1.42–2.48; aHR, 2.06; 95% CI, 1.55–2.72; respectively; all P<0.001). For CLIF-SOFA scores ≥6, in-hospital mortality was >10%; this is the cutoff point for the definition of sepsis.
Conclusions
Among cirrhosis patients presenting with infections at the ED, CLIF-SOFA scores showed a better predictive performance for mortality than both Sepsis-3 criteria and qSOFA scores, and can be a useful tool of risk stratification in cirrhotic patients requiring timely intervention for infection.

Citations

Citations to this article as recorded by  Crossref logo
  • A Serum DLL1 and CRP dual-marker model for bacterial infection detection in patients with decompensated cirrhosis: A dual-cohort diagnostic study
    Juanjun Huang, Luhu Yu, Debin Zeng, Yulin Wang, Zhi Wang, Jian Chen, Wei Zhu
    Science Progress.2025;[Epub]     CrossRef
  • Correlation between systemic inflammatory response syndrome and prognosis of patients with cirrhosis and hepatic encephalopathy
    Kaiyue Zhang, Ziqun Qu, Rongyu Tang, Hongliang Dong, Jing Fan, Wei Ye
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Management of patients with cirrhosis in the emergency department: Implications for hospitalization outcomes
    Sandeep Sikerwar, Sohrab Zand, Peter Steel, Arun Jesudian
    Liver Transplantation.2024; 30(1): 94.     CrossRef
  • Current Status of Prognostic Evaluation Model and Treatment of Acute-on-Chronic Liver Failure
    念 刘
    Advances in Clinical Medicine.2024; 14(04): 2500.     CrossRef
  • Prevalence and predictors of multidrug-resistant bacteremia in liver cirrhosis
    Aryoung Kim, Byeong Geun Song, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Myung Ji Goh
    The Korean Journal of Internal Medicine.2024; 39(3): 448.     CrossRef
  • Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment
    Do Seon Song, Hee Yeon Kim, Young Kul Jung, Tae Hyung Kim, Hyung Joon Yim, Eileen L Yoon, Ki Tae Suk, Jeong-ju Yoo, Sang Gyune Kim, Moon Young Kim, Young Chang, Soung Won Jeong, Jae Young Jang, Sung-Eun Kim, Jung-Hee Kim, Jung Gil Park, Won Kim, Jin Mo Ya
    Clinical and Molecular Hepatology.2024; 30(3): 388.     CrossRef
  • Correspondence to editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment”
    Do Seon Song, Dong Joon Kim
    Clinical and Molecular Hepatology.2024; 30(4): 1012.     CrossRef
  • Cirrhosis Management in the Intensive Care Unit
    Thomas N. Smith, Alice Gallo de Moraes, Douglas A. Simonetto
    Seminars in Liver Disease.2023; 43(01): 117.     CrossRef
  • 8,336 View
  • 145 Download
  • 7 Web of Science
  • Crossref

Hepatic neoplasm

Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area
Bo Hyun Kim, Dahhay Lee, Kyu-Won Jung, Young-Joo Won, Hyunsoon Cho
Clin Mol Hepatol 2022;28(2):242-253.
Published online February 7, 2022
DOI: https://doi.org/10.3350/cmh.2021.0355
Background/Aims
Primary liver cancer is one of the leading causes of cancer mortality worldwide. However, the causes of death have not been studied in detail in patients with liver cancer.
Methods
The causes of death and cause-specific mortality risks in patients with primary liver cancer, diagnosed during 2000–2016, were investigated using the nationwide population-based cancer registry data in South Korea (n=231,388). The cumulative incidence function and Fine-Gray models were used to estimate the cause-specific mortality under the competing risks. Risks of non-cancer deaths relative to the general population were compared by standardized mortality ratios (SMRs).
Results
Among 179,921 total deaths, 92.4%, 1.7%, and 6.0% of patients died of primary liver cancer, cancer from other sites, and non-cancer illnesses, respectively. Proportionate mortality from liver cancer remained high. The 5-year competing risks probability of death from liver cancer varied by tumor stage, from 42% to 94%, and it remained high 10 years after the diagnosis (61–95%). Competing mortality from other causes has continuously increased. The most common non-cancer causes of death were underlying liver diseases (SMR, 15.6; 95% confidence interval [CI], 15.1–16.1) and viral hepatitis (SMR, 46.5; 95% CI, 43.9–49.2), which demonstrated higher mortality risks compared to the Korean general population. Higher mortality risks of suicide (SMR, 2.6; 95% CI, 2.4–2.8) was also noted.
Conclusions
Patients with liver cancer are most likely to die from liver cancer and related liver disease, even 10 years after the diagnosis, highlighting a need for specialized long-term follow-up care.

Citations

Citations to this article as recorded by  Crossref logo
  • Tenofovir Is Associated With a Better Prognosis Than Entecavir for Hepatitis B Virus–Related Hepatocellular Carcinoma
    Sung Won Chung, Hyun Jun Um, Won-Mook Choi, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee
    Clinical Gastroenterology and Hepatology.2025; 23(2): 300.     CrossRef
  • Survival Benefits of Transarterial Chemoembolization Plus Ablation Therapy in Patients With Intermediate or Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study
    Jingyi Dai, Yadi Ding, Qiaomei Zheng, Guixin Zhao, Lingqing Zou, Jun Zhao, Yu Luo, Virasakdi Chongsuvivatwong
    Cancer Management and Research.2025; Volume 17: 483.     CrossRef
  • Bioactive Secondary Metabolites from Bauhinia variegata Linn. Roots: Isolation, Characterization, and Cytotoxic Evaluation
    Yousaf Kamal, Nighat Fatima, Amara Mumtaz, Irum Shahzadi, Abdul Mannan, Gerardo D. Anaya-Eugenio, Eric Daniel Salinas Arellano, Madiha Ahmed, Zahid Hussain, Esperanza J. Carcache de Blanco
    Current Pharmaceutical Design.2025; 31(15): 1239.     CrossRef
  • Pharmacological Evaluation of Angelica keiskei Extract: Molecular Interaction Analysis in Hepatocellular Carcinoma
    Alka Ashok Singh, Minseok Song, Gun-Do Kim
    Current Issues in Molecular Biology.2025; 47(6): 401.     CrossRef
  • Sex Disparity in Cancer and Non-cancer Mortality among Korean Cancer Survivors
    Ansun Jeong, Soyeoun Kim, Somin Jeon, Boyoung Park
    Journal of Cancer Prevention.2025; 30(4): 196.     CrossRef
  • Association between Unplanned Conversion and Patient Survival after Laparoscopic Liver Resection for Hepatocellular Carcinoma: A Propensity Score Matched Analysis
    Boram Lee, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, MeeYoung Kang, Yeshong Park, Jinju Kim
    Journal of Clinical Medicine.2024; 13(4): 1116.     CrossRef
  • Achieving Textbook Outcomes after Laparoscopic Resection in Posterosuperior Segments of the Liver: The Impact of the Learning Curve
    Mizelle D’Silva, Jai-Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae-Won Lee, Bo-Ram Lee, Mee-Young Kang, Ye-Shong Park, Jin-Ju Kim
    Cancers.2024; 16(5): 930.     CrossRef
  • Organ‐specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicentre, retrospective study
    Jaekyung Cheon, Sanghoon Jung, Jung Sun Kim, Beodeul Kang, Hyeyoung Kim, Landon L. Chan, Lars Becker, Vincent E. Gaillard, Stephen L. Chan, Chan Kim, Hong Jae Chon
    Liver International.2024; 44(8): 1961.     CrossRef
  • Development and validation of a prognostic nomogram including inflammatory indicators for overall survival in hepatocellular carcinoma patients treated primarily with surgery or loco-regional therapy: A single-center retrospective study
    Xin Wang, Jing Xu, Zhenya Jia, Guoping Sun
    Medicine.2024; 103(50): e40889.     CrossRef
  • Development and validation of prognostic nomograms for large hepatocellular carcinoma after HAIC
    Wang Yao, Ran Wei, Jia Jia, Wang Li, Mengxuan Zuo, Shuqing Zhuo, Ge Shi, Peihong Wu, Chao An
    Therapeutic Advances in Medical Oncology.2023;[Epub]     CrossRef
  • Impact of sarcopenia on clinical outcomes for patients with resected hepatocellular carcinoma: a retrospective comparison of Eastern and Western cohorts
    Berend R. Beumer, Kosei Takagi, Stefan Buettner, Yuzo Umeda, Takahito Yagi, Toshiyoshi Fujiwara, Jeroen L.A. van Vugt, Jan N.M. IJzermans
    International Journal of Surgery.2023; 109(8): 2258.     CrossRef
  • Isolated Hepatitis B Core Antibody Positivity and Long-Term Liver-Related Mortality in Korea: A Cohort Study
    Won Sohn, Yoosoo Chang, Yong Kyun Cho, Yun Soo Hong, Seungho Ryu
    American Journal of Gastroenterology.2023; 118(1): 95.     CrossRef
  • Barriers to palliative care in hepatocellular carcinoma: A review of the literature
    Mostafa Abasseri, Shakira Hoque, BA Slavica Kochovska, Kim Caldwell, Linda Sheahan, Amany Zekry
    Journal of Gastroenterology and Hepatology.2023; 38(7): 1047.     CrossRef
  • Dihydrotanshinone I inhibits hepatocellular carcinoma cells proliferation through DNA damage and EGFR pathway
    Linjun Wang, Xiangwei Xu, Dexing Chen, Chenghang Li
    PeerJ.2023; 11: e15022.     CrossRef
  • Primary non-response to antiviral therapy affects the prognosis of hepatitis B virus-related hepatocellular carcinoma
    Peng Wang, Xinhui Wang, Xiaoli Liu, Fengna Yan, Huiwen Yan, Dongdong Zhou, Lihua Yu, Xianbo Wang, Zhiyun Yang
    BMC Cancer.2023;[Epub]     CrossRef
  • Identification of ELOVL3 as a novel prognostic marker for liver cancer
    Yiyang Chen, Wanbang Zhou, Yiju Gon, Xi Ou
    AFMN Biomedicine.2023; 40(3): 279.     CrossRef
  • Applications of molecular barcode sequencing for the detection of low‐frequency variants in circulating tumour DNA from hepatocellular carcinoma
    Hye Won Lee, Esl Kim, Kyung Joo Cho, Hye Jung Park, Jieun Seo, Hyeonah Lee, Eunha Baek, Jong Rak Choi, Kwang‐Hyub Han, Seung‐Tae Lee, Jun Yong Park
    Liver International.2022; 42(10): 2317.     CrossRef
  • Incidence, mortality, and survival of liver cancer using Korea central cancer registry database: 1999-2019
    Sung Yeon Hong, Mee Joo Kang, Taegyu Kim, Kyu-Won Jung, Bong-Wan Kim
    Annals of Hepato-Biliary-Pancreatic Surgery.2022; 26(3): 211.     CrossRef
  • 10,053 View
  • 148 Download
  • 20 Web of Science
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Alcohol associated liver cirrhotics have higher mortality after index hospitalization: Long-term data of 5,138 patients
Priyanka Jain, Saggere Muralikrishna Shasthry, Ashok Kumar Choudhury, Rakhi Maiwall, Guresh Kumar, Ankit Bharadwaj, Vinod Arora, Rajan Vijayaraghavan, Ankur Jindal, Manoj Kumar Sharma, Vikram Bhatia, Shiv Kumar Sarin
Clin Mol Hepatol 2021;27(1):175-185.
Published online December 3, 2020
DOI: https://doi.org/10.3350/cmh.2020.0068
Background/Aims
Liver cirrhosis is an important cause of morbidity and mortality globally. Every episode of decompensation and hospitalization reduces survival. We studied the clinical profile and long-term outcomes comparing alcohol-related cirrhosis (ALC) and non-ALC.

Methods
Cirrhosis patients at index hospitalisation (from January 2010 to June 2017), with ≥1 year follow-up were included.

Results
Five thousand and one hundred thirty-eight cirrhosis patients (age, 49.8±14.6 years; male, 79.5%; alcohol, 39.5%; Child-A:B:C, 11.7%:41.6%:46.8%) from their index hospitalization were analysed. The median time from diagnosis of cirrhosis to index hospitalization was 2 years (0.2–10). One thousand and seven hundred seven patients (33.2%) died within a year; 1,248 (24.3%) during index hospitalization. 59.5% (2,316/3,890) of the survivors, required at least one readmission, with additional mortality of 19.8% (459/2,316). ALC compared to non-ALC were more often (P<0.001) male (97.7% vs. 67.7%), younger (40–50 group, 36.2% vs. 20.2%; P<0.001) with higher liver related complications at baseline, (P<0.001 for each), sepsis: 20.3% vs. 14.9%; ascites: 82.2% vs. 65.9%; spontaneous bacterial peritonitis: 21.8% vs. 15.7%; hepatic encephalopathy: 41.0% vs. 25.0%; acute variceal bleeding: 32.0% vs. 23.7%; and acute kidney injury 30.5% vs. 19.6%. ALC patients had higher Child-Pugh (10.6±2.0 vs. 9.0±2.3), model for end-stage liver-disease scores (21.49±8.47 vs. 16.85±7.79), and higher mortality (42.3% vs. 27.3%, P<0.001) compared to non-ALC.

Conclusions
One-third of cirrhosis patients die in index hospitalization. 60% of the survivors require at least one rehospitalization within a year. ALC patients present with higher morbidity and mortality and at a younger age.

Citations

Citations to this article as recorded by  Crossref logo
  • Global, regional, and national burdens of alcohol-related cirrhosis among women from 1992 to 2021 and its predictions
    Zhou Zhang, Chun-mei Xu, Wei Chen, Kai-tao Yao, Ting Sun, Jing-hui Wang
    Scientific Reports.2025;[Epub]     CrossRef
  • Machine learning-based nomogram for mortality risk stratification in cirrhotic patients with sepsis: a single-center predictive model
    Xing-Cheng Zhang, Bo-Wen Li, Xi-Qun Lei, Nan-Bing Shan, Jun-Ping Wei, Zhong-Hua Lu, Yun Sun
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Insights into the Multifaceted Roles and Pleiotropic Functions of ALDH1L2 with Implications in Gastrointestinal Diseases and Cancer
    Partha Pratim Das, Subhash Medhi, Sangit Dutta, Anjan Jyoti Talukdar, Samudrala Gourinath
    Current Genetic Medicine Reports.2025;[Epub]     CrossRef
  • Burden of caregiving of alcohol related liver disease patients: a possible role of training and caregiver groups frequency. Proposal of a method, preliminary results
    Patrizia BALBINOT, Rinaldo PELLICANO, Gianni TESTINO
    Minerva Gastroenterology.2024;[Epub]     CrossRef
  • Etiological Spectrum of Cirrhosis in India: A Systematic Review and Meta-analysis
    Shekhar Swaroop, Manas Vaishnav, Umang Arora, Sagnik Biswas, Arnav Aggarwal, Soumya Sarkar, Puneet Khanna, Anshuman Elhence, Ramesh Kumar, Amit Goel, Shalimar
    Journal of Clinical and Experimental Hepatology.2024; 14(2): 101291.     CrossRef
  • Alcohol consumption, alcohol use disorder and organ transplantation
    Gianni TESTINO, Rinaldo PELLICANO, Fabio CAPUTO
    Minerva Gastroenterology.2024;[Epub]     CrossRef
  • Outcomes and Recurrence Rate of Esophageal Varices after Endoscopic Treatment in Patients with Alcoholic Cirrhosis and Viral Cirrhosis
    Yoshihiro Furuichi, Ryohei Nishiguchi, Takeshi Shimakawa, Tomoyuki Fujiwara, Koichiro Sato, Hiroyuki Kato
    Journal of Nippon Medical School.2024; 91(2): 180.     CrossRef
  • Acute kidney injury development is associated with mortality in Japanese patients with cirrhosis: impact of amino acid imbalance
    Takao Miwa, Yuki Utakata, Tatsunori Hanai, Masashi Aiba, Shinji Unome, Kenji Imai, Koji Takai, Makoto Shiraki, Naoki Katsumura, Masahito Shimizu
    Journal of Gastroenterology.2024; 59(9): 849.     CrossRef
  • Incidence and risk factors of acute kidney injury in cirrhosis: a systematic review and meta-analysis of 5,202,232 outpatients, inpatients, and ICU-admitted patients
    Vasileios Lekakis, Aikaterini Gkoufa, John Vlachogiannakos, George V. Papatheodoridis, Evangelos Cholongitas
    Expert Review of Gastroenterology & Hepatology.2024; 18(7): 377.     CrossRef
  • Association of Alcohol Consumption With Liver Cancer and All-Cause Mortality in Chronic Hepatitis B Patients Without Cirrhosis
    BYUNGYOON Yun, JUYEON OH, SANG HOON AHN, JIN-HA Yoon, BEOM KYUNG Kim
    Clinical Gastroenterology and Hepatology.2023; 21(12): 3191.     CrossRef
  • Current and future treatment for alcoholic‐related liver diseases
    Eileen L. Yoon, Won Kim
    Journal of Gastroenterology and Hepatology.2023; 38(8): 1218.     CrossRef
  • Excess mortality in elderly hip fracture patients: An Indian experience
    Jaiben George, Vijay Sharma, Kamran Farooque, Vivek Trikha, Samarth Mittal, Rajesh Malhotra
    Chinese Journal of Traumatology.2023; 26(6): 363.     CrossRef
  • Overview of Complications in Cirrhosis
    Madhumita Premkumar, Anil C. Anand
    Journal of Clinical and Experimental Hepatology.2022; 12(4): 1150.     CrossRef
  • Liver cirrhosis
    Garima Singh, Suman Bala, Sonal Katoch, Lakhvinder Kaur, Anil Kumar, Abhishek Kumar, Alok Bharadwaj, Ardhariksa Zukhruf Kurniullah
    International journal of health sciences.2022; : 5547.     CrossRef
  • Microbiome-Based Metabolic Therapeutic Approaches in Alcoholic Liver Disease
    Ji Ye Hyun, Seul Ki Kim, Sang Jun Yoon, Su Been Lee, Jin-Ju Jeong, Haripriya Gupta, Satya Priya Sharma, Ki Kwong Oh, Sung-Min Won, Goo Hyun Kwon, Min Gi Cha, Dong Joon Kim, Raja Ganesan, Ki Tae Suk
    International Journal of Molecular Sciences.2022; 23(15): 8749.     CrossRef
  • Predictive Factors for the Prognosis of Alcoholic Liver Cirrhosis
    Anca Trifan, Horia Minea, Adrian Rotaru, Carol Stanciu, Remus Stafie, Ermina Stratina, Sebastian Zenovia, Robert Nastasa, Ana-Maria Singeap, Irina Girleanu, Cristina Muzica, Laura Huiban, Tudor Cuciureanu, Stefan Chiriac, Catalin Sfarti, Camelia Cojocariu
    Medicina.2022; 58(12): 1859.     CrossRef
  • Alcohol-related cirrhosis: The most challenging etiology of cirrhosis is more burdensome than ever
    Marta Tonon, Salvatore Piano
    Clinical and Molecular Hepatology.2021; 27(1): 94.     CrossRef
  • 8,914 View
  • 154 Download
  • 18 Web of Science
  • Crossref

Hepatic neoplasm

Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Won Sohn, Hyun Woong Lee, Sangheun Lee, Jin Hong Lim, Min Woo Lee, Chan Hyuk Park, Seung Kew Yoon
Clin Mol Hepatol 2021;27(1):157-174.
Published online November 26, 2020
DOI: https://doi.org/10.3350/cmh.2020.0176
Background/Aims
In this systematic review and meta-analysis, we aimed to clarify the effect of obesity on the occurrence of and mortality from primary liver cancer.
Methods
This study was conducted using a systematic literature search of MEDLINE, EMBASE, and the Cochrane Library until November 2018 using the primary keywords “obesity,” “overweight,” “body mass index (BMI),” “body weight,” “liver,” “cancer,” “hepatocellular carcinoma,” “liver cancer,” “risk,” and “mortality.” Studies assessing the relationship between BMI and occurrence of or mortality from primary liver cancer in prospective cohorts and those reporting hazard ratios (HRs) or data that allow HR estimation were included.
Results
A total of 28 prospective cohort studies with 8,135,906 subjects were included in the final analysis. These included 22 studies with 6,059,561 subjects for cancer occurrence and seven studies with 2,077,425 subjects for cancerrelated mortality. In the meta-analysis, an increase in BMI was associated with the occurrence of primary liver cancer (HR, 1.69; 95% confidence interval, 1.50–1.90, I2=56%). A BMI-dependent increase in the risk of occurrence of primary liver cancer was reported. HRs were 1.36 (95% CI, 1.02–1.81), 1.77 (95% CI, 1.56–2.01), and 3.08 (95% CI, 1.21–7.86) for BMI >25 kg/m2, >30 kg/m2, and >35 kg/m2, respectively. Furthermore, increased BMI resulted in enhanced liver cancer-related mortality (HR, 1.61; 95% CI, 1.14–2.27, I2=80%).
Conclusions
High BMI increases liver cancer mortality and occurrence of primary liver cancer. Obesity is an independent risk factor for the occurrence of and mortality from primary liver cancer.

Citations

Citations to this article as recorded by  Crossref logo
  • Unravelling the obesity paradox in cancer: An umbrella review of protective associations and evidence credibility across 13 malignancies
    Lulin Yu, Jing Yuan, Mingxian Meng, Hejing Pan, Long Ge, Liaoyao Wang, Xuanlin Li
    Metabolism.2026; 175: 156461.     CrossRef
  • Burden, trends, and predictions of liver cancer in China, Japan, and South Korea: analysis based on the Global Burden of Disease Study 2021
    Si Yang, Yujiao Deng, Yi Zheng, Jing Zhang, Dongdong He, Zhijun Dai, Changcun Guo
    Hepatology International.2025; 19(2): 441.     CrossRef
  • The impact of metabolic syndrome on hepatocellular carcinoma: a mendelian randomization study
    Chendong Yuan, Xufeng Shu, Xiaoqiang Wang, Wenzheng Chen, Xin Li, Wenguang Pei, Xujie Su, Zhenzhen Hu, Zhigang Jie
    Scientific Reports.2025;[Epub]     CrossRef
  • Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer risk
    Núria Granel, Gemma Iserte, Concepció Bartres, Neus Llarch, Anna Pla, Víctor Sapena, Zoe Mariño, Sabela Lens, Ramón Vilana, Isabel Nuñez, Anna Darnell, Ernest Belmonte, Ángeles García-Criado, Alba Díaz, Marco Sanduzzi-Zamparelli, Carla Fuster, Sergio Muño
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • The associations of obesity with demographic and lifestyle factors among Hong Kong adults
    Cynthia Sau Chun Yip
    Nutrition and Health.2025; 31(4): 1563.     CrossRef
  • Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic
    Hiroyuki Suzuki, Naoto Fujiwara, Amit G. Singal, Thomas F. Baumert, Raymond T. Chung, Takumi Kawaguchi, Yujin Hoshida
    Hepatology.2025;[Epub]     CrossRef
  • The impact of alpha-fetoprotein (AFP), child-turcotte-pugh (CTP) score and disease staging on the survival of hepatocellular carcinoma (HCC) patients: a retrospective cohort from single oncology center
    DUAA S. ALKHAYAT, NASSER MULLA, MOHAMED MOSAAD, YOUSEF KATIB, ASIM M. ALMUGHAMSI, SAMIR T. ALFOTIH, RAWAN ALAOFI
    Oncology Research.2025; 33(1): 149.     CrossRef
  • The role and mechanism of selenium in the prevention and progression of hepatocellular carcinoma
    Qinying Luo, Xiaofang Bai, Xiaojiao Li, Chang Liu
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Association of BMI with mortality and health‐related quality of life among 4.4 million adults: Evidence from a nationwide, population‐based, prospective cohort study
    Yi Wu, Chunying Lin, Chunqi Wang, Runsi Wang, Bolin Jin, Xiaoyan Zhang, Bowang Chen, Yang Yang, Jianlan Cui, Wei Xu, Lijuan Song, Hao Yang, Wenyan He, Yan Zhang, Xi Li
    Diabetes, Obesity and Metabolism.2025; 27(6): 3132.     CrossRef
  • Liver Cancer Etiology in Asian Subgroups and American Indian, Black, Latino, and White Populations
    Paulo S. Pinheiro, Juanjuan Zhang, Veronica Wendy Setiawan, Hannah M. Cranford, Robert J. Wong, Lihua Liu
    JAMA Network Open.2025; 8(3): e252208.     CrossRef
  • The role of nutrition in cancer prevention: the effect of dietary patterns, bioactive compounds, and metabolic pathways on cancer development
    Sebastián Chapela, Julieta Locatelli, Facundo Saettone, Carla Antonella Forte, Pasqualina Memoli, Gabriela Cucalon, Florencia Ceriani, Gerardo Sarno, Luigi Coppola, Evelyn Frias-Toral
    Food and Agricultural Immunology.2025;[Epub]     CrossRef
  • Vitamin D: What role in obesity-related cancer?
    Pierrick Martinez, William B. Grant
    Seminars in Cancer Biology.2025; 112: 135.     CrossRef
  • Diagnosis and treatment of metabolic dysfunction-associated fatty liver disease -related hepatocellular carcinoma
    Ke-Gong Xiong, Tai-Shun Lin, Qing-Biao Lin, Jin-Feng Kong, Kun-Yu Ke
    Egyptian Liver Journal.2025;[Epub]     CrossRef
  • The spatio-temporal trends and determinants of liver cancer attributable to specific etiologies: a systematic analysis from the Global Burden of Disease Study 2021
    Jinli Liu, Tingling Xu, Yanan Wang, Fanpu Ji, Lei Zhang
    Global Health Research and Policy.2025;[Epub]     CrossRef
  • Insulin resistance in cancer risk and prognosis
    Emmanuel Jacobo-Tovar, Andrea Medel-Sánchez, Cosette Durán-Castillo, Rodolfo Guardado-Mendoza
    Seminars in Cancer Biology.2025; 114: 73.     CrossRef
  • The multifaceted impact of circadian disruption on cancer risk: a systematic review of insights and economic implications
    Vicente Javier Clemente-Suarez, Eduardo Navarro-Jiménez, Juan Camilo Benitez-Agudelo, Ana Isabel Beltrán-Velasco, Pedro Belinchón-deMiguel, Domingo Jesús Ramos-Campo, Carlota Valeria Villanueva-Tobaldo, Alexandra Martín-Rodríguez, Jose Francisco Tornero-A
    Journal of the National Cancer Center.2025; 5(5): 524.     CrossRef
  • The impact of diabetes and social, biologic and behavioral determinants of health on liver cancer risk
    Marwa Shouman, Ayad A. Jaffa, Miran A. Jaffa
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Comparing the trends of cancer burden attributed to high BMI in China and globally from 1990 to 2021, with multi-model prediction to 2036
    Nanting Chen, Lingzhi Xing, Fengyun Xiang, Chengmiao Li, Letai Li, Jingsong Cheng, Yangfan Yu, Yubowen Gong, Xiao Liu, Fangjiao Xie, Ling Chen
    Frontiers in Public Health.2025;[Epub]     CrossRef
  • Advances in resistant starch: mechanisms, applications, and challenges in obesity management and low-fat food development
    Yangchao Ou, Ke Chen, Jie Guo, Chanjuan Ye, Xinqiao Zhou, Dagang Chen, Biansheng Li, Chuanguang Liu, Juan Liu
    International Journal of Biological Macromolecules.2025; 320: 145679.     CrossRef
  • Cancer prevention and interception with antidiabetic and anti-obesity drugs: Current and future perspectives
    Adriana Albini, Anna Rita Cantelmo, Lorenzo Mortara, Douglas M. Noonan, Giovanni Corso
    Seminars in Cancer Biology.2025; 115: 40.     CrossRef
  • Exploring the Epidemiologic Burden, Pathogenetic Features, and Clinical Outcomes of Primary Liver Cancer in Patients with Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Scoping Review
    Mario Romeo, Fiammetta Di Nardo, Carmine Napolitano, Claudio Basile, Carlo Palma, Paolo Vaia, Marcello Dallio, Alessandro Federico
    Diabetology.2025; 6(8): 79.     CrossRef
  • Synergistic impact of high body-mass index on HBV/HCV-related liver cancer burden globally: Analysis and projections 1990–2050
    Yicheng Liang, Xiaohong Lin, Min Zhang, Shuai Wang, Yuqi Dong, Zhonghao Xie, Xiaoshun He, Weiqiang Ju, Maogen Chen
    Public Health.2025; 247: 105893.     CrossRef
  • Dynapenic obesity and all-Cause mortality: A systematic review and Meta-analysis of prospective cohort studies
    Amirabbas Nikkhah, Farshad Sharifi, Pouya Ebrahimi, Marjan Rahimi, Elaheh Karimi, Amirhosein Kefayat, Moloud Payab, Bagher Larijani, Mahbube Ebrahimpur
    Aging Clinical and Experimental Research.2025;[Epub]     CrossRef
  • Analysis of influencing factors of concurrent primary liver cancer in hepatitis B patients and construction of column chart prediction model
    Qunmei Cao, Yilin Zhou, Changlong Wen, Qinglan Li
    Epidemiology and Infection.2025;[Epub]     CrossRef
  • Temporal trends in cancer mortality attributable to high BMI in Asia: an age-period-cohort analysis based on GBD 1992–2021
    Minguang Huang, Liejiong Wang, Ying Lou, Zhaoqi Qiu, Shengjian Yu, Feng Xuan
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Global, regional, and national epidemiology and risk factors of geriatric digestive system cancers from 1990 to 2021
    Congcong Xu, Jing Chen, Qingliang Wang, Ziyu Zheng, Chunju Fang, Hanyu Yu, Qingna Liang, Xin Wang
    Frontiers in Public Health.2025;[Epub]     CrossRef
  • Assessment of Adipokine and Inflammation Biomarkers with Cancer Risk among Chinese Men: A Prospective Cohort Study
    Douglas DeMoulin, Hui Cai, Qiuyin Cai, Wei Zheng, Xiao-Ou Shu
    Cancer Epidemiology, Biomarkers & Prevention.2025; 34(11): 2104.     CrossRef
  • Association of nutritional status and mortality in a population with cardiovascular disease: Predictive role of CONUT score
    Luo-Xiang Fang, Tao Yao, Peng Zheng, Zi Tao, Yuan-Nan Lin
    Obesity Research & Clinical Practice.2025; 19(6): 490.     CrossRef
  • Liver cancer burden attributable to high body mass index and high fasting plasma glucose in BRICS countries (1990–2021): a Global Burden of Disease 2021 analysis with projections to 2050
    Jianya Cai, Yanhong Lan, Ying Wang, Hongwei Cheng, Shuangta Xu
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • The impact of genetic and environmental risk factors on adverse liver outcomes
    Xinyuan Zhang, Longgang Zhao, Peter T. Campbell, Yun Chen, Aiping Fang, Zhenqiu Liu, Xue Li, Wanshui Yang, Jiangao Fan, Jessica L. Petrick, Katherine A. McGlynn, Michelle Lai, Xuehong Zhang
    International Journal of Cancer.2025;[Epub]     CrossRef
  • Visceral and ectopic fat are more predictively associated with primary liver cancer than overall obesity from genetic sights: A Mendelian randomization study
    Fei‐Qi Xu, Qing‐Yun Xu, Zhang‐Ji Zhu, Lei Jin, Tai‐Wei Ye, Cheng‐Fei Du, Zhen‐Yu Gao, Xiao‐Kun Huang, Zhe Zhang, Li‐Ming Jin, Wei‐Feng Yao
    International Journal of Cancer.2024; 154(3): 530.     CrossRef
  • Association between hypertension grades and cancer mortality among Japanese men and women
    Tsubasa Tanabe, Masayuki Teramoto, Kokoro Shirai, Akiko Tamakoshi, Hiroyasu Iso
    Cancer Causes & Control.2024; 35(3): 497.     CrossRef
  • Association of systemic inflammation with the obesity paradox in cancer: results from multi-cohort studies
    Hailun Xie, Lishuang Wei, Heyang Zhang, Guotian Ruan, Xiaoyue Liu, Shiqi Lin, Jinyu Shi, Chenan Liu, Xin Zheng, Yue Chen, Hanping Shi
    Inflammation Research.2024; 73(2): 243.     CrossRef
  • The Growing Landscape of NAFLD-Associated Hepatocellular Carcinoma and Its Impact in Surveillance
    Mariana Verdelho Machado
    GE - Portuguese Journal of Gastroenterology.2024; 31(1): 14.     CrossRef
  • Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data
    Yimo Qu, Xiaocheng Gong, Ziyuan Zhao, Zimei Zhang, Qian Zhang, Yuting Huang, Qingsong Xie, Yunfei Liu, Jinfen Wei, Hongli Du
    International Journal of Molecular Sciences.2024; 25(2): 919.     CrossRef
  • Identification of phenomic data in the pathogenesis of cancers of the gastrointestinal (GI) tract in the UK biobank
    Shirin Hui Tan, Catherina Anak Guan, Mohamad Adam Bujang, Wei Hong Lai, Pei Jye Voon, Edmund Ui Hang Sim
    Scientific Reports.2024;[Epub]     CrossRef
  • Obesity and Cancer Rehabilitation for Functional Recovery and Quality of Life in Breast Cancer Survivors: A Comprehensive Review
    Lorenzo Lippi, Alessandro de Sire, Arianna Folli, Alessio Turco, Stefano Moalli, Marco Marcasciano, Antonio Ammendolia, Marco Invernizzi
    Cancers.2024; 16(3): 521.     CrossRef
  • Insulin Resistance: The Increased Risk of Cancers
    Leszek Szablewski
    Current Oncology.2024; 31(2): 998.     CrossRef
  • Obesity- and lipid-related indices as a predictor of type 2 diabetes in a national cohort study
    Ying Wang, Xiaoyun Zhang, Yuqing Li, Jiaofeng Gui, Yujin Mei, Xue Yang, Haiyang Liu, Lei-lei Guo, Jinlong Li, Yunxiao Lei, Xiaoping Li, Lu Sun, Liu Yang, Ting Yuan, Congzhi Wang, Dongmei Zhang, Jing Li, Mingming Liu, Ying Hua, Lin Zhang
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • RETRACTED: Effect of body mass index on the wound infection and complications in patients with liver cancer: A meta‐analysis
    Yan‐Ping Li, Zhuo Gan, Bing Shi
    International Wound Journal.2024;[Epub]     CrossRef
  • Anthropometric indicators may explain the high incidence of follicular lymphoma in Europeans: Results from a bidirectional two-sample two-step Mendelian randomisation
    Yanqun Zhou, Xiongfeng Zhang, Xiaozhen Li, Guoqing Zhu, Tianqi Gao, Yingying Deng, Liming Huang, Zenghui Liu
    Gene.2024; 911: 148320.     CrossRef
  • Lifestyle factors, glycemic traits, and lipoprotein traits and risk of liver cancer: a Mendelian randomization analysis
    Honglu Zhang, Jiyong Liu
    Scientific Reports.2024;[Epub]     CrossRef
  • Combined effects of smoking and alcohol consumption on the risk of liver cancer according to metabolic syndrome: A nested case–control study in South Korea
    Thi Tra Bui, Eunjung Park, Hee‐Yeon Kang, Jin‐Kyoung Oh
    International Journal of Cancer.2024; 155(4): 654.     CrossRef
  • Role of body mass index and weight change in the risk of cancer: A systematic review and meta-analysis of 66 cohort studies
    Xiaoye Shi, Gengwen Deng, Haiteng Wen, Anqi Lin, Haitao Wang, Lingxuan Zhu, Weiming Mou, Zaoqu Liu, Xiaohua Li, Jian Zhang, Quan Cheng, Peng Luo
    Journal of Global Health.2024;[Epub]     CrossRef
  • Lean body mass index is a marker of advanced tumor features in patients with hepatocellular carcinoma
    Andrew Scott deLemos, Jing Zhao, Milin Patel, Banks Kooken, Karan Mathur, Hieu Minh Nguyen, Areej Mazhar, Maggie McCarter, Heather Burney, Carla Kettler, Naga Chalasani, Samer Gawrieh
    World Journal of Hepatology.2024; 16(3): 393.     CrossRef
  • Molecular Genealogy of Metabolic-associated Hepatocellular Carcinoma
    Takahiro Kodama, Tetsuo Takehara
    Seminars in Liver Disease.2024; 44(02): 147.     CrossRef
  • Separating the effects of early and later life body mass index on liver diseases: A Mendelian randomization study
    Feixiang Zhou, Xia Liu, Canyan Chang, Jing Liu, Simin He, Yan Yan
    Clinics and Research in Hepatology and Gastroenterology.2024; 48(6): 102352.     CrossRef
  • WITHDRAWN: Unveiling the Protective Role of Metabolic and Bariatric Surgery Against Primary Liver Cancer in Obesity - A Nationwide French Administrative Data Study.
    Andrea CHIERICI, Fanny FOUR, Julie BULSEI, Eric FONTAS, Antonio IANNELLI
    Surgery for Obesity and Related Diseases.2024;[Epub]     CrossRef
  • Association between human blood metabolome and the risk of gastrointestinal tumors
    Jiamin Lu, Yuqian Feng, Kaibo Guo, Leitao Sun, Shanming Ruan, Kai Zhang, Catherine Mounier
    PLOS ONE.2024; 19(5): e0304574.     CrossRef
  • Pivotal role of intestinal cholesterol and nuclear receptor LXR in metabolic liver steatohepatitis and hepatocarcinoma
    Elena Piccinin, Maria Arconzo, Emanuela Pasculli, Angela Fulvia Tricase, Silvia Cultrera, Justine Bertrand-Michel, Nicolas Loiseau, Gaetano Villani, Hervé Guillou, Antonio Moschetta
    Cell & Bioscience.2024;[Epub]     CrossRef
  • Advantages and Limitations of the Body Mass Index (BMI) to Assess Adult Obesity
    Yilun Wu, Dan Li, Sten H. Vermund
    International Journal of Environmental Research and Public Health.2024; 21(6): 757.     CrossRef
  • Transcriptome analysis suggests broad jejunal alterations in Linghu’s obesity-diarrhea syndrome: A pilot study
    Xiao-Tong Niu, Xiang-Yao Wang, Yan Wang, Ke Han, Nan Ru, Jing-Yuan Xiang, En-Qiang Linghu
    World Journal of Gastroenterology.2024; 30(21): 2777.     CrossRef
  • Phospholipid Acyltransferases: Characterization and Involvement of the Enzymes in Metabolic and Cancer Diseases
    Jan Korbecki, Mateusz Bosiacki, Maciej Pilarczyk, Magdalena Gąssowska-Dobrowolska, Paweł Jarmużek, Izabela Szućko-Kociuba, Justyna Kulik-Sajewicz, Dariusz Chlubek, Irena Baranowska-Bosiacka
    Cancers.2024; 16(11): 2115.     CrossRef
  • Association between obesity and cancer risk in adults with HIV in Korea
    Yoonyoung Jang, Taehwa Kim, Yunsu Choi, Kyoung Hwan Ahn, Jung Ho Kim, Hye Seong, Youn Jeong Kim, Shin-Woo Kim, Jun Yong Choi, Hyo Youl Kim, Joon Young Song, Hee Jung Choi, Sang Il. Kim, Jang Wook Sohn, BumSik Chin, Bo-Youl Choi, Boyoung Park
    AIDS.2024; 38(9): 1386.     CrossRef
  • Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients
    Maria Eva Argenziano, Mi Na Kim, Michele Montori, Alessandro Di Bucchianico, Daniele Balducci, Sang Hoon Ahn, Gianluca Svegliati Baroni
    Hepatology International.2024; 18(S2): 922.     CrossRef
  • High-Fat Diet Delays Liver Fibrosis Recovery and Promotes Hepatocarcinogenesis in Rat Liver Cirrhosis Model
    Daisuke Taguchi, Yohei Shirakami, Hiroyasu Sakai, Toshihide Maeda, Takao Miwa, Masaya Kubota, Kenji Imai, Takashi Ibuka, Masahito Shimizu
    Nutrients.2024; 16(15): 2506.     CrossRef
  • Extracellular vesicles in tumor-adipose tissue crosstalk: key drivers and therapeutic targets in cancer cachexia
    Cátia C. Ramos, José Pires, Esperanza Gonzalez, Clara Garcia-Vallicrosa, Celso A. Reis, Juan M. Falcon-Perez, Daniela Freitas
    Extracellular Vesicles and Circulating Nucleic Acids.2024; 5(3): 471.     CrossRef
  • Association between obesity and liver cancer from 2012 to 2023: Bibliometric analysis and global trends
    Donghong Wang, Zhibin Ma
    Medicine.2024; 103(31): e39167.     CrossRef
  • Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies
    Fouad Jaber, George Cholankeril, Hashem B El-Serag
    Journal of the Canadian Association of Gastroenterology.2024; 7(5): 331.     CrossRef
  • Impact of exercise on cancer: mechanistic perspectives and new insights
    Ye Feng, Xingting Feng, Renwen Wan, Zhiwen Luo, Lijun Qu, Qing Wang
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Long-Term Effect of Temperature Increase on Liver Cancer in Australia: A Bayesian Spatial Analysis
    Ting Gan, Hilary Bambrick, Yumin Li, Kristie L. Ebi, Wenbiao Hu
    Environmental Health Perspectives.2024;[Epub]     CrossRef
  • Ovothiol-A Mitigates High-Fat Diet-Induced Non-alcoholic Fatty Liver Disease in Rats
    Nada Hussien Arafa, Mohamed Refaat Shehata, Ayman Saber Mohamed
    Current Bioactive Compounds.2024;[Epub]     CrossRef
  • Utilization of Microfluidic Droplet-Based Methods in Diagnosis and Treatment Methods of Hepatocellular Carcinoma: A Review
    Akvilė Zajanckauskaite, Miah Lingelbach, Dovilė Juozapaitė, Algirdas Utkus, Greta Rukšnaitytė, Goda Jonuškienė, Aistė Gulla
    Genes.2024; 15(10): 1242.     CrossRef
  • The Role of Dietary Ingredients and Herbs in the Prevention of Non-Communicable Chronic Liver Disease
    Monika Maćków, Tomasz Dziubyna, Tatiana Jamer, Dmytro Slivinskyi, Tomasz Pytrus, Katarzyna Neubauer, Małgorzata Zwolińska-Wcisło, Andrzej Stawarski, Ewa Piotrowska, Dorian Nowacki
    Nutrients.2024; 16(20): 3505.     CrossRef
  • Neighborhood-level deprivation mediates racial and ethnic disparities in HCC diagnosis in Texas
    Itunu O. Sokale, Aaron P. Thrift, Hashem B. El-Serag, Abiodun O. Oluyomi
    Hepatology Communications.2024;[Epub]     CrossRef
  • Benefits of laparoscopic liver resection for liver tumors in obese patients: a meta-analysis
    Jie Zhang, Cuifang Zeng, Rui Chen, Gang Tang, Rongxing Zhou
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Projected epidemiological trends and burden of liver cancer by 2040 based on GBD, CI5plus, and WHO data
    Qianqian Guo, Xiaorong Zhu, Narasimha M. Beeraka, Ruiwen Zhao, Siting Li, Fengying Li, Padukudru Anand Mahesh, Vladimir N. Nikolenko, Ruitai Fan, Junqi Liu
    Scientific Reports.2024;[Epub]     CrossRef
  • Research progress on natural products against hepatocellular carcinoma
    LINGLI ZHANG, YAN LI, JINGXIN MAO
    BIOCELL.2024; 48(6): 905.     CrossRef
  • Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim
    European Journal of Clinical Investigation.2023;[Epub]     CrossRef
  • Updated epidemiology of gastrointestinal cancers in East Asia
    Junjie Huang, Don Eliseo Lucero-Prisno, Lin Zhang, Wanghong Xu, Sunny H. Wong, Siew C. Ng, Martin C. S. Wong
    Nature Reviews Gastroenterology & Hepatology.2023; 20(5): 271.     CrossRef
  • Why Are Obese People Predisposed to Severe Disease in Viral Respiratory Infections?
    Rafia Aziz, Afak Yusuf Sherwani, Saeed Al Mahri, Shuja Shafi Malik, Sameer Mohammad
    Obesities.2023; 3(1): 46.     CrossRef
  • The higher body mass index is associated with a lower somatic mutation dependency in hepatocellular carcinoma
    Nazanin Hosseinkhan, Zahra Narimani, Nastaran Masoudi-Khoram, Mohammad E. Khamseh
    Informatics in Medicine Unlocked.2023; 37: 101187.     CrossRef
  • Body Mass Index and Cancer Risk: An Umbrella Review of Meta-Analyses of Observational Studies
    Junhao Chen, Kaimin Ke, Zhenghuan Liu, Luchen Yang, Linchun Wang, Jing Zhou, Qiang Dong
    Nutrition and Cancer.2023; 75(4): 1051.     CrossRef
  • Anthropometric indicators of adiposity and risk of primary liver cancer: A systematic review and dose–response meta-analysis
    Lun-Jie Yan, Long-Shan Yang, Yu-Chuan Yan, Si-Yu Tan, Zi-Niu Ding, Hui Liu, Dong-Xu Wang, Zhao-Ru Dong, Tao Li
    European Journal of Cancer.2023; 185: 150.     CrossRef
  • Body mass index and serum alpha-fetoprotein level associated with PD1 expression and prognosis in patients with hepatocellular carcinoma
    Lili Yang, Jili Wang, Linpeng Yao, Cheng Chen, Junhan Pan, Ling Peng, Feng Chen
    Heliyon.2023; 9(4): e14460.     CrossRef
  • Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
    Yi-wen Shi, Jian-Gao Fan
    Clinical and Molecular Hepatology.2023; 29(Suppl): S228.     CrossRef
  • Can type 1 diabetes be an unexpected complication of obesity?
    Paulina Oboza, Natalia Ogarek, Magdalena Olszanecka-Glinianowicz, Piotr Kocelak
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation
    Carlo Bosi, Margherita Rimini, andrea Casadei-Gardini, Giorgio Ercolani
    Expert Review of Anticancer Therapy.2023; 23(5): 503.     CrossRef
  • Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study
    Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith
    Clinical and Molecular Hepatology.2023; 29(2): 433.     CrossRef
  • Occurrence of Liver Cancer in People without Traditional Risk Factors
    Junho Choi, Joohyun Park, Jae Kwang Lee, Kyunghee Cho
    Korean Journal of Clinical Geriatrics.2023; 24(1): 41.     CrossRef
  • Change in skeletal muscle mass is associated with hepatic steatosis in nonalcoholic fatty liver disease
    Ik Hyun Jo, Do Seon Song, U Im Chang, Jin Mo Yang
    Scientific Reports.2023;[Epub]     CrossRef
  • Body composition and risk of liver cancer: a population-based prospective cohort study on gender difference
    Sainan Pi, Anran Liu, Beibei Zhu, Yunxiao Zhu, Jinqiu Yuan, Zheming Zhang, Chang Gao, Jinxian Fu, Yao Liu, Xujing Liang, Bin Xia, Youpeng Chen
    Frontiers in Nutrition.2023;[Epub]     CrossRef
  • Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
    Beom Kyung Kim, Sang Hoon Ahn
    Journal of the Formosan Medical Association.2023; 122(12): 1238.     CrossRef
  • Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes
    Vivek Chavda, Kelsee K. Zajac, Jenna Lynn Gunn, Pankti Balar, Avinash Khadela, Dixa Vaghela, Shruti Soni, Charles R. Ashby, Amit K. Tiwari
    Cancer Reports.2023;[Epub]     CrossRef
  • Physiological and environmental factors affecting cancer risk and prognosis in obesity
    Paul F. Seke Etet, Lorella Vecchio, Armel H. Nwabo Kamdje, Patrice N. Mimche, Alfred K. Njamnshi, Abdu Adem
    Seminars in Cancer Biology.2023; 94: 50.     CrossRef
  • Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
    Byeong Geun Song, Sung Chul Choi, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik
    JHEP Reports.2023; 5(9): 100810.     CrossRef
  • Regional and sex differences in the mortality risk associated with primary liver cancer in obesity: A systematic review and meta-analysis
    Long-Shan Yang, Lun-Jie Yan, Yu-Chuan Yan, Zi-Niu Ding, Hui Liu, Si-Yu Tan, Zhao-Ru Dong, Dong-Xu Wang, Tao Li
    Nutrition.2023; 113: 112097.     CrossRef
  • Adipose distribution patterns as prognostic factors in patients with HCC: A systematic review and meta-analysis
    Shuo Shi, Haiyan Yi, Yi Zheng, Yuxuan Zhao, Dexin Yu
    European Journal of Radiology.2023; 167: 111025.     CrossRef
  • Impacto de la cirugía bariátrica en la incidencia de diferentes cánceres. Revisión narrativa
    Santiago Otero Parra, Juliana Pineda Ortega, Jorge Sebastián Ramírez Valbuena, William Alberto Otero Regino
    Revista colombiana de Gastroenterología.2023; 38(3): 321.     CrossRef
  • Latin American and the Caribbean Code Against Cancer 1st edition: Weight, physical activity, diet, breastfeeding, and cancer
    Tania C. Aburto, Isabelle Romieu, Mariana C. Stern, Simón Barquera, Camila Corvalán, Pedro C. Hallal, Luz M. Reynales-Shigematsu, Joaquín Barnoya, Tania M. Cavalcante, Carlos Canelo-Aybar, Marilina Santero, Ariadna Feliu, Carolina Espina, Juan A. Rivera
    Cancer Epidemiology.2023; 86: 102436.     CrossRef
  • Clinical significance of serum oxidative stress and serum uric acid levels before surgery for hepatitis B-related liver cancer
    Jin-Xia Hou, Yu-Bin Wang, Jing Wu, Guo-sheng Ding, Yang Wu, Lian-Hua Wei, Fang Wang, Zhe-Mei Zhang
    World Journal of Gastrointestinal Surgery.2023; 15(9): 1995.     CrossRef
  • Cancers attributable to overweight and obesity in Italy
    Matteo Di Maso, Claudio Pelucchi, Giulia Collatuzzo, Gianfranco Alicandro, Matteo Malvezzi, Fabio Parazzini, Eva Negri, Paolo Boffetta, Carlo La Vecchia, Federica Turati
    Cancer Epidemiology.2023; 87: 102468.     CrossRef
  • Development and External Validation of a Nomogram Including Body Composition Parameters for Predicting Early Recurrence of Hepatocellular Carcinoma After Hepatectomy
    Shuo Shi, Yu-Xuan Zhao, Jin-Lei Fan, Ling-Yu Chang, De-Xin Yu
    Academic Radiology.2023; 30(12): 2940.     CrossRef
  • Life‐course adiposity and severe liver disease: a Mendelian randomization analysis
    Xinyu Wang, Zhiyu Wu, Jun Lv, Canqing Yu, Dianjianyi Sun, Pei Pei, Ling Yang, Iona Y. Millwood, Robin Walters, Yiping Chen, Huaidong Du, Mingqiang Yuan, Dan Schmidt, Maxim Barnard, Junshi Chen, Zhengming Chen, Liming Li, Yuanjie Pang
    Obesity.2023; 31(12): 3077.     CrossRef
  • Non-alcoholic fatty liver disease and the risk of malignant tumors
    M. A. Livzan, M. I. Syrovenko, T. S. Krolevets
    Meditsinskiy sovet = Medical Council.2023; (18): 75.     CrossRef
  • Association between pro-inflammatory diet and liver cancer risk: a systematic review and meta-analysis
    Kaixia Chen, Fen Yang, Xinhong Zhu, Guiyuan Qiao, Chunmei Zhang, Junxiu Tao, Xiaolian Gao, Mingzhong Xiao
    Public Health Nutrition.2023; 26(12): 2780.     CrossRef
  • Life-long consumption of high level of fruits and vegetables reduces tumor incidence and extends median lifespan in mice
    Weimin Guo, Edwin F. Ortega, Dayong Wu, Lijun Li, Roderick T. Bronson, Sarah K. Boehm, Simin Nikbin Meydani
    Frontiers in Nutrition.2023;[Epub]     CrossRef
  • Association between glycolysis markers and prognosis of liver cancer: a systematic review and meta-analysis
    Boqin Wang, Rong Pu
    World Journal of Surgical Oncology.2023;[Epub]     CrossRef
  • Modeling the Risk of Liver Cancer in Adults: A Machine Learning Investigation into the Role of Obesity and Overweight
    Karamo Bah, Adama Ns Bah, Amadou Wurry Jallow
    Archives of Pathology and Clinical Research.2023; 7(1): 034.     CrossRef
  • Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL
    Hye Won Lee, Soo Young Park, Yu Rim Lee, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    American Journal of Gastroenterology.2022; 117(2): 288.     CrossRef
  • NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options
    Friedrich Foerster, Simon Johannes Gairing, Lukas Müller, Peter Robert Galle
    Journal of Hepatology.2022; 76(2): 446.     CrossRef
  • Changes in general and central fatness are associated with hepatocellular carcinoma: A Korean nationwide longitudinal study
    Mi Na Kim, Kyungdo Han, Juhwan Yoo, Yeonjung Ha, Young Eun Chon, Ju Ho Lee, Seong Gyu Hwang
    International Journal of Cancer.2022; 150(10): 1587.     CrossRef
  • Stratifying individuals into non-alcoholic fatty liver disease risk levels using time series machine learning models
    Ofir Ben-Assuli, Arie Jacobi, Orit Goldman, Shani Shenhar-Tsarfaty, Ori Rogowski, David Zeltser, Itzhak Shapira, Shlomo Berliner, Shira Zelber-Sagi
    Journal of Biomedical Informatics.2022; 126: 103986.     CrossRef
  • Study on the Application of Doxorubicin-Loaded Magnetic Nanodrugs in Targeted Therapy of Liver Cancer
    Lei Wang, Liping Liang, Shuzhen Shi, Chao Wang, Fahd Abd Algalil
    Applied Bionics and Biomechanics.2022; 2022: 1.     CrossRef
  • Insulin and cancer: a tangled web
    Brooks P. Leitner, Stephan Siebel, Ngozi D. Akingbesote, Xinyi Zhang, Rachel J. Perry
    Biochemical Journal.2022; 479(5): 583.     CrossRef
  • Effects of image-guided adaptive radiotherapy combined with hepatic artery chemoembolization in primary liver cancer patients
    Yingchun Zhao, Changwang Zhang, Yongqian Zhang, Changwen Bo, Yonghui An, Na Li, Wenhua Ma, Changpeng Zou, Liping Zhao, Sujing Zhang
    Clinics and Research in Hepatology and Gastroenterology.2022; 46(5): 101889.     CrossRef
  • Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the Apoptosis
    Zijun Yan, Kun Yang, Xiang Tang, Yunfeng Bi, Yuzhen Ding, Mengyue Deng, Die Xia, Yunqi Zhao, Tong Chen, Fu Wang
    Journal of Immunology Research.2022; 2022: 1.     CrossRef
  • Risk factors of liver malignancies in workers chronically exposed to ionizing radiation
    Galina V. Zhuntova, Mariya V. Bannikova, Tamara V. Azizova
    Ekologiya cheloveka (Human Ecology).2022; 29(5): 333.     CrossRef
  • Exercise in cancer prevention and anticancer therapy: Efficacy, molecular mechanisms and clinical information
    Chuanmei Zhu, Hongbo Ma, Anqi He, Yi Li, Chengqi He, Yong Xia
    Cancer Letters.2022; 544: 215814.     CrossRef
  • Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma
    Pil Soo Sung
    Clinical and Molecular Hepatology.2022; 28(3): 333.     CrossRef
  • The timing of adiposity and changes in the life course on the risk of cancer
    Zhe Fang, Edward L. Giovannucci
    Cancer and Metastasis Reviews.2022; 41(3): 471.     CrossRef
  • Association between metabolic syndrome, C-reactive protein, and the risk of primary liver cancer: a large prospective study
    Mengmeng Song, Tong Liu, Hai Liu, Qi Zhang, Qingsong Zhang, Yiming Wang, Xiangming Ma, Liying Cao, Hanping Shi
    BMC Cancer.2022;[Epub]     CrossRef
  • Response to Liao et al.
    Byungyoon Yun, Jin-Ha Yoon, Beom Kyung Kim
    American Journal of Gastroenterology.2022; 117(10): 1718.     CrossRef
  • Current cancer burden in China: epidemiology, etiology, and prevention
    Maomao Cao, He Li, Dianqin Sun, Siyi He, Xinxin Yan, Fan Yang, Shaoli Zhang, Changfa Xia, Lin Lei, Ji Peng, Wanqing Chen
    Cancer Biology & Medicine.2022; 19(8): 1121.     CrossRef
  • Metabolic syndrome, obesity and cancer risk
    Federico Belladelli, Francesco Montorsi, Alberto Martini
    Current Opinion in Urology.2022; 32(6): 594.     CrossRef
  • Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    Cancers.2022; 14(20): 5002.     CrossRef
  • Gender Dimorphism in Hepatic Carcinogenesis-Related Gene Expression Associated with Obesity as a Low-Grade Chronic Inflammatory Disease
    Andrea G. Izquierdo, Marcos C. Carreira, Gemma Rodriguez-Carnero, Raquel Perez-Lois, Luisa M. Seoane, Felipe F. Casanueva, Ana B. Crujeiras
    International Journal of Molecular Sciences.2022; 23(23): 15002.     CrossRef
  • UEG position paper: Obesity and digestive health
    Patrizia Burra, Marianna Arvanitakis, Jorge Amil Dias, Michael Bretthauer, Ana Dugic, Daniel Hartmann, Patrick Michl, Thomas Seufferlein, Joana Torres, Hans Törnblom, Monique E. van Leerdam, Shira Zelber‐Sagi, Andreea Botos
    United European Gastroenterology Journal.2022; 10(10): 1199.     CrossRef
  • Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis
    Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim
    Diagnostics.2022; 13(1): 3.     CrossRef
  • Obesity as a Risk Factor for Different Cancers: Systematic Review
    Abdelrahman Mohamed Ahmed Abukanna, Ziyad Mubarak S Alanazi, Amer Meshal H Alanazi, Atheer Humaidy S Alenazi, Abdulrahman Obaid A Alanazi, Khaloud Attaulla Alenezi, Gharam Mahmood Alsalmi
    Clinical Cancer Investigation Journal.2022; 11(6): 45.     CrossRef
  • Obesity as a Risk Factor for Various Cancers: A Systematic Review
    Abdelrahman Mohamed Ahmed Abukanna, Ziyad Mubarak S Alanazi, Amer Meshal H Alanazi, Atheer Humaidy S Alenazi, Abdulrahman Obaid A Alanazi, Khaloud Attaulla Alenezi, Gharam Mahmood Alsalmi
    Asian journal of Current Research in Clinical Cancer.2022; 2(2): 6.     CrossRef
  • Metabolic disease as a risk of hepatocellular carcinoma
    Naoshi Nishida
    Clinical and Molecular Hepatology.2021; 27(1): 87.     CrossRef
  • Transcript levels of spindle and kinetochore-associated complex 1/3 as prognostic biomarkers correlated with immune infiltrates in hepatocellular carcinoma
    De-Chen Yu, Xiang-Yi Chen, Xin Li, Hai-Yu Zhou, De-Quan Yu, Xiao-Lei Yu, Yi-Cun Hu, Rui-Hao Zhang, Xiao-Bo Zhang, Kun Zhang, Jiang-Dong An
    Scientific Reports.2021;[Epub]     CrossRef
  • Obesity as a risk factor for diseases of the digestive system
    Dmitry N. Andreev, Yury A. Kucheryavyy
    Terapevticheskii arkhiv.2021; 93(8): 954.     CrossRef
  • Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1
    Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho
    International Journal of Molecular Sciences.2021; 22(18): 10027.     CrossRef
  • Lifestyle and Hepatocellular Carcinoma What Is the Evidence and Prevention Recommendations
    Shira Zelber-Sagi, Mazen Noureddin, Oren Shibolet
    Cancers.2021; 14(1): 103.     CrossRef
  • 16,660 View
  • 487 Download
  • 124 Web of Science
  • Crossref

COVID-19

Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: A multicenter study in South Korea
Yu Rim Lee, Min Kyu Kang, Jeong Eun Song, Hyun Jung Kim, Young Oh Kweon, Won Young Tak, Se Young Jang, Jung Gil Park, Changhyeong Lee, Jae Seok Hwang, Byoung Kuk Jang, Jeong Ill Suh, Woo Jin Chung, Byung Seok Kim, Soo Young Park
Clin Mol Hepatol 2020;26(4):562-576.
Published online October 1, 2020
DOI: https://doi.org/10.3350/cmh.2020.0126
Background/Aims
Although coronavirus disease 2019 (COVID-19) has spread rapidly worldwide, the implication of pre-existing liver disease on the outcome of COVID-19 remains unresolved.

Methods
A total of 1,005 patients who were admitted to five tertiary hospitals in South Korea with laboratory-confirmed COVID-19 were included in this study. Clinical outcomes in COVID-19 patients with coexisting liver disease as well as the predictors of disease severity and mortality of COVID-19 were assessed.

Results
Of the 47 patients (4.7%) who had liver-related comorbidities, 14 patients (1.4%) had liver cirrhosis. Liver cirrhosis was more common in COVID-19 patients with severe pneumonia than in those with non-severe pneumonia (4.5% vs. 0.9%, P=0.006). Compared to patients without liver cirrhosis, a higher proportion of patients with liver cirrhosis required oxygen therapy; were admitted to the intensive care unit; had septic shock, acute respiratory distress syndrome, or acute kidney injury; and died (P<0.05). The overall survival rate was significantly lower in patients with liver cirrhosis than in those without liver cirrhosis (log-rank test, P=0.003). Along with old age and diabetes, the presence of liver cirrhosis was found to be an independent predictor of severe disease (odds ratio, 4.52; 95% confidence interval [CI], 1.20–17.02;P=0.026) and death (hazard ratio, 2.86; 95% CI, 1.04–9.30; P=0.042) in COVID-19 patients.

Conclusions
This study suggests liver cirrhosis is a significant risk factor for COVID-19. Stronger personal protection and more intensive treatment for COVID-19 are recommended in these patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Global geographic and socioeconomic disparities in COVID-associated acute kidney injury: a systematic review and meta-analysis
    Danyang Dai, Pedro Franca Gois, Digby Simpson, Souhayel Hedfi, Sally Shrapnel, Jason Donald Pole
    Journal of Global Health.2025;[Epub]     CrossRef
  • Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors
    Levente Zsichla, Viktor Müller
    Viruses.2023; 15(1): 175.     CrossRef
  • SARS-CoV-2 induced liver injury: Incidence, risk factors, impact on COVID-19 severity and prognosis in different population groups
    George D Liatsos
    World Journal of Gastroenterology.2023; 29(16): 2397.     CrossRef
  • COVID-19 and severity of liver diseases: Possible crosstalk and clinical implications
    Mohammad T. Imam, Ziyad S. Almalki, Abdullah R. Alzahrani, Saeed S. Al-Ghamdi, Alaa H. Falemban, Ibrahim M. Alanazi, Naiyer Shahzad, Munira Muhammad Alrooqi, Qaiser Jabeen, Imran Shahid
    International Immunopharmacology.2023; 121: 110439.     CrossRef
  • Clinical Effect of Hepatitis B Virus on COVID-19 Infected Patients: A Nationwide Population-Based Study Using the Health Insurance Review & Assessment Service Database
    Jung Wan Choe, Young Kul Jung, Hyung Joon Yim, Gi Hyeon Seo
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis
    Abraham Degarege, Zaeema Naveed, Josiane Kabayundo, David Brett-Major
    Pathogens.2022; 11(5): 563.     CrossRef
  • COVID-19 Severity and Mortality Among Chronic Liver Disease Patients: A Systematic Review and Meta-Analysis
    Ramya Nagarajan, Yuvaraj Krishnamoorthy, Sathish Rajaa, Vishnu Shankar Hariharan
    Preventing Chronic Disease.2022;[Epub]     CrossRef
  • Forms of cholangitis to be considered after SARS-CoV-2 infection
    Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim
    Clinical and Molecular Hepatology.2022; 28(4): 929.     CrossRef
  • A systems biology approach for investigating significantly expressed genes among COVID-19, hepatocellular carcinoma, and chronic hepatitis B
    Babak Sokouti
    Egyptian Journal of Medical Human Genetics.2022;[Epub]     CrossRef
  • Autoimmune liver disease represented as primary biliary cholangitis after SARS-CoV-2 infection: A need for population-based cohort study
    Soon Kyu Lee, Jung Hyun Kwon, Nara Yoon, Soon Woo Nam, Pil Soo Sung
    Clinical and Molecular Hepatology.2022; 28(4): 926.     CrossRef
  • Prognostic Impact of Myosteatosis on Mortality in Hospitalized Patients with COVID-19
    Min-Kyu Kang, Yu-Rim Lee, Jeung-Eun Song, Young-Oh Kweon, Won-Young Tak, Se-Young Jang, Jung-Gil Park, Soo-Young Park
    Diagnostics.2022; 12(9): 2255.     CrossRef
  • The association of chronic liver disorders with exacerbation of symptoms and complications related to COVID‐19: A systematic review and meta‐analysis of cohort studies
    Maryam Afraie, Pardis Mohammadzedeh, Mobin Azami, Sorour Khateri, Kamran Zamani, Farhad Moradpour, Yousef Moradi
    The Clinical Respiratory Journal.2022; 16(12): 777.     CrossRef
  • COVID-19 With Preexisting Hypercoagulability Digestive Disease
    Mingshan Jiang, Jingxi Mu, Silan Shen, Hu Zhang
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • A narrative review on characterization of acute respiratory distress syndrome in COVID-19-infected lungs using artificial intelligence
    Jasjit S. Suri, Sushant Agarwal, Suneet K. Gupta, Anudeep Puvvula, Mainak Biswas, Luca Saba, Arindam Bit, Gopal S. Tandel, Mohit Agarwal, Anubhav Patrick, Gavino Faa, Inder M. Singh, Ronald Oberleitner, Monika Turk, Paramjit S. Chadha, Amer M. Johri, J. M
    Computers in Biology and Medicine.2021; 130: 104210.     CrossRef
  • COVID‐19 in hospitalized liver transplant recipients: An early systematic review and meta‐analysis
    Kumar Jayant, Isabella Reccia, Francesco Virdis, Jordan S. Pyda, Piotr J. Bachul, Diego di Sabato, Rolf N. Barth, John Fung, Talia Baker, Piotr Witkowski
    Clinical Transplantation.2021;[Epub]     CrossRef
  • Management of Patients with Chronic Liver Disease: The Era of the COVID-19 Pandemic
    Yu Rim Lee
    The Korean Journal of Gastroenterology.2021; 77(4): 156.     CrossRef
  • Patients with cirrhosis during the COVID-19 pandemic: Current evidence and future perspectives
    Hung-Yuan Su, Yin-Chou Hsu
    World Journal of Clinical Cases.2021; 9(13): 2951.     CrossRef
  • Italian association for the study of the liver position statement on SARS-CoV2 vaccination
    Francesco Paolo Russo, Salvatore Piano, Raffaele Bruno, Patrizia Burra, Massimo Puoti, Mario Masarone, Sara Montagnese, Francesca Romana Ponziani, Salvatore Petta, Alessio Aghemo
    Digestive and Liver Disease.2021; 53(6): 677.     CrossRef
  • Angiotensin-converting enzyme 2 receptors, chronic liver diseases, common medications, and clinical outcomes in coronavirus disease 2019 patients
    Wattana Leowattana
    World Journal of Virology.2021; 10(3): 86.     CrossRef
  • Impact of COVID-19 on liver
    Yu-Jang Su, Chen-Wang Chang, Ming-Jen Chen, Yen-Chun Lai
    World Journal of Clinical Cases.2021; 9(27): 7998.     CrossRef
  • Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline
    Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim
    Clinical and Molecular Hepatology.2021; 27(4): 515.     CrossRef
  • Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies
    Paul Middleton, Catherine Hsu, Mark P Lythgoe
    BMJ Open Gastroenterology.2021; 8(1): e000739.     CrossRef
  • Multicenter Analysis of Clinical Features and Prognosis of COVID-19 Patients with Hepatic Impairment
    Jeong Eun Song, Min Kyu Kang, Yu Rim Lee, Chang Hyeong Lee, Jung Gil Park, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jae Seok Hwang, Byoung Kuk Jang, Won Young Jang, Jeong Ill Suh, Woo Jin Chung, Byung Seok Kim
    Gut and Liver.2021; 15(4): 606.     CrossRef
  • Critical Update on the Diagnosis and Management of COVID-19 in Advanced Cirrhosis and Liver Transplant Recipients
    Cyriac Abby Philips, Mohamed Rela, Arvinder Singh Soin, Subhash Gupta, Sudhindran Surendran, Philip Augustine
    Journal of Clinical and Translational Hepatology.2021; 000(000): 000.     CrossRef
  • 11,628 View
  • 190 Download
  • 23 Web of Science
  • Crossref

Viral hepatitis

Are there differences in risk factors, microbial aspects, and prognosis of cellulitis between compensated and decompensated hepatitis C virus-related cirrhosis?
Elham Ahmed Hassan, Abeer Sharaf El-Din Abdel Rehim, Mohamed Omar Abdel-Malek, Asmaa Omar Ahmed, Nourhan Mahmoud Abbas
Clin Mol Hepatol 2019;25(3):317-325.
Published online June 10, 2019
DOI: https://doi.org/10.3350/cmh.2018.0097
Background/Aims
Cellulitis is a common infection in patients with liver cirrhosis. We aimed to compare risk factors, microbial aspects, and outcomes of cellulitis in compensated and decompensated hepatitis C virus (HCV)-related cirrhosis.
Methods
Six hundred twenty consecutive HCV-related cirrhotic patients were evaluated for cellulitis. Demographic and clinical data were evaluated, along with blood and skin cultures. Severity of cirrhosis was assessed using Child-Pugh score. In-hospital mortality was assessed.
Results
Seventy-seven (12.4%) cirrhotic patients had cellulitis (25 with compensated and 52 with decompensated disease). Smoking and venous insufficiency were risk factors of cellulitis in compensated cirrhosis. Leg edema, ascites, hyperbilrubinemia and hypoalbuminemia were risk factors in decompensated cirrhosis. Gram-positive bacteria (Staphylococcus spp. and Streptococcus pyogenes) were the infective organisms in compensated patients, while gram negative bacteria (Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa) were the predominant organisms in decompensated cirrhosis. Fungi (Candida albicans and Aspergillus niger) were detected in 3 decompensated cases. In-hospital mortality in patients with cellulitis was 27.3%, approaching 100% in decompensated patients with gram-negative cellulitis. Prolonged hospitalization, higher model for end-stage liver disease (MELD)-Na score, septic shock, local complication, and recurrent cellulitis were predictors of mortality.
Conclusions
Cellulitis in compensated cirrhosis is different from that of decompensated patients regarding microorganisms, pathogenesis, and prognosis. Cellulitis has a poor prognosis, with mortality rates approaching 100% in decompensated patients with gram-negative cellulitis. Stratifying patients according to severity of cirrhosis is important to identify the proper empirical antibiotic and to decide the proper means of care.

Citations

Citations to this article as recorded by  Crossref logo
  • Fungal mycobiome dysbiosis in choledocholithiasis concurrent with cholangitis
    Zhiyuan Hao, Yiting Lu, Yarong Hao, Yuanyuan Luo, Kaiming Wu, Changpeng Zhu, Peimei Shi, Feng Zhu, Yong Lin, Xin Zeng
    Journal of Gastroenterology.2025; 60(3): 340.     CrossRef
  • Mortality trends for cellulitis-related death in older adults in the United States: 24-year CDC analysis of gender, race, and geographical disparities
    Muhammad Shaheer Bin Faheem, Syeda Umbreen Munir, Mahnoor Javed, Syed Tawassul Hassan, Muhammad Bilal Masood, Kanz Ul Eman Maryam, Shamikha Cheema, Sumaya Samadi, Muhammad Idrees Khan
    Annals of Medicine & Surgery.2025; 87(12): 8471.     CrossRef
  • Epidemiological Trend of Sepsis in Patients with Hospital Admissions Related to Hepatitis C in Spain (2000–2015): A Nationwide Study
    Alejandro Alvaro-Meca, Irene Maté-Cano, Pablo Ryan, Verónica Briz, Salvador Resino
    Journal of Clinical Medicine.2020; 9(6): 1607.     CrossRef
  • 14,310 View
  • 131 Download
  • 4 Web of Science
  • Crossref

Review

Viral hepatitis

Unmet need in chronic hepatitis B management
Lilian Yan Liang, Grace Lai-Hung Wong
Clin Mol Hepatol 2019;25(2):172-180.
Published online February 12, 2019
DOI: https://doi.org/10.3350/cmh.2018.0106
Despite all these exciting developments, there remain some unmet needs in the management for patients with chronic hepatitis B (CHB). As majority of CHB patients are going to use oral nucleos(t)ide analogues (NAs) for decades, Safety profile of NAs is of no doubt an important issue. The newest nucleotide analogue tenofovir alafenamide is potent in terms of viral suppression, together with favourable renal and bone safety profile. Biochemical response as reflected by alanine aminotransferase (ALT) normalization is recently found to be prognostically important. Patients who achieved ALT normalization have reduced the risk of hepatic events by 49%. Functional cure as reflected by hepatitis B surface antigen seroclearance not only implies patients may stop NA treatment, it also confers to a reduced risk of hepatocellular carcinoma and other hepatic events. Hence functional cure should be the ultimate treatment goal in CHB patients. Preemptive antiviral treatment may reduce mother-to-child transmission of hepatitis B virus, especially if birth dose of vaccination cannot be given in the first two hours after delivery. Lastly, despite the currently first-line NAs have high-genetic barrier to drug resistance mutations, there are still are many patients who were previously treated with low barrier of resistance including lamivudine, telbivudine or adefovir dipivoxil which could lead to antiviral resistance and affecting the choice of NAs.

Citations

Citations to this article as recorded by  Crossref logo
  • Why and when could nucleos(t)ide analogues treatment be withdrawn?
    Jimmy Che-To Lai, Piero Colombatto, Grace Lai-Hung Wong, Maurizia Rossana Brunetto
    Digestive and Liver Disease.2025; 57(2): 558.     CrossRef
  • Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination
    Grace Lai-Hung Wong, Henry Lik-Yuen Chan
    Hepatology.2025; 82(5): 1056.     CrossRef
  • Long-Term Safety and Efficacy of Tenofovir Alafenamide in Chronic Hepatitis B: Raising the Need for Studies on Functional Cure—Editorial on “Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B”
    Soon Kyu Lee
    The Korean Journal of Gastroenterology.2025; 85(3): 245.     CrossRef
  • Nationwide analysis of renal outcomes in chronic hepatitis B patients treated with Tenofovir Alafenamide vs. Entecavir
    Hyuk Kim, Jae Young Kim, Hye-Jin Yoo, Log Young Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
    Scientific Reports.2025;[Epub]     CrossRef
  • Envisioning a Multidisciplinary HBV Cure Research Agenda
    Karine Dubé, Ali Ahmed, Chari Cohen, Yasmin Ibrahim, George A. Yendewa, Edward R. Cachay, Su Wang, Kristen Marks, Arthur Y. Kim, Jeremy Sugarman, David L. Thomas, Chloe L. Thio, Debika Bhattacharya
    Current HIV/AIDS Reports.2025;[Epub]     CrossRef
  • Effect of antiviral therapy on 3-year recurrence and prognosis of hepatocellular carcinoma after curative radiofrequency ablation
    Bai-Guo Xu, Xue Zhang, Fang Liu, Feng-Hui Li, Xu Zhang, Hui-Ling Xiang, Jing Liang
    World Journal of Gastrointestinal Oncology.2025;[Epub]     CrossRef
  • Management of Hepatitis B in Pregnancy
    Jeanette Rios, Lital Aliasi-Sinai, Natalia Schmidt, Tatyana Kushner
    Current Hepatology Reports.2024; 23(2): 278.     CrossRef
  • Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy
    Jae Seung Lee, Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Beom Seok Kim, Seung Up Kim
    Alimentary Pharmacology & Therapeutics.2023; 58(1): 99.     CrossRef
  • Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir
    Gui-Cai Yuan, Ai-Zhen Chen, Wei-Xin Wang, Xu-Lan Yi, Long Tu, Fang Peng, Zhi-Hong Qiu
    World Journal of Clinical Cases.2023; 11(34): 8139.     CrossRef
  • Air pollution impede ALT normalization in chronic hepatitis B patients treated with nucleotide/nucleoside analogues
    Tyng-Yuan Jang, Chi-Chang Ho, Chih-Da Wu, Chia-Yen Dai, Pau-Chung Chen
    Medicine.2023; 102(43): e34276.     CrossRef
  • Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL
    Hye Won Lee, Soo Young Park, Yu Rim Lee, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    American Journal of Gastroenterology.2022; 117(2): 288.     CrossRef
  • Clinical Outcomes of Hepatitis B Virus–Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels
    Jong-In Chang, Dong Hyun Sinn, Hyun Cho, Seonwoo Kim, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
    Digestive Diseases and Sciences.2022; 67(9): 4565.     CrossRef
  • External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, In Kyung Min, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2022; 14(3): 711.     CrossRef
  • Long‐term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study
    Young Eun Chon, Soo Young Park, Seung Up Kim, Han Pyo Hong, Jae Seung Lee, Hye Won Lee, Mi Na Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Viral Hepatitis.2022; 29(4): 289.     CrossRef
  • Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation
    Zili Hu, Huilan Zeng, Jingyu Hou, Juncheng Wang, Li Xu, Yaojun Zhang, Minshan Chen, Zhongguo Zhou
    Viruses.2022; 14(4): 656.     CrossRef
  • Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles
    Hung-Yao Lin, Tai-Chung Tseng
    Clinical and Molecular Hepatology.2022; 28(2): 181.     CrossRef
  • Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate
    Lilian Yan Liang, Terry Cheuk‐Fung Yip, Jimmy Che‐To Lai, Amy Shuk‐Man Lam, Yee‐Kit Tse, Vicki Wing‐Ki Hui, Henry Lik‐Yuen Chan, Vincent Wai‐Sun Wong, Grace Lai‐Hung Wong
    Journal of Medical Virology.2022; 94(9): 4440.     CrossRef
  • Discovery and antiviral profile of new sulfamoylbenzamide derivatives as HBV capsid assembly modulators
    Leda Ivanova Bencheva, Lorena Donnici, Luca Ferrante, Adolfo Prandi, Roberta Sinisi, Marilenia De Matteo, Pietro Randazzo, Matteo Conti, Pietro Di Lucia, Elisa Bono, Leonardo Giustini, Maria Vittoria Orsale, Alexandros Patsilinakos, Edith Monteagudo, Matt
    Bioorganic & Medicinal Chemistry Letters.2022; 73: 128904.     CrossRef
  • Development and Validation of Prognostic Nomograms for Hepatocellular Carcinoma After Hepatectomy Based on Inflammatory Markers
    Zili Hu, Yu Yuan, Zhiwen Hu, Qingbo Liu, Yizhen Fu, Jingyu Hou, Xuqi Sun, Shaoqiang Li, Wenbin Duan, Minshan Chen
    Journal of Hepatocellular Carcinoma.2022; Volume 9: 1403.     CrossRef
  • Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues
    Tyng-Yuan Jang, Yu-Ju Wei, Ming-Lun Yeh, Shu-Fen Liu, Cheng-Ting Hsu, Po-Yao Hsu, Ta-Wei Liu, Yi-Hung Lin, Po-Cheng Liang, Meng-Hsuan Hsieh, Yu-Min Ko, Yi-Shan Tsai, Kuan-Yu Chen, Ching-Chih Lin, Pei-Chien Tsai, Shu-Chi Wang, Ching-I. Huang, Zu-Yau Lin, S
    Journal of the Formosan Medical Association.2021; 120(1): 303.     CrossRef
  • Cost-Effectiveness Analysis of Antiviral Therapy for Untreated Minimally Active Chronic Hepatitis B to Prevent Liver Disease Progression
    Hankil Lee, Beom Kyung Kim, Sungin Jang, Sang Hoon Ahn
    Clinical and Translational Gastroenterology.2021; 12(2): e00299.     CrossRef
  • External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals
    Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Viral Hepatitis.2021; 28(6): 951.     CrossRef
  • Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact
    Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong
    Clinical and Molecular Hepatology.2021; 27(2): 273.     CrossRef
  • Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
    Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
    Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123.     CrossRef
  • B Cell-mediated Humoral Immunity in Chronic Hepatitis B Infection
    Yang Li, Shengxia Yin, Rahma Issa, Xin Tong, Guiyang Wang, Juan Xia, Rui Huang, Guangmei Chen, Dan Weng, Chen Chen, Chao Wu, Yuxin Chen
    Journal of Clinical and Translational Hepatology.2021; 000(000): 000.     CrossRef
  • The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
    Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 467.     CrossRef
  • Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients
    David Sooik Kim, Soo Young Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Yu Rim Lee, Won Young Tak, Young Oh Kweon, Inkyung Jung, Minkyung Han, Eun Hwa Kim, Sang Hoon Ahn, Seung Up Kim
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus–related hepatocellular carcinoma
    Ji Hyun Lee, Beom Kyung Kim, Soo Young Park, Won Young Tak, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Dong Hyun Sinn, Seung Up Kim
    European Journal of Internal Medicine.2021; 89: 48.     CrossRef
  • Benefits and Risks of Antiviral Treatment during Pregnancy in Patients with Chronic Hepatitis B
    Yoon Seok Lee, Soo Min Bang, Young-Sun Lee
    Journal of Clinical Medicine.2021; 10(11): 2320.     CrossRef
  • Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial
    Do Seon Song, Won Kim, Sang Hoon Ahn, Hyung Joon Yim, Jae Young Jang, Young Oh Kweon, Yong Kyun Cho, Yoon Jun Kim, Gun Young Hong, Dong Joon Kim, Young Kul Jung, Joo Hyun Sohn, Jin-Woo Lee, Sung Jae Park, Byung Seok Lee, Ju Hyun Kim, Hong Soo Kim, Seung K
    Clinical and Molecular Hepatology.2021; 27(2): 346.     CrossRef
  • Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
    Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim
    Cancers.2021; 13(14): 3424.     CrossRef
  • Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Journal of Viral Hepatitis.2021; 28(11): 1570.     CrossRef
  • Reactivation of Resolved Hepatitis B After Daratumumab for Multiple Myeloma
    Soon Kyu Lee, Pil Soo Sung, Sung-Soo Park, Chang-Ki Min, Heechul Nam, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon
    Clinical Infectious Diseases.2021; 73(6): e1372.     CrossRef
  • The effect of nucleos(t)ide analogues on clinical outcomes of patients treated with transarterial chemoembolization and radiofrequency ablation for hepatitis B virus-related hepatocellular carcinoma
    Jae Min Park, Won Hyeok Choe, Jeong Han Kim, So Young Kwon, Byung Chul Yoo
    Journal of Liver Cancer.2021; 21(2): 155.     CrossRef
  • Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2021; 13(23): 5892.     CrossRef
  • Tenofovir disoproxil fumarate directly ameliorates liver fibrosis by inducing hepatic stellate cell apoptosis via downregulation of PI3K/Akt/mTOR signaling pathway
    Sung Won Lee, Sung Min Kim, Wonhee Hur, Byung-Yoon Kang, Hae Lim Lee, Heechul Nam, Sun Hong Yoo, Pil Soo Sung, Jung Hyun Kwon, Jeong Won Jang, Seong-Jun Kim, Seung Kew Yoon, Partha Mukhopadhyay
    PLOS ONE.2021; 16(12): e0261067.     CrossRef
  • An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory‐Wide Study From 2000 to 2017
    Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong, Becky Wing‐Yan Yuen, Yee‐Kit Tse, Hester Wing‐Sum Luk, Terry Cheuk‐Fung Yip, Vicki Wing‐Ki Hui, Lilian Yan Liang, Grace Chung‐Yan Lui, Henry Lik‐Yuen Chan
    Hepatology.2020; 71(2): 444.     CrossRef
  • Reply to: “Comment on – A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea”
    Beom Kyung Kim
    Journal of Hepatology.2020; 72(1): 198.     CrossRef
  • Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy
    Mi Na Kim, Ju Ho Lee, Young Eun Chon, Yeonjung Ha, Seong Gyu Hwang
    European Journal of Gastroenterology & Hepatology.2020; 32(3): 433.     CrossRef
  • Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase
    Hye Won Lee, Eun Hwa Kim, Jinae Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Beom Kyung Kim
    Clinical and Translational Gastroenterology.2020; 11(3): e00140.     CrossRef
  • Preferences of Patients with Chronic Hepatitis B – A Discrete Choice Experiment on the Acceptability of Functional Cure


    Fraence Hardtstock, Urbano Sbarigia, Zeki Kocaata, Thomas Wilke, Shirley V Sylvester
    Patient Preference and Adherence.2020; Volume 14: 613.     CrossRef
  • Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance
    Hyun Woong Lee, Jung Il Lee, Saein Kim, Sora Kim, Hye Young Chang, Kwan Sik Lee
    BMC Gastroenterology.2020;[Epub]     CrossRef
  • An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well‐controlled viremia
    Hye W. Lee, Soo Y. Park, Myeongjee Lee, Eun J. Lee, Jinae Lee, Seung U. Kim, Jun Y. Park, Do Y. Kim, Sang H. Ahn, Beom K. Kim
    Liver International.2020; 40(7): 1736.     CrossRef
  • Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
    Hyun Young Woo, Jun Yong Park, Si Hyun Bae, Chang Wook Kim, Jae Young Jang, Won Young Tak, Dong Joon Kim, In Hee Kim, Jeong Heo, Sang Hoon Ahn
    Clinical and Molecular Hepatology.2020; 26(3): 352.     CrossRef
  • Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents
    Jingying Qiu, Qingqing Zhou, Yinpeng Zhang, Mingyu Guan, Xin Li, Yueting Zou, Xuan Huang, Yali Zhao, Wang Chen, Xiaoke Gu
    European Journal of Medicinal Chemistry.2020; 205: 112581.     CrossRef
  • Editorial: tenofovir disoproxil fumarate vs entecavir in patients with chronic hepatitis B and renal impairment—still an open issue
    Sung Won Lee, Seung Up Kim
    Alimentary Pharmacology & Therapeutics.2020; 52(5): 889.     CrossRef
  • A multi‐centre study of trends in hepatitis B virus‐related hepatocellular carcinoma risk over time during long‐term entecavir therapy
    Seung Up Kim, Yong Eun Chon, Yeon Seok Seo, Hye Won Lee, Han Ah Lee, Mi Na Kim, In Kyung Min, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Won Young Tak, Beom Kyung Kim, Soo Young Park
    Journal of Viral Hepatitis.2020; 27(12): 1352.     CrossRef
  • Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop
    Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, Eileen L. Yoon, Hana Park, Jung Hyun Kwon, Dong Hyun Sinn, Sae Hwan Lee, Jeong-Hoon Lee, Hyun Woong Lee
    Clinical and Molecular Hepatology.2020; 26(4): 411.     CrossRef
  • Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion


    Sojung Han, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Dai Hoon Han, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2020; Volume 7: 403.     CrossRef
  • Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study
    Seung Up Kim, Yeon Seok Seo, Han Ah Lee, Mi Na Kim, Eun Ju Lee, Hye Jung Shin, Yu Rim Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Soon Ho Um, Won Young Tak, Young Oh Kweon, Beom Kyung Kim, Soo Young Park
    Cancer Epidemiology, Biomarkers & Prevention.2020; 29(4): 832.     CrossRef
  • Reply to: “Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction”
    Beom Kyung Kim
    Journal of Hepatology.2019; 71(4): 847.     CrossRef
  • 13,965 View
  • 411 Download
  • 50 Web of Science
  • Crossref

Original Articles

Liver fibrosis, cirrhosis, and portal hypertension

The refit model for end-stage liver disease-Na is not a better predictor of mortality than the refit model for end-stage liver disease in patients with cirrhosis and ascites
Jun Jae Kim, Jeong Han Kim, Ja Kyung Koo, Yun Jung Choi, Soon Young Ko, Won Hyeok Choe, So Young Kwon
Clin Mol Hepatol 2014;20(1):47-55.
Published online March 26, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.1.47
Background/Aims

The modification of the Model for End-Stage Liver Disease (MELD) scoring system (Refit MELD) and the modification of MELD-Na (Refit MELDNa), which optimized the MELD coefficients, were published in 2011. We aimed to validate the superiority of the Refit MELDNa over the Refit MELD for the prediction of 3-month mortality in Korean patients with cirrhosis and ascites.

Methods

We reviewed the medical records of patients admitted with hepatic cirrhosis and ascites to the Konkuk University Hospital between January 2006 and December 2011. The Refit MELD and Refit MELDNa were compared using the predictive value of the 3-month mortality, as assessed by the Child-Pugh score.

Results

In total, 530 patients were enrolled, 87 of whom died within 3 months. Alcohol was the most common etiology of their cirrhosis (n=271, 51.1%), and the most common cause of death was variceal bleeding (n=20, 23%). The areas under the receiver operating curve (AUROCs) for the Child-Pugh, Refit MELD, and Refit MELDNa scores were 0.754, 0.791, and 0.764 respectively; the corresponding values when the analysis was performed only in patients with persistent ascites (n=115) were 0.725, 0.804, and 0.796, respectively. The significant difference found among the Child-Pugh, Refit MELD, and Refit MELDNa scores was between the Child-Pugh score and Refit MELD in patients with persistent ascites (P=0.039).

Conclusions

Refit MELD and Refit MELDNa exhibited good predictability for 3-month mortality in patients with cirrhosis and ascites. However, Refit MELDNa was not found to be a better predictor than Refit MELD, despite the known relationship between hyponatremia and mortality in cirrhotic patients with ascites.

Citations

Citations to this article as recorded by  Crossref logo
  • Multimodal ultrasound: a non-invasive method for identifying dedifferentiation of papillary thyroid carcinoma during active surveillance
    Qian-Yi Dou, Huan-Ling Guo, Wan-Bing Qiu, Ming Xu, Shu-Ling Chen, Xiao-Er Zhang, Xiao-Yan Xie, Jin-Yu Liang
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • The diagnostic accuracy of ascitic calprotectin for the early diagnosis of spontaneous bacterial peritonitis: systematic review and meta-analysis
    Alexandros Hadjivasilis, Alexander Tzanis, Kalliopi J. Ioakim, Ioanna Poupoutsi, Aris P. Agouridis, Panayiotis Kouis
    European Journal of Gastroenterology & Hepatology.2021; 33(3): 312.     CrossRef
  • Influence of preoperative sodium concentration on outcome of patients with hepatitis B virus cirrhosis after liver transplantation
    Peijie Wang, Gang Huang, Ngalei Tam, Chenglin Wu, Shunjun Fu, Bridget P. Hughes, Linwei Wu, Xiaoshun He
    European Journal of Gastroenterology & Hepatology.2016; 28(10): 1210.     CrossRef
  • 9,194 View
  • 51 Download
  • 6 Web of Science
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Predictive factors that influence the survival rates in liver cirrhosis patients with spontaneous bacterial peritonitis
Pei Chuan Tsung, Soo Hyung Ryu, In Hye Cha, Hee Won Cho, Jin Nam Kim, You Sun Kim, Jeong Seop Moon
Clin Mol Hepatol 2013;19(2):131-139.
Published online June 27, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.2.131
Background/Aims

Spontaneous bacterial peritonitis (SBP) has been known to greatly influence the survival rate of patients with liver cirrhosis. However, the factors that affect the survival rate in patients with SBP need to be clarified.

Methods

This study enrolled 95 liver cirrhosis patients diagnosed with SBP. The laboratory findings of their serum and ascitic fluid were examined and the characteristics of the isolated microorganisms in their peritoneal fluid were analyzed.

Results

The proportion of patients with culture-positive SBP was 41.1%, and 47 microorganisms were isolated from the ascitic fluid. The proportions of cultured bacteria that were Gram negative and Gram positive were 57.4% and 40.4%, respectively. The proportions of Escherichia coli, Klebsiella species, and Streptococcus species were 25.5%, 19.1%, and 19.1%, respectively. Enterococcus species represented 12.8% of the microorganisms cultured. The overall survival rates at 6, 12, and 24 months were 44.5%, 37.4%, and 32.2%, respectively. There was no relationship between the bacterial factors and the survival rate in SBP. Multivariate analysis revealed that the presence of hepatocellular carcinoma (HCC; P=0.001), higher serum bilirubin levels (≥3 mg/dL, P=0.002), a prolonged serum prothrombin time (i.e., international normalized ratio >2.3, P<0.001), renal dysfunction (creatinine >1.3 mg/dL, P<0.001), and lower glucose levels in the ascitic fluid (<50 mg/dL, P<0.001) were independent predictive factors of overall survival rate.

Conclusions

HCC, higher serum bilirubin levels, a prolonged serum prothrombin time, renal dysfunction, and lower ascitic glucose levels are associated with higher mortality rates in cirrhotic patients with SBP.

Citations

Citations to this article as recorded by  Crossref logo
  • Von Willebrand factor and VITRO score as useful markers predict spontaneous bacterial peritonitis with and without hepatorenal syndrome in Egyptian cirrhotic patients
    Helal Mohammed Salem, Hanan Ahmed Elbassat, Amal Said El Bendary, Shimaa Mahmoud El_Sharawy
    Tanta Medical Journal.2025; 53(1): 114.     CrossRef
  • Spontaneous Bacterial Peritonitis as a Precipitating Factor of Hepatic Encephalopathy and Its Outcomes During Hospital Admission
    Muntazir Mahdi, Maqsood Ahmad
    Indus Journal of Bioscience Research.2025; 3(3): 419.     CrossRef
  • Bacterial profile, drug resistance pattern, clinical and laboratory predictors of ascites infection in cirrhosis patients
    Abubeker Shemsu Helil, Shambel Araya Haile, Yohannis Birhanu, Hailemichael Desalegn, Daniel Melese Desalegn, Rozina Ambachew Geremew, Zenebe Gebreyohannes, Awad Mohammed, Daniel Dejene Wondimagegnehu, Gonfa Ayana, Anteneh Mehari Tizazu, Kassu Desta
    BMC Infectious Diseases.2024;[Epub]     CrossRef
  • Initial treatment response and short-term mortality of spontaneous bacterial peritonitis in cirrhotic patients with hepatocellular carcinoma
    Chang Hun Lee, Hye Jin Kang, Song Yi Yu, Seung Young Seo, Seong Hun Kim, Sang Wook Kim, Seung Ok Lee, Soo Teik Lee, In Hee Kim
    Scientific Reports.2023;[Epub]     CrossRef
  • Clinical features, microbial spectrum, and antibiotic susceptibility patterns of spontaneous bacterial peritonitis in cirrhotic patients
    Xin Zhang, Xiao-Xi Li, Jin-Wen Song, Xiao-Chang Zhang, Cheng Zhen, Jing-Feng Bi, Fu-Yu Lu, Su-Ming Chen, Dan Dan Huo, Peng Zhao, Da-Wei Zhang, Bo Tu, Chun-Mei Bao, Fu-Sheng Wang, Lei Huang
    Digestive and Liver Disease.2023; 55(11): 1554.     CrossRef
  • Spontan bakteriyel peritonitli hastalarda hastane içi mortaliteyi etkileyen faktörler
    Ramazan GÖKDEMİR, Müge USTAOĞLU, Hasan ERUZUN, Ahmet BEKTAŞ
    Akademik Gastroenteroloji Dergisi.2022; 20(3): 150.     CrossRef
  • Spontaneous bacterial peritonitis in hepatocellular carcinoma after PD-1 inhibitor therapy: two clinical cases
    Jianwei Liu, Hui Xue, Shilei Bai, Jie Wang, Yue Zhang, Liu Liu, Lei Zhang, Zhao Yang, KuiWang
    Heliyon.2022; 8(11): e11248.     CrossRef
  • Recurrent and Treatment-Unresponsive Spontaneous Bacterial Peritonitis Worsens survival in Decompensated Liver Cirrhosis
    Edmondo Falleti, Sara Cmet, Anna R. Cussigh, Elena Salvador, Davide Bitetto, Ezio Fornasiere, Elisa Fumolo, Carlo Fabris, Pierluigi Toniutto
    Journal of Clinical and Experimental Hepatology.2021; 11(3): 334.     CrossRef
  • Predictors of Short-Term Mortality Following First Episode of Spontaneous Bacterial Peritonitis in Hospitalized Cirrhotic Patients
    Abdel-Naser Elzouki, Abdelrahman Hamad, Hussam Almasri, Mohamed Ata, Anas Ashour, Muftah Othman, Ahmad Badi, Mehdi Errayes, Muhammad Zahid, Mohammed Danjuma
    Cureus.2021;[Epub]     CrossRef
  • Development and Validation of a Prognostic Model for One-year Survival of Cirrhosis Patients with First-ever Spontaneous Bacterial Peritonitis
    Rui-Rui Wang, Hong-Qiu Gu, Ying-Ying Wei, Jin-Xiang Yang, Yi-Xin Hou, Hui-Min Liu, Zhi-Yun Yang, Xian-Bo Wang, Yu-Yong Jiang
    Journal of Clinical and Translational Hepatology.2021; 000(000): 000.     CrossRef
  • An Epidemiological Meta-Analysis on the Worldwide Prevalence, Resistance, and Outcomes of Spontaneous Bacterial Peritonitis in Cirrhosis
    Phoebe Wen Lin Tay, Jieling Xiao, Darren Jun Hao Tan, Cheng Ng, Yan Nerng Lye, Wen Hui Lim, Vanessa Xin Yi Teo, Ryan Rui Yang Heng, Marcus Wei Xuan Yeow, Lionel Hon Wai Lum, Eunice Xiang Xuan Tan, Guan Sen Kew, Guan Huei Lee, Mark D. Muthiah
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • The pattern of microbial flora in Spontaneous bacterial peritonitis in Cirrhotic patients
    Sehrish Jahan Asif, Murataza Gondal, Shahida Parveen, Sumera Mushtaq, Shumaila Awan, Tassawar Hussain
    Journal of Rawalpindi Medical College.2020; : 62.     CrossRef
  • Multivariate predictive model for asymptomatic spontaneous bacterial peritonitis in patients with liver cirrhosis
    Bo Tu, Yue-Ning Zhang, Jing-Feng Bi, Zhe Xu, Peng Zhao, Lei Shi, Xin Zhang, Guang Yang, En-Qiang Qin
    World Journal of Gastroenterology.2020; 26(29): 4316.     CrossRef
  • Short- and long-term predictors of spontaneous bacterial peritonitis in Singapore
    YJ Wong, RC Kalki, KW Lin, R Kumar, J Tan, EK Teo, JW Li, TL Ang
    Singapore Medical Journal.2020; 61(8): 419.     CrossRef
  • Follow-up Creatinine Level Is an Important Predictive Factor of In-hospital Mortality in Cirrhotic Patients with Spontaneous Bacterial Peritonitis
    Baek Gyu Jun, Woong Cheul Lee, Jae Young Jang, Soung Won Jeong, Young Don Kim, Gab Jin Cheon, Yun Nah Lee, Sang Gyune Kim, Young Seok Kim, Young Sin Cho, Sae Hwan Lee, Hong Soo Kim
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • Spontaneous bacterial and fungal peritonitis in patients with liver cirrhosis: A literature review
    Toru Shizuma
    World Journal of Hepatology.2018; 10(2): 254.     CrossRef
  • The first episode of spontaneous bacterial peritonitis is a threat event in children with end-stage liver disease
    Sandra M.G. Vieira, Fernando P. Schwengber, Melina Melere, Marília R. Ceza, Melina Souza, Carlos O. Kieling
    European Journal of Gastroenterology & Hepatology.2018; 30(3): 323.     CrossRef
  • Predicting mortality in patients with spontaneous bacterial peritonitis using routine inflammatory and biochemical markers
    Raim Iliaz, Tahsin Ozpolat, Bulent Baran, Kadir Demir, Sabahattin Kaymakoglu, Fatih Besisik, Filiz Akyuz
    European Journal of Gastroenterology & Hepatology.2018; 30(7): 786.     CrossRef
  • Clinical and bacteriological features and prognosis of ascitic fluid infection in Chinese patients with cirrhosis
    Nian-zhi Ning, Tao Li, Ju-ling Zhang, Fen Qu, Jie Huang, Xiong Liu, Zhan Li, Wei Geng, Jun-liang Fu, Wang Huan, Shu-yong Zhang, Chun-mei Bao, Hui Wang
    BMC Infectious Diseases.2018;[Epub]     CrossRef
  • Spontaneous Bacterial Peritonitis
    Do Seon Song
    The Korean Journal of Gastroenterology.2018; 72(2): 56.     CrossRef
  • Bacterascites: A study of clinical features, microbiological findings, and clinical significance
    Rosalie C. Oey, Henk R. van Buuren, David M. de Jong, Nicole S. Erler, Robert A. de Man
    Liver International.2018; 38(12): 2199.     CrossRef
  • KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications

    Clinical and Molecular Hepatology.2018; 24(3): 230.     CrossRef
  • Rifaximin has the potential to prevent complications of cirrhosis
    Steven L. Flamm, Kevin D. Mullen, Zeev Heimanson, Arun J. Sanyal
    Therapeutic Advances in Gastroenterology.2018;[Epub]     CrossRef
  • Prognosis of Spontaneous Bacterial Peritonitis in Hepatocellular Carcinoma Patients
    Jeong Han Kim, Won Hyeok Choe, So Young Kwon, Byung-chul Yoo
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • Assessment of calprotectin in ascitic fluid as a marker for spontaneous bacterial peritonitis diagnosis in cirrhotic patients
    Fayrouz O. Selim, Nahawand A. El-Deeb, Hesham A. Farrag, Azza M. Ahmed
    The Egyptian Journal of Internal Medicine.2018; 30(4): 223.     CrossRef
  • Treatment for cirrhotic ascites
    Hideto Kawaratani, Hiroshi Fukui, Hitoshi Yoshiji
    Hepatology Research.2017; 47(2): 166.     CrossRef
  • Prognostic impact of peritonitis in hemodialysis patients: A national-wide longitudinal study in Taiwan
    Yueh-An Lu, Kun-Hua Tu, Cheng-Chia Lee, Patricia W. Wu, Chee-Jen Chang, Ya-Chung Tian, Chih-Wei Yang, Pao-Hsien Chu, Tatsuo Shimosawa
    PLOS ONE.2017; 12(3): e0173710.     CrossRef
  • Prognostic factors of liver cirrhosis mortality after a first episode of spontaneous bacterial peritonitis. A multicenter study
    Luigi Melcarne, Julia Sopeña, Francisco José Martínez-Cerezo, Mercedes Vergara, Mireia Miquel, Jordi Sánchez-Delgado, Blai Dalmau, Salvador Machlab, Dustin Portilla, Yonaisy Gonzàlez-Padrón, Mónica Real Álvarez, Chantal Carpintero, Meritxell Casas
    Revista Española de Enfermedades Digestivas.2017;[Epub]     CrossRef
  • Effect of different therapeutic modalities on systemic, renal, and hepatic hemodynamics and short-term outcomes in cirrhotic patients with spontaneous bacterial peritonitis
    Tary A. Salman, Ahmed M. Edrees, Hala H. El-Said, Osama L. El-Abd, Gasser I. El-Azab
    European Journal of Gastroenterology & Hepatology.2016; 28(7): 777.     CrossRef
  • Predictive model of mortality in patients with spontaneous bacterial peritonitis
    M. Poca, E. Alvarado‐Tapias, M. Concepción, C. Pérez‐Cameo, N. Cañete, I. Gich, C. Romero, M. Casas, E. Román, L. Castells, V. Vargas, J. A. Carrión, C. Guarner, G. Soriano
    Alimentary Pharmacology & Therapeutics.2016; 44(6): 629.     CrossRef
  • Spontaneous fungal peritonitis: Epidemiology, current evidence and future prospective
    Marco Fiore, Sebastiano Leone
    World Journal of Gastroenterology.2016; 22(34): 7742.     CrossRef
  • The Negative Prognostic Impact of a First Ever Episode of Spontaneous Bacterial Peritonitis in Cirrhosis and Ascites
    Greta Ra, Cynthia Tsien, Eberhard L. Renner, Florence Suet-Hing Wong
    Journal of Clinical Gastroenterology.2015; 49(10): 858.     CrossRef


  • Experimental and Clinical Transplantation.2015;[Epub]     CrossRef
  • Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites
    Philipp Schwabl, Theresa Bucsics, Kathrin Soucek, Mattias Mandorfer, Simona Bota, Alexander Blacky, Alexander M. Hirschl, Arnulf Ferlitsch, Michael Trauner, Markus Peck‐Radosavljevic, Thomas Reiberger
    Liver International.2015; 35(9): 2121.     CrossRef
  • 12,044 View
  • 104 Download
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Clinical features and outcomes of gastric variceal bleeding: retrospective Korean multicenter data
Moon Young Kim, Soon Ho Um, Soon Koo Baik, Yeon Seok Seo, Soo Young Park, Jung Il Lee, Jin Woo Lee, Gab Jin Cheon, Joo Hyun Sohn, Tae Yeob Kim, Young Suk Lim, Tae Hyo Kim, Tae Hee Lee, Sung Jae Park, Seung Ha Park, Jin Dong Kim, Sang Young Han, Chang Soo Choi, Eun Young Cho, Dong Joon Kim, Jae Seok Hwang, Byoung Kuk Jang, June Sung Lee, Sang Gyune Kim, Young Seok Kim, So Young Kwon, Won Hyeok Choe, Chang Hyeong Lee, Byung Seok Kim, Jae Young Jang, Soung Won Jeong, Byung Ho Kim, Jae Jun Shim, Yong Kyun Cho, Moon Soo Koh, Hyun Woong Lee
Korean J Hepatol 2013;19(1):36-44.
Published online March 25, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.1.36
Background/Aims

While gastric variceal bleeding (GVB) is not as prevalent as esophageal variceal bleeding, it is reportedly more serious, with high failure rates of the initial hemostasis (>30%), and has a worse prognosis than esophageal variceal bleeding. However, there is limited information regarding hemostasis and the prognosis for GVB. The aim of this study was to determine retrospectively the clinical outcomes of GVB in a multicenter study in Korea.

Methods

The data of 1,308 episodes of GVB (males:females=1062:246, age=55.0±11.0 years, mean±SD) were collected from 24 referral hospital centers in South Korea between March 2003 and December 2008. The rates of initial hemostasis failure, rebleeding, and mortality within 5 days and 6 weeks of the index bleed were evaluated.

Results

The initial hemostasis failed in 6.1% of the patients, and this was associated with the Child-Pugh score [odds ratio (OR)=1.619; P<0.001] and the treatment modality: endoscopic variceal ligation, endoscopic variceal obturation, and balloon-occluded retrograde transvenous obliteration vs. endoscopic sclerotherapy, transjugular intrahepatic portosystemic shunt, and balloon tamponade (OR=0.221, P<0.001). Rebleeding developed in 11.5% of the patients, and was significantly associated with Child-Pugh score (OR=1.159, P<0.001) and treatment modality (OR=0.619, P=0.026). The GVB-associated mortality was 10.3%; mortality in these cases was associated with Child-Pugh score (OR=1.795, P<0.001) and the treatment modality for the initial hemostasis (OR=0.467, P=0.001).

Conclusions

The clinical outcome for GVB was better for the present cohort than in previous reports. Initial hemostasis failure, rebleeding, and mortality due to GVB were universally associated with the severity of liver cirrhosis.

Citations

Citations to this article as recorded by  Crossref logo
  • Treatment of Gastric Varices
    Thomas J. Wang, Marvin Ryou
    Current Hepatology Reports.2024; 23(2): 287.     CrossRef
  • Endoscopic Treatment and Prevention of Acute Variceal Hemorrhage
    Youngdae Kim
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2024; 24(1): 5.     CrossRef
  • Plug-Assisted Retrograde Transvenous Obliteration: A Modified Balloon-Occluded Retrograde Transvenous Obliteration of Gastric Varices
    Dong Il Gwon, Hyun-Ki Yoon
    Digestive Disease Interventions.2024; 08(03): 183.     CrossRef
  • Coil- and Plug-Assisted Transvenous Retrograde Obliteration (CARTO/PARTO) in the Treatment of Gastric Varices: A European Single Centre Experience
    Giuseppe Pelle, Flavio Andresciani, Massimo Messina, Silvia Nardelli, Lorenzo Ridola, Ermanno Notarianni, Adelchi Saltarelli, Stefania Gioia, Alessandro Tanzilli, Cesare Ambrogi
    Gastrointestinal Disorders.2024; 6(3): 742.     CrossRef
  • Ендоскопічне лікування кровотеч із варикозно розширених вен шлунка
    S.M. Chooklin, S.S. Chuklin, Ya.R. Dutka
    EMERGENCY MEDICINE.2022; 18(5): 44.     CrossRef
  • Diagnosis and Management of Esophageal and Gastric Variceal Bleeding: Focused on 2019 KASL Clinical Practice Guidelines for Liver Cirrhosis
    Min Kyung Park, Yun Bin Lee
    The Korean Journal of Gastroenterology.2021; 78(3): 152.     CrossRef
  • Comparison of the Effects of TIPS versus BRTO on Bleeding Gastric Varices: A Meta-Analysis
    Zi Wen Wang, Jin Chao Liu, Fang Zhao, Wen Guang Zhang, Xu Hua Duan, Peng Fei Chen, Si Fu Yang, Hong Wei Li, Fu Wen Chen, Hong Sheng Shi, Jian Zhuang Ren
    Canadian Journal of Gastroenterology and Hepatology.2020; 2020: 1.     CrossRef
  • KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications

    Clinical and Molecular Hepatology.2020; 26(2): 83.     CrossRef
  • Balloon-Occluded Retrograde Transvenous Obliteration (BRTO) Versus Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Treatment of Gastric Varices Because of Portal Hypertension
    Swathi Paleti, Venkat Nutalapati, Jihan Fathallah, Sravan Jeepalyam, Tarun Rustagi
    Journal of Clinical Gastroenterology.2020; 54(7): 655.     CrossRef
  • Endoscopic Therapy and Radiologic Intervention of Acute Gastroesophageal Variceal Bleeding
    Jeong Eun Song, Byung Seok Kim
    Clinical Endoscopy.2019; 52(5): 407.     CrossRef
  • Detection of fundic varices obturation by endoscopic ultrasound versus multidetector computed tomography
    Amr Elrabat, Salah El-Gamal, Mohammad M. Kashwaa, Mohamed M. El-Rakhawy
    The Egyptian Journal of Internal Medicine.2019; 31(4): 487.     CrossRef
  • Plug-Assisted Retrograde Transvenous Obliteration for the Treatment of Gastric Varices: The Role of Intra-Procedural Cone-Beam Computed Tomography
    Dong Il Gwon, Gi-Young Ko, Young Baek Kwon, Hyun-Ki Yoon, Kyu-Bo Sung
    Korean Journal of Radiology.2018; 19(2): 223.     CrossRef
  • Prevention and management of gastroesophageal varices
    Yeon Seok Seo
    Clinical and Molecular Hepatology.2018; 24(1): 20.     CrossRef
  • Innovative Technique for Endoscopic Placement of Sengstaken-Blakemore Tube
    Arleen M. Ortiz, Cesar J. Garcia, Mohamed O. Othman, Marc J. Zuckerman
    Southern Medical Journal.2018; 111(5): 307.     CrossRef
  • Balloon-Occluded Retrograde Transvenous Obliteration versus Transjugular Intrahepatic Portosystemic Shunt for the Management of Gastric Variceal Bleeding
    Geunwu Gimm, Young Chang, Hyo-Cheol Kim, Aesun Shin, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
    Gut and Liver.2018; 12(6): 704.     CrossRef
  • Management of different types of gastric varices with band ligation: a 3-year experience
    Waseem M. Seleem, Amr S. Hanafy
    European Journal of Gastroenterology & Hepatology.2017; 29(8): 968.     CrossRef
  • Balloon‐occluded retrograde transvenous obliteration versus transjugular intrahepatic portosystemic shunt for treatment of gastric varices due to portal hypertension: A meta‐analysis
    Yun‐Bing Wang, Jian‐Ying Zhang, Jian‐Ping Gong, Fan Zhang, Yong Zhao
    Journal of Gastroenterology and Hepatology.2016; 31(4): 727.     CrossRef
  • Usefulness of intra-procedural cone-beam computed tomography in modified balloon-occluded retrograde transvenous obliteration of gastric varices
    Edward Wolfgang Lee, Naomi So, Ryan Chapman, Justin P McWilliams, Christopher T Loh, Ronald W Busuttil, Stephen T Kee
    World Journal of Radiology.2016; 8(4): 390.     CrossRef
  • Cyanoacrylate Injection Versus Band Ligation in the Endoscopic Management of Acute Gastric Variceal Bleeding
    Weiguang Qiao, Yutang Ren, Yang Bai, Side Liu, Qiang Zhang, Fachao Zhi
    Medicine.2015; 94(41): e1725.     CrossRef
  • Novel Use of Glidescope Indirect Laryngoscopy for Insertion of a Minnesota Tube for Variceal Bleeding
    Adam B. Schlichting, Jayna M. Gardner-Gray, Gina Hurst
    The Journal of Emergency Medicine.2015; 49(1): 40.     CrossRef
  • Re-Bleeding in Patients With Cirrhosis: Evaluation of Esophageal and Gastric Variceal Bleeding and Their Relationship With a Model for the End-Stage Liver Disease (MELD) Score and Child-Pugh Score
    Mohsen Ebrahimi, Hamidreza Reihani, Mohammadreza Sheikhian, Ehsan Bolvardi, Masumeh Pashayi, Elham Pishbin
    Razavi International Journal of Medicine.2014;[Epub]     CrossRef
  • Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension
    Jae Hyun Kim, Jung Min Kim, Youn Zoo Cho, Ji Hoon Na, Hyun Sik Kim, Hyoun A Kim, Hye Won Kang, Soon Koo Baik, Sang Ok Kwon, Seung Hwan Cha, Young Ju Kim, Moon Young Kim
    Clinical and Molecular Hepatology.2014; 20(4): 376.     CrossRef
  • The secondary prophylactic efficacy of beta-blocker after endoscopic gastric variceal obturation for first acute episode of gastric variceal bleeding
    Moon Han Choi, Young Seok Kim, Sang Gyune Kim, Yun Nah Lee, Yu Ri Seo, Min Jin Kim, Sae Hwan Lee, Soung Won Jeong, Jae Young Jang, Hong Soo Kim, Boo Sung Kim
    Clinical and Molecular Hepatology.2013; 19(3): 280.     CrossRef
  • 13,146 View
  • 86 Download
  • Crossref

Current status of Liver diseases in Korea: Hepatocellular carcinoma
Il Han Song , Kyung Sik Kim
Korean J Hepatol 2009;15(60):50-59.
Published online December 31, 2009
DOI: https://doi.org/10.3350/kjhep.2009.15.S6.S50

Citations

Citations to this article as recorded by  Crossref logo
  • Radiologic Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Suppressed Chronic Hepatitis B
    Hyeki Cho, Young Chang, Jeong-Hoon Lee, Young Youn Cho, Joon Yeul Nam, Yun Bin Lee, Dong Ho Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jeong Min Lee, Jung-Hwan Yoon
    Journal of Clinical Gastroenterology.2020; 54(7): 633.     CrossRef
  • Examining Liver Cancer Patients and a High-Risk Group in a Vulnerable Area: An Experience from the Ulleung Liver Cancer Prevention and Management Project
    Dong-Hee Ryu, Yu-Mi Lee, Ji Mi Park, Won Young Tak, Nam-Soo Hong
    International Journal of Environmental Research and Public Health.2020; 17(21): 7757.     CrossRef
  • Alterations of the Gut Microbiome in Chronic Hepatitis B Virus Infection Associated with Alanine Aminotransferase Level
    Yeojun Yun, Yoosoo Chang, Han-Na Kim, Seungho Ryu, Min-Jung Kwon, Yong Kyun Cho, Hyung-Lae Kim, Hae Suk Cheong, Eun-Jeong Joo
    Journal of Clinical Medicine.2019; 8(2): 173.     CrossRef
  • Entecavir and tenofovir reduce hepatitis B virus‐related hepatocellular carcinoma recurrence more effectively than other antivirals
    H. Cho, H. Ahn, D. H. Lee, J.‐H. Lee, Y. J. Jung, Y. Chang, J. Y. Nam, Y. Y. Cho, D. H. Lee, E. J. Cho, S. J. Yu, J. M. Lee, Y. J. Kim, J.‐H. Yoon
    Journal of Viral Hepatitis.2018; 25(6): 707.     CrossRef
  • Prognosis of Spontaneous Bacterial Peritonitis in Hepatocellular Carcinoma Patients
    Jeong Han Kim, Won Hyeok Choe, So Young Kwon, Byung-chul Yoo
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • Establishment of Hepatocellular Cancer Induced Pluripotent Stem Cells Using a Reprogramming Technique
    Han Joon Kim, Jaemin Jeong, Sunhoo Park, Young-Woo Jin, Seung-Sook Lee, Seung Bum Lee, Dongho Choi
    Gut and Liver.2017; 11(2): 261.     CrossRef
  • Expression of Hepatocyte Hepatitis B Core Antigen and Hepatitis B Surface Antigen as a Marker in the Management of Chronic Hepatitis B Patients
    Sun Young Yim, Tae Hyung Kim, Suh Sang Jun, Eun Sun Kim, Bora Keum, Yeon Seok Seo, Hyung Joon Yim, Yoon Tae Jeen, Hoon Jai Chun, Hong Sik Lee, Soon Ho Um, Chang Duck Kim, Nam Hee Won, Ho Sang Ryu
    Gut and Liver.2017; 11(3): 417.     CrossRef
  • Cancer Mortality Projections in Korea up to 2032
    Mia Son, Jae-Won Yun
    Journal of Korean Medical Science.2016; 31(6): 892.     CrossRef
  • Insulin resistance increases loss of antibody to hepatitis B surface antigen in nondiabetic healthy adults
    E.‐J. Joo, J.‐S. Yeom, M.‐J. Kwon, Y. Chang, S. Ryu
    Journal of Viral Hepatitis.2016; 23(11): 889.     CrossRef
  • Blood Neutrophil-to-Lymphocyte Ratio Predicts Tumor Recurrence in Patients with Hepatocellular Carcinoma within Milan Criteria after Hepatectomy
    Xu-Guang Hu, Wei Mao, Yong-Keun Park, Wei-Guang Xu, Bong-Wan Kim, Hee-Jung Wang
    Yonsei Medical Journal.2016; 57(5): 1115.     CrossRef
  • Nurse‐led hepatocellular carcinoma surveillance clinic provides an effective method of monitoring patients with cirrhosis
    Saroj Nazareth, Nadine Leembruggen, Rhoda Tuma, Sook‐Ling Chen, Samarth Rao, Nick Kontorinis, Wendy Cheng
    International Journal of Nursing Practice.2016; 22(S2): 3.     CrossRef
  • Clinical characteristics and potential aetiologies of non‐B non‐C hepatocellular carcinoma in hepatitis B virus endemic area
    Seung Bum Lee, Kang Mo Kim, Jihyun An, Danbi Lee, Ju Hyun Shim, Young‐Suk Lim, Han Chu Lee, Young‐Hwa Chung, Yung Sang Lee
    Liver International.2016; 36(9): 1351.     CrossRef
  • Predictive Value of Antiviral Effects in the Development of Hepatocellular Carcinoma in the General Korean Population with Chronic Hepatitis B
    Jae-Jun Shim, In Hwan Oh, Sang Bae Kim, Jung Wook Kim, Chang Kyun Lee, Jae Young Jang, Ju-Seog Lee, Byung-Ho Kim
    Gut and Liver.2016; 10(6): 962.     CrossRef
  • High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation
    Eung Chang Lee, Seong Hoon Kim, Seung Duk Lee, Hyeongmin Park, Soon-Ae Lee, Sang-Jae Park
    World Journal of Gastroenterology.2016; 22(14): 3803.     CrossRef
  • Hepatectomy is a reasonable option for older patients with hepatocellular carcinoma
    Jong Man Kim, Bong Ick Cho, Choon Hyuck David Kwon, Jae-Won Joh, Jae Berm Park, Joon Hyeok Lee, Sung Joo Kim, Seung Woon Paik, Cheol Keun Park
    The American Journal of Surgery.2015; 209(2): 391.     CrossRef
  • Clinicopathological factors and long-term outcome comparing between lung and peritoneal metastasectomy after hepatectomy for hepatocellular carcinoma in a tertiary institution
    Alfred Wei Chieh Kow, Choon Hyuck David Kwon, Sanghyun Song, Jong Man Kim, Jae-Won Joh
    Surgery.2015; 157(4): 645.     CrossRef
  • High liver fibrosis index FIB‐4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers
    Beomseok Suh, Sehhoon Park, Dong Wook Shin, Jae Moon Yun, Hyung‐Kook Yang, Su Jong Yu, Cheong‐Il Shin, Jin‐Soo Kim, Eunmi Ahn, Hyejin Lee, Jin Ho Park, BeLong Cho
    Hepatology.2015; 61(4): 1261.     CrossRef
  • Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels
    Junggyu Lee, Dong Hyun Sinn, Jung Hee Kim, Geum-Youn Gwak, Hye Seung Kim, Sin-Ho Jung, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Byung Chul Yoo, Seung Woon Paik
    Journal of Korean Medical Science.2015; 30(11): 1618.     CrossRef
  • Altered microRNA expression profile in hepatitis B virus-related hepatocellular carcinoma
    Keon Uk Park, Young-Su Seo, Yun-Han Lee, Jungwook Park, Ilseon Hwang, Koo Jeong Kang, Jehyun Nam, Sang-Woo Kim, Jin Young Kim
    Gene.2015; 573(2): 278.     CrossRef
  • The Effect of the Curcumae Longae Rhizoma (CLR) Extract on the Hepatocellular Carcinogenesis and Acute Liver Damage Induced by Diethylnitrosamine (DENA) and CCl4in Rats
    Tae-San Jung, Chang-Won Choi
    Herbal Formula Science.2014; 22(1): 177.     CrossRef
  • Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma
    Chang Joon Kim, Hong Joo Kim, Jung Ho Park, Dong Il Park, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Min‐Ji Kim
    Liver International.2014; 34(2): 305.     CrossRef
  • Burden of disease in Korea during 2000-10
    K. S. Lee, J. H. Park
    Journal of Public Health.2014; 36(2): 225.     CrossRef
  • Oral antiviral therapy improves the diagnostic accuracy of alpha‐fetoprotein levels in patients with chronic hepatitis B
    Jae‐Jun Shim, Jung Wook Kim, Chang Kyun Lee, Jae Young Jang, Byung‐Ho Kim
    Journal of Gastroenterology and Hepatology.2014; 29(9): 1699.     CrossRef
  • miR-429 represses cell proliferation and induces apoptosis in HBV-related HCC
    Huijie Gao, Chao Liu
    Biomedicine & Pharmacotherapy.2014; 68(8): 943.     CrossRef
  • Comparison of Clinical Manifestations and Outcomes between Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma: Analysis of a Nationwide Cohort
    Dong Hyun Sinn, Geum-Youn Gwak, Juhee Cho, Seung Woon Paik, Byung Chul Yoo, Pierre Roques
    PLoS ONE.2014; 9(11): e112184.     CrossRef
  • Burden of cancer in Korea during 2000–2020
    Jae-Hyun Park, Kwang-Sig Lee, Kyu-Sik Choi
    Cancer Epidemiology.2013; 37(4): 353.     CrossRef
  • Factors influencing hepatocellular carcinoma prognosis after hepatectomy: a single-center experience
    Sung Keun Park, Young Kul Jung, Dong Hae Chung, Keon Kuk Kim, Yeon Ho Park, Jung Nam Lee, Oh Sang Kwon, Yun Soo Kim, Duck Joo Choi, Ju Hyun Kim
    The Korean Journal of Internal Medicine.2013; 28(4): 428.     CrossRef
  • The Korean National Liver Cancer Surveillance Program: Experience of a Single Healthcare Center in 2011
    Jae-Jun Shim, Hyun Jin Park, Jung-Wook Kim, Eun Jung Hwang, Chang Kyun Lee, Jae Young Jang, Seong Jin Park, Hyun Rim Choi, Byung-Ho Kim
    Korean Journal of Medicine.2013; 84(5): 672.     CrossRef
  • Hepatoprotective Effects of Hovenia dulcis Extract on Acute and Chronic Liver Injuries induced by Alcohol and Carbon Tetrachloride
    Young-Sik Kim, Juyeon Park, Yongbeom Kwon, Dong Wook Lim, MiKyung Song, Ho-Young Choi, Hocheol Kim
    The Korea Journal of Herbology.2013; 28(4): 25.     CrossRef
  • Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma
    Sang Soo Lee, Sook-Hyang Jeong, Young-Sang Byoun, Seong Min Chung, Mun Hyuk Seong, Hyung Rae Sohn, Bo-young Min, Eun Sun Jang, Jin-Wook Kim, Guan Jung Park, Yoon Jin Lee, Kyoung Ho Lee, Soyeon Ahn
    BMC Cancer.2013;[Epub]     CrossRef
  • Status of Primary Liver Cancer Found through Routine Health Check-up
    Changhyun Lee, Jong In Yang, Hee Jin Byun, Jung Mook Kang, Seoungho Choi, Jeong Yoon Yim
    Journal of Korean Medical Science.2013; 28(10): 1449.     CrossRef
  • Comparison of Steroid-Free Immunosuppression and Standard Immunosuppression for Liver Transplant Patients with Hepatocellular Carcinoma
    Tonghai Xing, Li Huang, Zhenhai Yu, Lin Zhong, Shuyun Wang, Zhihai Peng, Peter Starkel
    PLoS ONE.2013; 8(8): e71251.     CrossRef
  • C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion
    Jong Man Kim, Choon Hyuck David Kwon, Jae-Won Joh, Justin Sangwook Ko, Jae Berm Park, Joon Hyeok Lee, Sung Joo Kim, Seung Woon Paik, Cheol-Keun Park
    World Journal of Surgical Oncology.2013;[Epub]     CrossRef
  • Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience
    Sang Seok Lee, Hyun Sung Shin, Hyung Joon Kim, Su Jin Lee, Hyun Suk Lee, Kyung Hee Hyun, Yong Hyun Kim, Byoung Woon Kwon, Jin Hyung Han, Hoon Choi, Bae Hwan Kim, Joon Hyuk Lee, Ha Yan Kang, Hyun Deok Shin, Il Han Song
    The Korean Journal of Hepatology.2012; 18(1): 48.     CrossRef
  • Serum Selenium Levels in Korean Hepatoma Patients
    In-Wook Kim, Su-Mi Bae, Yong-Wan Kim, Hai-Bo Liu, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Pankaj Kumar Chaturvedi, Gantumur Battogtokh, Woong Shick Ahn
    Biological Trace Element Research.2012; 148(1): 25.     CrossRef
  • Risk Factors of Peritoneal Recurrence and Outcome of Resected Peritoneal Recurrence After Liver Resection in Hepatocellular Carcinoma: Review of 1222 Cases of Hepatectomy in a Tertiary Institution
    Alfred Wei Chieh Kow, Choon Hyuck David Kwon, Sanghyun Song, Milljae Shin, Jong Man Kim, Jae-Won Joh
    Annals of Surgical Oncology.2012; 19(7): 2246.     CrossRef
  • NS-398 induces caspase-dependent, mitochondria-mediated intrinsic apoptosis of hepatoma cells
    Il Han Song, Suk Bae Kim, Hyun Duk Shin, Ha Yan Kang, Eun Young Kim
    Advances in Bioscience and Biotechnology.2012; 03(06): 649.     CrossRef
  • Noninvasive diagnosis of hepatocellular carcinoma
    Byung Seok Kim
    Clinical and Molecular Hepatology.2012; 18(2): 245.     CrossRef
  • Comparison of usefulness of clinical diagnostic criteria for hepatocellular carcinoma in a hepatitis B endemic area
    So Young Bae, Moon Seok Choi, Geum-Youn Gwak, Yong Han Paik, Joon Hyoek Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo
    Clinical and Molecular Hepatology.2012; 18(2): 185.     CrossRef
  • A Genetic Variant in Long Non-Coding RNA HULC Contributes to Risk of HBV-Related Hepatocellular Carcinoma in a Chinese Population
    Yao Liu, Shandong Pan, Li Liu, Xiangjun Zhai, Jibin Liu, Juan Wen, Yixin Zhang, Jianguo Chen, Hongbing Shen, Zhibin Hu, Rui Medeiros
    PLoS ONE.2012; 7(4): e35145.     CrossRef
  • The Role of Preoperative [18F]Fluorodeoxyglucose Positron Emission Tomography in Predicting Early Recurrence After Curative Resection of Hepatocellular Carcinomas
    Sung Gwe Ahn, Sung Hoon Kim, Tae Joo Jeon, Ho Jin Cho, Sae Byeol Choi, Mi Jin Yun, Jong Doo Lee, Kyung Sik Kim
    Journal of Gastrointestinal Surgery.2011; 15(11): 2044.     CrossRef
  • 7,785 View
  • 51 Download
  • Crossref

Hepatology Elsewhere

The Korean Journal of Risk factors for mortality after surgery in patients with cirrhosis
Joon Hyeok Lee
Korean J Hepatol 2008;14(4):541-545.
Published online December 31, 2008
DOI: https://doi.org/10.3350/kjhep.2008.14.4.541
Background & Aims
Current methods of predicting risk of postoperative mortality in patients with cirrhosis are suboptimal. The utility of the Model for End-stage Liver Disease (MELD) in predicting mortality after surgery other than liver transplantation is unknown. The aim of this study was to determine the risk factors for postoperative mortality in patients with cirrhosis. Methods: Patients with cirrhosis (N=772) who underwent major digestive (n=586), orthopedic (n=107), or cardiovascular (n=79) surgery were studied. Control groups of patients with cirrhosis included 303 undergoing minor surgical procedures and 562 ambulatory patients. Univariate and multivariable proportional hazards analyses were used to determine the relationship between risk factors and mortality. Results: Patients undergoing major surgery were at increased risk for mortality up to 90 days postoperatively. By multivariable analysis, only MELD score, American Society of Anesthesiologists class, and age predicted mortality at 30 and 90 days, 1 year, and long-term, independently of type or year of surgery. Emergency surgery was the only independent predictor of duration of hospitalization postoperatively. Thirty-day mortality ranged from 5.7% (MELD score, <8) to more than 50% (MELD score, >20). The relationship between MELD score and mortality persisted throughout the 20-year postoperative period. Conclusions: MELD score, age, and American Society of Anesthesiologists class can quantify the risk of mortality postoperatively in patients with cirrhosis, independently of the procedure performed. These factors can be used in determining operative mortality risk and whether elective surgical procedures can be delayed until after liver transplantation.
  • 4,996 View
  • 32 Download
Original Articles
Amatoxins Poisonings in Korea
Byung-Min Ahn, M.D., Dong-Soo Lee, M.D., Kang-Moon Lee, M.D., Sang-Bum Kang, M.D., Jin-Mo Yang, M.D., Young-Min Park, M.D., Young-Sok Lee, M.D., Kyu-Won Chung, M.D., Hee-Sik Sun, Doo-Ho Park, M.D., Hyun-Joo Rho, M.D.1, Young-Mo Kang, M.D.1, Jong-Myung Lee, M.D.1, Jung-Wook Hur, M.D.2, Sung-Gon Choi, M.D.3, Jeong-Ho Kim, M.D.4, Sang-In Lee, M.D.4, Seung-Ok Choi, M.D.5, Hong-Youp Choi, M.D.6, Oh-Sun Kwon, M.D.6, Chang Duck Koo, Ph.D.7, Soon-Ja Seok, Ph.D.8 and Yang-Sup Kim, Ph.D.8
Korean J Hepatol 2000;6(3):340-349.
Background/Aims
: From the review of Korean literature most fatal mushroom poisonings have been due to amatoxins with high mortality. So far there have never been investigations on the amatoxins poisonings such as annual incidence, mortality, common causal species, and endemic areas. This study was carried out to develop some basic statistics as part of studies for an effective management of amatoxins intoxications . Method: For the year 1999 authors collected cases of mushroom poisonings which had been mainly gathered from hospitals nation- wide. All of the cases with suggestive amatoxins poisonings were screened by symptomatology and laboratory findings . The causal species of mushrooms were identified grossly and microscopically. Res ults : A total of 54 victims with mushroom poisonings were evaluated. The causal mushroom toxins were diagnosed or strongly sugges ted as amatoxins in 43 of 54 victims. Eleven of 54 victims did not conform to the category of amatoxins intoxication due to absent or minimal elevation of aminotrans ferase. Mean age of the victims was 44.3 ± 23.3 (range: 7- 78) with male predominance (1.2 : 1). The causal species were confirmed, or strongly suggested, as Amanita virosa in 25 victims, Amanita subjunquillea in 14, and unknown species in 4. Thirty- five out of a total of 43 were regarded as moderate to severe intoxication (AST or ALT > 1,000 IU/L) with 20% mortality. Most fatal victims showed marked thrombocytopenia (40,000 ± 1a9,000/mm3) compared to non- fatal victims (109,066 ± 42,245/mm3). A total of 88.4% of victims was developed in the Kangwon and Kyungpuk provinces. Both are wes t of the Taebaek Mountains (38/43). Conclus ions : Although the common causal species for amatoxins poisonings in Korea are different from European countries and North America, the mortality is similar to that of those areas. In order to further reduce the mortality, beds ide diagnostic
methods
us ing biological fluids and more effective therapy for liver failure should be established.
  • 2,842 View
  • 31 Download
Comparison of Predictive Factors Related to the Mortality and Rebleeding Caused by Variceal Bleeding: Child-Pugh Score, MELD Score, and Rockall Score
Ja Young Lee, M.D., Jin Heon Lee, M.D., Soo Jin Kim, M.D., Dae Rho Choi, M.D., Kyung Ho Kim, M.D., Yong Bum Kim, M.D., Hak Yang Kim, M.D. and Jae Young Yoo, M.D.
Korean J Hepatol 2002;8(4):458-464.
Background/Aims
The first episode of variceal bleeding is one of the most frequent causes of death in patients with liver cirrhosis. The Child-Pugh(CP) scoring system has been widely accepted for prognostic assessment. Recently, MELD has been known to be better than the CP scoring system for predicting mortality in patients with end-stage liver diseases. The Rockall risk scoring system was developed to predict the outcome of upper GI bleeding including variceal bleeding. The aim of this study was to investigate the mortality rate of first variceal bleeding and the predictability of each scoring system. Methods: We evaluated the 6-week mortality rate, rebleeding rate, and 1-year mortality rate of all the 136 patients with acute variceal bleeding without previous episode of hemorrhage between January 1, 1998 and December 31, 2000. The CP score, MELD score, and Rockall score were estimated and analyzed. Results: Among 136 patients, 35 patients with hepatoma and 8 patients with follow-up loss were excluded. Six-week mortality rate, 1-year mortality rate, and rebleeding rate of first variceal bleeding were 24.7%, 35.5%, and 12.9%, respectively. The c-statistics of CP, MELD, and Rockall score for predicting 6-week mortality rate were 0.809 (p<0.001, 95% CI, 0.720-0.898), 0.804 (p<0.001, 95% CI, 0.696-0.911), 0.787 (p<0.001, 95% CI, 0.683-0.890), respectively. For 1-year mortality rate, c-statistics were 0.765 (p<0.005, 95% CI, 0.665-0.865), 0.780 (p<0.005, 95% CI, 0.676-0.883), 0.730 (p<0.01, 95% CI, 0.627-0.834), respectively. Conclusion: The CP, MELD, and Rockall scores were reliable measures of mortality risk in patients with first variceal bleeding. The CP classification is useful in its easy applicability. (Korean J Hepatol 2002;8:458-464)
  • 3,570 View
  • 42 Download
Risk Factors of Morbidity and Mortality Following Surgical Resection for Hepatocellular Carcinoma
Wan Wook Kim, M.D., Kwang-Woong Lee, M.D., Sung Ho Choi, M.D., Jin Seok Heo, M.D., Yong Il Kim, M.D., Sung Ju Kim, M.D., Dae Sung Lee, M.D., Hwan Hyo Lee, M.D., Seung Woon Paik, M.D.1, Kwang Cheol Koh, M.D.1, Joon Hyoek Lee, M.D.1, Moon Seok Choi, M.D.1 , Byung Chul Yoo, M.D.1 and Jae Won Joh, M.D.
Korean J Hepatol 2004;10(1):51-61.
Background/Aims
Recently, mortality following surgical resection for hepatocelluar carcinoma has been reduced significantly. Morbidity, however, is still significant. This study evaluated the risk factors leading to morbidity and mortality. Methods: 510 patients who had a hepatic resection form Nov. 1994 to Dec. 2001 were included. The patient demographics showed a mean age of 51.6 years with a male to female ratio of 4:1. The HBsAg was positive in 76.0% and the anti-HCV was positive in 8.2%. The mean tumor size was 5.2 cm, 26.2% of patients had preoperative transcatheter arterial embolization (TAE), and 8.7% had preoperative percutaneous transhepatic portal embolization (PTPE). Limited resection was performed in 259 cases (50.7%), and major resection was conducted in 251 cases (49.1%). Risk factors included age, sex, laboratory findings (liver function test, prothrombin time, albumin, glucose, α-fetoprotein, ICG test), preoperative TAE, PTPE, operation type, operation time, intraoperative transfusion, tumor size, and cirrhosis.
Results
The morbidity was 10.5% (54 cases). Operative death occurred in 5 cases (1.0%). Hospital death, including operative death, occurred in 6 cases (1.2%). Five cases were associated with hepatic failure and 1 case was associated with aspiration pneumonia accompanying hepatic failure. Transfusion (P=0.002), glucose (P=0.002), and prothrombin time (P=0.038) were significantly related to morbidity. Age (P=0.028), glucose (P=0.011), and TAE (P=0.046) were significantly related to mortality. Conclusions: Intraoperative transfusion, which is mainly related to intraoperative bleeding, should be reduced if possible to decrease morbidity. Diabetes mellitus patients and the elderly need careful perioperative management.(Korean J Hepatol 2004;10:51-61)
  • 3,748 View
  • 20 Download